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Summary
There is currently an alarming increase in the world-wide incidence of 
tuberculosis (TB), the disease caused due to infection by Mycobacterium 
tuberculosis. There is no easy treatment for TB which currently requires a regime of 
four drugs administered over a six month time course. The rise in strains of M. 
tuberculosis resistant to one or more of these frontline anti-tubercular drugs, is a 
strong incentive to develop novel anti-tubercular agents.
The shikimate pathway has been identified as a potential target for the 
development of new antimicrobial drugs and knockout strains of M. tuberculosis 
lacking shikimate kinase have been shown to be non-viable.In this study the third 
enzyme in the pathway, type II dehydroquinase is considered an attractive target as 
many pathogenic bacteria possess the type II enzyme whereas many bacteria that 
inhabit the human gut posses the type I form. Structure based ligand design was used 
to identify potential inhibitors of the enzyme type II 3-dehydroquinate deydratase 
(DHQase) from M. tuberculosis (MTDHQase). This methodology allows the 
identification of non-substrate like inhibitors that have solubility profiles more 
amenable to development as potential drugs. The crystal structures of MTDHQase 
available in house, were analysed to generate Pharmacophore models, which were 
subsequently used to screen a virtual compound library, to generate a list of potential 
inhibitors. This process was repeated for the type II DHQases from Streptomyces 
coelicolor (SCDHQase) and Helicobacter pylori (HPDHQase) and the hit lists for 
each enzyme compared. The hits unique to MTDHQase were screened in vitro, 
identifying six compounds that were active inhibitors.
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In tandem the cloning and structural analysis of the type II 3-dehydroquinase 
from Helocobacter pylori was undertaken as a series of inhibitors of this enzyme 
obtained from a traditional high throughput screen (HTS) against a compound library 
was available from GlaxoSmithKline.
The structure of HPDHQase in complex with the transition state analogue 2,3 
anhydro quinic acid was determined to 3.1 Â resolution. While the structure of 
HPDHQase in complex with inhibitor AH9095, an HPDHQase specific non­
substrate-like inhibitor, was determined to 1.5Â resolution. Both structures were 
solved using the molecular replacement method.
Comparison of the structures of HPDHQase with those of SCDHQase and 
MTDHQase provided significant insight into the factors that affect ligand specificity. 
The complex of HPDHQase and AH9095 provided the first crystal structure of a type 
II 3-dehydroquinase with a non-substrate like ligand. This structure allowed the 
identification of new, unexploited areas of the type II 3-dehydroquinase active site 
which may be utilised to develop specificity and potency of inhibitors.
The present assay for 3-dehydroquinase activity is based upon UV 
absorbance at 234nm from the product 3-dehydroshikimate. Detection of UV 
absorbance at this wavelength is not possible when the assay is carried out in plastic 
96 well plates, therefore not amenable for high throughput methods. Development of 
a simple colorimetric assay for 3-dehydroquinase activity was investigated to permit 
high throughput testing of compounds. By coupling the dehydroquinase step to 
dehydroshikimate dehydratase, the third enzyme in the quinate degradation pathway, 
the product protoctaechuate can be detected by a strong colour change in the
111
presence of ferric chloride or sodium molybdate. The amount of protocatechuate 
detectable by this method, in 96 well plate format, was investigated and expression 
studies were carried out upon the coupling enzyme dehydroshikimate dehydratase 
from Acinetobacter coalceticus.
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Chapter 1 -  Introduction
1.1 Overview
The organism Mycobacterium tuberculosis (Figure 1.1 ) is the causative agent 
of the disease tuberculosis (TB), one of the most common infectious diseases known 
to man. Current statistics estimate that around 32% of the world’s population (1.86 
billion people) are infected with M. tuberculosis of which approximately 8 million 
people will develop active TB. Of those suffering from active TB, 2 million people 
will die (WHO, 2003).
Figures from the World Health Organisation (WHO) show that the areas 
where TB is most prevalent are sub-Saharan Africa, the former Soviet Union and the 
far east (Figure 1.2), however in the developed world cases of TB are on the rise.
Figure 1.1: Electron micrograph o f a single M. tuberculosis bacillus
Despite increasing numbers of multi drug resistant strains of M. tuberculosis 
no new anti-tubercular agents have been developed in over 30 years. As we begin to 
understand the cellular, molecular and structural biology of M. tuberculosis the 
search for novel anti-tubercular agents has accelerated in response to the growing re- 
emergence of the ‘white plague’.
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Figure 1.2: Estimated world wide incidence of TB. Figure from WHO (2003)
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1.2 Tuberculosis -  from inhalation to infection
M. tuberculosis passes from host to host via inhalation of aerosols containing 
the bacilli. In most cases the bacilli are ingested by alveolar phagocytic macrophages 
and are killed or grow intracellulary in small lesions called tubercles. At this point of 
infection, a disease state referred to as primary tuberculosis, the host shows few 
obvious symptoms relating to the infection. Despite the actions of the primary 
immune response, some viable M. tuberculosis bacilli persist within the host from 
which the disease can develop.
When the infection activates, the bacilli spread from the initial point of 
infection via the blood or lymphatic system to infect other areas of the body. At this 
point the disease is referred to as post-primary tuberculosis. Despite a large number 
of bacilli being killed, the number of phagocytes killed is also significant, resulting in 
solid necrosis in the lung in which the bacilli can survive. At this point the infection 
can be arrested by the immune system although a large amount of tissue damage will 
remain. If the necrosis expands to form a cavity within the lung, large numbers of 
bacilli will multiply which can then be transmitted to the outside world via coughing. 
As the disease progresses further the solid necrosis may liquefy, resulting in a rich 
medium for the proliferation of the bacilli.
The symptoms of TB; weakness, fever, coughing and severe chest pain are a 
result of the pathological and inflammatory response. Bloody sputum is observed 
when blood vessels within the lungs become eroded and burst. In cases where 
patients are immuno-compromised, such as AIDS patients, the onset of disease is 
much more rapid, usually resulting in fatality.
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1.3.1 Current drug regimen
The current standard chemotherapeutic regimen for TB involves a 
combination of 4 drugs (Figure 1.3) over a time period of six months split into 2 
phases. The fust phase, which runs for 2 months involves the administration of 
isonizid (INH), rifampicin (RMP), pyrazanimide (PZA) and ethambutol (EMB), is 
followed by 4 months of INH and RMP only (Global Alliance for TB drug 
development, 2001).
RMP shows poor bioavailability in some multi-drug formulations and is 
prohibitively expensive for many developing countries. Therefore in some areas 
RMP is replaced by thiacetozone.
0^NHNH2 C ,K
isoniazid (INH)
N CONH^ 
Pyrazanimide (PZA)
2' '5
H
Ethambutol (EMB)
HO
OH , 
OH OH
NH
— N - N N—
OH
Rifampicin (RMP)
Figure 1.3: Frontline dugs used in the treatment o f tuberculosis
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1.3.2 Modes of action of current drugs
Both INH and EMB have been shown to inhibit the biosynthesis of the 
unique mycobacterial cell wall, which is rich in mycolic acids (Figure 1.4). INH is a 
prodrug activated by a catalase-peroxidase, katG, and its target is an enzyme 
involved in mycolic acid biosynthesis, encoded by inhA. Most INH-resistant M. 
tuberculosis isolates have mutations in katG as opposed to inhA (Slayden and Barry, 
2000). EMB appears to hi-jack the construction of arabinogalactan, a major 
constituent of the cell wall, by introducing a rogue arabinose moiety into the 
molecule (Lee et a l ,  1995).
PZA is also a prodrug, activated by conversion to pyrazanoic acid by a 
hydrolytic pyrazamidase encoded by pncA. Clinical isolates from PZA resistant 
patients often carry mutations in the pncA (Scorpio and Zhang, 1996). PZA has been 
proposed to have many specific and non-specific effects upon the bacilli.
RMP is a transcription inhibitor which has been shown to act upon the (3- 
subunit of RNA polymerase encoded by rpoB (Cole, 1996).
dimyrojTr
o
-rrptKJcxHv'»,
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Figure 1.4: Schem atic diagram of the mycobacterial cell wall. (From Tonge, 2000)
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1.3.3 Multidrug-resistance in M. tuberculosis
The re-emergence of TB as global killer has been accompanied by rising 
numbers of clinical strains resistant to at least one of the four frontline anti-TB drugs. 
In the year 2000 an estimated 3.2% (273 000) of new TB cases were classed as 
multi-drug resistant (MDR), i.e. resistant to both INH and RMP (Dye et a l, 2002). 
The prevalence of MDR TB is much greater in cases where the patient has been 
treated previously for TB infection. However, 70% of the cases of MDR TB are 
found in only 10 countries. The eost of treating MDR TB is many times greater than 
the cost of treating susceptible TB, prohibitively so in many of the developing 
countries where the disease is most prevalent.
The increase in MDR TB has been attributed to patients not taking the full 
course of drugs prescribed, resulting in ‘selection’ of stronger mutant strains of M. 
tuberculosis. To tackle this problem, directly observed therapy short course (DOTS), 
where patients are supervised by medical staff while taking the drugs, has been 
introduced in many developing countries.
1.4 Current targets in TB drug development
As opposed to modifying current anti-tubercular drugs to combat resistance, 
current TB drug development programmes are focussed upon novel targets. This 
strategy may be a ‘long road’ to the development of a drug, however, the generation 
of novel agents may prevent a rapid rise in resistance towards the drug. The 
sequencing of the complete genome of M. tuberculosis strain H37Rv (Cole et a l,
1998) has allowed the identification of novel targets for anti-tubercular drug 
development.
The structure determination of antigen 85c (Ronning et a l, 2000), an enzyme 
involved in the biosynthesis of the mycobacterial cell wall again highlighted that the
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unique nature of the cell wall provides an attractive drug target. Recent studies by 
Kuo and co-workers (Kuo et a l, 2003) have targeted the FAS-II fatty acid synthesis 
pathway, responsible for the production of pre-cursors for the cell wall, in the search 
for anti-tubercular agents which resulted in the identifieation of active compounds.
Current TB drugs are effective only against multiplying bacteria, however the 
ability of bacilli to enter a persistent state of infection where growth is minimal 
renders these drugs ineffective. While in the persistent state, M. tuberculosis bacilli 
downshift their metabolism and begin to degrade long chain fatty acids, utilising the 
glyoxylate shunt pathway (Bishai, 2000). McKinney and co-workers (McKinney et 
al, 2000) demonstrated that the enzyme isocitrate lyase (ICL) is essential for the 
survival of persistent bacilli. Structure determination of ICL (Sharma et al, 2000) has 
aided progress towards inhibition of this enzyme.
Studies by Parish and co-workers (Parish and Stoker, 2002) have shown that 
disruption of the shikimate pathway in M. tuberculosis results in the generation of 
non-viable strains of the organism.
1.5 Shikimate Pathway
The shikimate pathway, sometimes referred to as the common aromatic 
amino acid biosynthesis pathway, is a seven step pathway starting from phosphoenol 
pyruvate (PEP) and D-erythrose-4-phosphate (E4P) leading to the production of 
chorismate (Figure 1.5). Chorismate is a precursor for the biosynthesis of aromatic 
amino acids, folic acid, ubiquinone and other essential aromatic compounds (Haslam, 
1993; Bentley, 1990). The shikimate pathway is present in bacteria, fungi, protozoa 
and plants but not mammals (Bentley, 1990; Roberts et al, 1998), presenting an ideal 
target for anti-infective agents (Payne et a l, 2000). A schematic diagram of the
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pathway showing representative crystal structures of each enzyme is shown in figure 
1.5.
In bacteria each step is catalysed by a single enzyme transcribed from a single 
gene, whereas in higher plant species the activities of dehydroquinate dehydratase 
and shikimate dehydrogenase are coupled together on a bi-functional polypeptide 
(Deka et a l, 1994). In filamentous fungi such zs Aspergillus nidulans a large multi­
enzyme complex referred to as AROM incorporates the activities of dehydroquinate 
synthase, dehydroquinate dehydratase, shikimate dehydrogenase, shikimate kinase 
and EPSP synthase (Coggins et a l, 1987).
Structures of DAHP synthase (Shumilin et a l, 1999), Dehydroquinate 
synthase (Carpenter et a l, 1998), type I and type II Dehydroquinate dehydratase 
(Gourley et a l, 1999), Shikimate dehydrogenase (Miehel et a l, 2003), Shikimate 
kinase (Krell et al, 1998) and EPSP synthase (Stallings et a l, 1991) have been 
determined by X-ray crystallography.
Number Structure PDB I.D. Reference
1 DAHP synthase 1QR7 Shumilin et a l, 1999
2 Dehydroquinate synthase IDQS Carpenter et a l, 1998
3 Type I Dehydroquinase IQFE Gourley et a l, 1999
4 Type II Dehydroquinase 2DHQ Gourley et a l, 1999
5 Shikimate dehydrogenase INYT Michel et a l, 2003
6 Shikimate kinase ISHK Krell et a l, 1998
7 EPSP synthase lEPS Stallings et a l, 1991
Table 1.1 References and PDB codes for structures o f shikim ate pathway enzymes shown in 
figure 1.5
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Figure 1.5: Schematic diagram of the enzymatic steps that form the shikimate pathway. 
Representative crystal structures of each enzyme are shown where available. For key to crystal 
structures see table 1.1 on previous page.
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1.5.1 The Shikimate Pathway as a drug target
The history of the shikimate pathway as a drug target dates back to research 
by the Monsanto Corporation in the 1970’s where the compound N- 
phosphonomethyl glycine (Glyphosate^’^ ) was shown to act upon the shikimate 
pathway (Jaworski, 1972). Glyphosate went on to become a billion-dollar herbicide. 
The enzyme inhibited by glyphosate was shown to be 5-enolpyruvyIshikimate acid 3- 
phosphate synthase (EPSP synthase) (Steinrucken and Amrhein, 1980), the 
penultimate step in the shikimate pathway. Compounds that inhibit shikimate 
dehydrogenase (Bailie et a l, 1972) and chorismate synthase (Davies et al., 1994) 
have also been demonstrated to show herbicidal and anti-microbial activity.
The use of aro deficient mutants of infectious microorganisms as attenuated 
live vaccines has also been investigated. Hoiseth and Stocker (1981) demonstrated 
that disrupting the aroA gene, encoding EPSP synthase, of Salmonella typhimurium 
resulted in strains that were not only auxotrophic for the aromatic amino acids 
tryptophan, tyrosine and phenylalanine but non-virulent and effective as live 
vaccines. Mice innoculated with S. typhimurium aroA' strains that expressed antigens 
from streptococcal species were shown to produce an immune response after 
challenge with Streptococccus pyogenes, suggesting that aro' strains could be used 
as a vehicle for vaccination (Poirier et al, 1988). Aro' strains of Yersinia 
enterocolitica (Bowe et al, 1989) and Bacillus anthracis (Ivins et al, 1990) have 
also been shown to be effective as attenuated live vaccines.
In this study the enzyme 3-dehydroquinate dehydratase (dehydroquinase, 
DHQase) was studied to develop novel anti-mycobacterial compounds.
1 0
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1.6 3-Dehydroquinate Dehydratase
The enzyme 3-Dehydroquinate dehydratase (DHQase) performs the third 
reaction in the shikimate pathway, converting 3-dehydroquinate to 3- 
dehydroshikimate (Figure 1.6).
OH OH
OH OH
3-Dehydroquinate 3-Dehydroshikimate
F igurel.6  Conversion o f 3-dehydroquinate to 3-dehydroshikimate, the reaction catalysed by 
DHQase
DHQase also performs the second step of the quinate degradation pathway, 
active in filamentous fungi, allowing the use of quinate as a carbon source. The end 
point of the quinate pathway is the production of the aromatic compound 
protocatechuate (Figure 1.7)
Quinate Pathway
HO OH
^  I OH 
OH
Protocatechuate
OH 
Quinic Acid DHQase
OH 'OH
OH OH
3-Dehydroquinate 3-Dehydroshlkimate
'OH
OH
Shikimate Pathway HO OH
OH
3-Dehydroxy-D-arabino-heptulose 
-7-phospahte (DAHP)
Shikimate
Figure 1.7: Dehydroquinase is active in the shikimate and quinate pathway
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Two structurally and mechanistically unrelated forms of DHQase have been 
characterised (Gourley et al, 1999). The type I DHQase is associated exclusively 
with the shikimate pathway, where as the type II DHQase is involved with both the 
shikimate and the quinate pathways.
1.6.1 Two types of Dehydroquinase
Biophysical characterisation of the biosynthetic DHQases from E. coli (type
I) and the catabolic DHQase for A. nidulans (type II) revealed striking differences 
between the two forms (Kleanthous et a l, 1992). The type I DHQase was shown to 
be dimeric and of approximate molecular weight 56kDa in solution whereas the type 
II enzyme formed a dodecamer in solution with approximate molecular mass 
190kDa.
The type II enzyme was shown to be more stable to thermal and chemical 
dénaturation. Using differential scanning calorimetry (DSC) three discrete transitions 
were observed before the enzyme completely denatured above 82°C, whereas the 
type I enzyme denatured in a single transition at 57°C. Price et a l (1999) 
demonstrated that the three transitions observed in the thermal dénaturation of the 
type II DHQase resulted from the dissociation of the dodecamer units into trimer 
units, then into monomers before completely unfolding.
The reaction mechanisms of the two types of DHQase were shown by NMR 
studies to proceed via different sterochemical paths (Harris et a l, 1993). It was 
shown that the type I DHQase reaction proceeded via a syn elimination whereas the 
type II DHQase reaction was shown to proceed via an anti elimination.
1 2
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1.6.2 Crystal structures of type I and type II Dehydroquinases
The structures of the type I DHQase from S. typhi and the type II DHQase 
from M. tuberculosis were elucidated by X-ray crystallography (Gourley et a l,
1999). The type I DHQase monomer was shown to have an oc/p^  barrel fold, 
exemplified by the structure of triose phosphate isomerase (TIM) (Figure 1.8a), 
whereas the type II DHQase monomer was shown to posses an oc/p fold consisting of 
a central 5 stranded anti-parallel p-sheet flanked by 4 a-helices (Figure 1.8c). The 
21345 strand order of the central sheet is similar to that of flavodoxin. The type I 
dimer is a simple side-by-side dimer formed via interactions between a-helices from 
both monomers (Figure 1.8b) whereas the quaternary structure of the type II enzyme 
is dodecameric, as predicted from biophysical studies, the dodecamer possessing 
unusual 23 tetrahedral symmetry creating a tetramer of trimers (Figure 1.8d). Each 
monomer of type II DHQase therefore interacts with other subunits at two interfaces; 
one which contributes to forming the trimer unit (referred to as the trimer interface), 
and the other which forms the interaction between two trimer units (the dimer 
interface).
13
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Figure 1.8: The enzyme folds of type I and II Dehydroquinases shown in ribbon representation. 
A) type I DHQase monomer fold, B) type I DHQase quaternary structure, C) type II DHQase 
monomer fold, D) type II DHQase quaternary structure. In A and C the ribbons are coloured 
by residue number from N terminus (Blue) to C terminus (Red). In B each chain is coloured 
separately and in D each trim er unit is coloured separately.
14
Chapter 1___________________________________________________ Introduction
1.6.3 Type I Dehydroquinase
The type I DHQase from E. coli (Duncan et a l, 1986) has been studied 
extensively as the model for type I DHQase activity, however many more type I 
DHQases have been isolated including the enzymes from Salmonella typhi (Servos et 
al., 1991) and Shigella dysenteriae (Walker and Verma, 1997).
The reaction mechanism of type I DHQase proceeds via formation of a 
Schiff-base intermediate as shown in figure 1.9 (Butler et a l, 1974). The residue that 
forms the enzyme-substrate bond was suggested to be an invariant lysine identified 
by borohydride reduction (Chaudhuri et al., 1991) and NMR (Leech et a l, 1995).
The crystal structure of the S. typhi type I DHQase was determined as the enzyme- 
substrate complex confirming Lys 170 as the active residue (Gourley et a l, 1999). 
His 143 was postulated to act as the proton donor to complete the reaction, however 
no structures of type I enzymes have been determined with this residue in the 
appropriate orientation for catalysis (Deka et a l, 1992; Leech et a l, 1998).
lY
I m"
ÇH
+ HiO
Figure 1.9 Proposed reaction m echanism  for type I D HQase (Gourley et a l ,  1999)
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1.6.4 Type II Dehydroquinase
Type II deydroquinases have been identified, isolated and characterised from 
many species including M. tuberculosis (Garbe etal., 1991), Streptomyces coelicolor 
(White et al, 1990), Helicobacter pylori (Bottomley et a l, 1996) znd Aspergillus 
nidulans (Beri et a l, 1990). Crystal structures of the type II DHQases from M. 
tuberculosis (Gourley et a l, 1999) (PDB I D. 2DHQ), S. coelicolor (Roszak et a l, 
2002) (PDB I D. IGUO) and Bacillus subtilis (PDB I.D. IGQO) have been 
elucidated previously.
Analysis of the kinetic parameters of the type II DHQases previously isolated 
have shown that there are two broad classes of enzyme (Evans et a l, 2002). The type 
II DHQases from S. coelicolor (SCDHQase) and A. nidulans (ANDHQase) have 
high kcat values of -100-1000 s '\  whereas the enzymes from M. tuberculosis 
(MTDHQase) and H. pylori (HPDHQase) have low values for kcat -10 s’^
The reaction catalysed by type II DHQase was proposed to proceed via an 
EiCB mechanism (Harris e ta l,  1993). Kinetic isotope studies (Harris e ta l, 1996a) 
provided further evidence for this reaction proceeding via an enolate intermediate.
HO
OH
OH
HO. HO.
.OH
OH
+ H2OH
Figure 1.10: Proposed reaction m echanism  for type II DHQase
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Chemical modification experiments (Krell et al, 1996) identified two key 
residues required for catalysis, a hyper-reactive arginine residue and a tyrosine 
residue. This strongly suggested that the hyper-reactive arginine residue would act as 
the general base in the initial step of the reaction.
The first crystal structure of MTDHQase (Gourley et a l, 1999) revealed the 
position of the hyper-reactive arginine on a flexible loop between strand pi and helix 
a l .  The essential tyrosine residue also identified by Krell and co-workers was also 
on this loop however this section of polypeptide was disordered in the crystal 
structure. From this structure, the location of residues conserved throughout all type 
II DHQases were identified (Figure 1.11), and many were found to be at the C- 
terminal ends of the p-strands, or on loops near to the P-strands. The identification of 
a Glu-His pair near the proposed active site suggested that these residues removed 
the proton in the initial step of the reaction, with the intermediate stabilised by 
arginine residues (Gourley et a l, 1999; Price et a l, 1999).
The structure determination of SCDHQase in complex with phosphate ions 
and a transition state analogue (Roszak et a l, 2002) provided a solution to the 
reaction mechanism. The transition state analogue 2,3-anhydro quinic acid was 
identified within the area of the proposed active site, however it was orientated very 
differently from the proposed model. The Glu-His pair implicated in the proton 
abstraction step were found to coordinate the C5 hydroxyl of the ligand whereas the 
C2 carbon, the site of the proton abstraction, was located near the flexible loop 
between strand p-1 and helix a-1.
17
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Figure 1.11: A sequence alignment of type II DHQases from representative prokaryotic and 
eukaryotic organisms. Alpha helices and beta strands are represented as helices and arrows 
respectively, and beta turns are marked with TT. The first row under the aligned sequences 
highlights those amino acid residues buried at the dimer interface (cyan), and the trim er 
interface, surface 1 (green) and surface 2 (orange). Some am ino acid residues are buried at both 
the dimer and trim er interfaces (magenta) or both trimer interfaces (yellow). Key residues in 
the active site are marked with triangle in blue, those responsible for catalysis are marked with 
star in red. The sequence alignment was created using the following sequences (Organism ,
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Genebank/Swissprot accession in parentheses): AROQ_STRCO (S. coelicolor, P15474), 
AROQ_CAUCR (Caulobacter crescentus, AAK23857), AROQ_SYNY3 (Synechocystis sp. 
P73367), 3DHQ EM ENI (Emericella nidulans, P05147), A R O Q l_PSEA E {Pseudomonas 
aeruginosa  AF010322), AROQ2_PSEAE (P. aeruginosa, AAG03634), AROQ_VIBCH {Vibrio 
cholerae, AAF93471), AROQ_M YTUB (M. tuberculosis, P36918), AROQ_CLOAC {Clostridium  
acetobutylicum, AAK78875), AROQ_HELPY {Helicobacterpylori, Q48255), AROQ THEMA  
{Thermotoga maritima, Q9W YI4), AROQ_DEIRA {Deinococcus radiodurans, P54517). Open 
reading fram es (ORE) from  the incom plete genome sequences were obtained from  The Institute 
for Genom ic Research website at “ http://www.tigr.org” for PORGI (Porphyromonas gingivalis), 
GEOSU (Geobacter sulfurreducens) and BAG AN {Bacillus anthracis), from the Sanger Centre 
Sequencing Project website at “http://www.sanger.ac.uk/Proiects/” BO RPE (Bordetella 
pertussis) and YERPE {Yersinia pestis), and Prelim inary sequence data was obtained from The 
DOE Joint Genome Institute (JGI) at “http://www.igi.doe.gov/JGI m icrobial/htm l/index.html" 
for RHOSP {Rhodobacter sphaeroides) and SYNSP {Synechococcus sp.).
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The lid domain not visible in the MTDHQase structure was fully resolved in 
all the SCDHQase structures determined, thus allowing the locations of the essential 
arginine residue (Arg23) and tyrosine residues (Tyr28) to be determined. Figure 1.12 
shows the location of the transition state analogue 2,3-anhydro quinic acid in the 
active site of SCDHQase. Key conserved residues required for catalysis are shown 
and labelled for clarity.
Figure 1.12: SCDHQase with 2,3-anhydroquinic acid bound in the active site. Key residues are 
shown in stick representation and labelled for clarity.
From the SCDHQase structures determined, Roszak et al. (2002) proposed 
the following reaction mechanism for type II DHQase (Figure 1.13)
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Figure 1.13: Reaction mechanism for type II DHQase (From Roszak e t a l ,  2002)
The reaction is proposed to proceed as follows. The residue Tyr28 is de- 
protonated by virtue of its basic micro-environment in close proximity to Argll3. 
The pro-S proton is removed from the C2 carbon of dehydroquinate, with an enol 
being formed at the C3 carbonyl group, stabilised by a bound water molecule and 
Asnl6. This transition state subsequently collapses, eliminating water with the loss 
of the Cl hydroxyl group.
1.6.5 Selective inhibition of 3-Dehydroquinate dehydratase.
In order to develop a successful anti-mycobacterial agent targeting DHQase, 
the compound must not only be potent, but must also be selective towards 
MTDHQase. Work carried out using transition state analogues to determine the 
differing stereochemical paths of the type I and type I DHQase reactions illustrated 
that selective inhibition of type II DHQases over type I DHQase was possible (Harris 
et a l, 1996b; Bello et a l, 2000; Frederickson et a l, 1999). These findings make the 
type II DHQases attractive targets for drug design as many pathogenic bacteria 
including M. tuberculosis and H. pylori posses type II DHQases, whereas organisms 
that inhabit the human gut such as E. coli posses only the type I enzyme. Therefore, 
any therapy targeting type II DHQase would reduce unwanted side-effects resulting 
from disruption of the fauna of the human gut.
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Further studies developing transition state analogues to probe the active site 
of type II DHQases resulted in the generation of compounds that showed selectivity 
between MTDHQase and SCDHQase of over 2 orders of magnitude (Frederickson et 
a l ,  1999, 2002).
These results suggest that compounds may be identified that show high 
potency and high selectivity towards the type II DHQase from M. tuberculosis.
1.7 The drug discovery process
The development of a novel drug is a long and arduous path, which on 
average takes 8-10 years from target selection to final approval for sale. Each 
pharmaceutical and biotechnology company approaches the development process in 
a different manner (Ratti and Trist, 2001). Figure 1.14 shows the general ‘pipeline’ 
illustrating the discovery process.
Target 
Identification
a
T arget H it to C lim cal
Toxicology I
V alid ation  Id en tifica tion O p tim isation j Trials
■Hi—
Figure 1.14 General ‘pipeline’ diagram illustrating the stages of the drug discovery process.
1.7.1 Target Selection and Validation
The drug development target can be identified via many processes. In many 
historical cases, compounds based upon natural products that showed the desired 
biological activity were developed. In some cases, such as the mode of action of INH 
towards M. tuberculosis (developed in 1952), the target that the molecule acts upon 
was not identified until decades after the drug went on the market (Quemard et a l ,  
1995).
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With the recent explosion in genome technologies, many drug discovery 
programmes use genome based target identification processes. The use of micro­
array, or gene-chip, technology combined with proteomics techniques allows 
comparison of the transcription and translation of genes between ‘normal’ specimens 
and ‘diseased’ specimens. It is therefore possible to identify genes that are up or 
down regulated during the disease state of interest.
The validation of target involves determining whether inhibition (or 
stimulation) of target does indeed confer a change in phenotype of the specimen. In 
many cases animal models are used for this process. The validation process involves 
the development of initial m-vitro and m-vivo assays to follow the action of 
compounds upon the target using generic inhibitors of the protein class in question. 
At this stage the tractability of the target is also assessed. A target may be identified 
that appears to provide a ‘silver-bullet’ cure for a disease, however if there is no 
feasible way to analyse the inhibition of the target, then the target is less attractive 
for the development process.
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1.7.2 Hit identification to lead optimisation
Once a target has been identified and suitably validated for drug discovery, 
chemical matter must then be discovered that shows some potency towards the 
target; the hit identification process. In the current drug discovery environment, high 
throughput screening (HTS) is most commonly used to identify compounds that 
show some degree of activity against the target of choice.
In HTS an entire compound collection (typically between five hundred 
thousand and two million compounds) is run through a simple assay to determine the 
activity of each compound towards the target. The HTS process only became feasible 
within the last two decades as automation was developed to cope with such high 
numbers of sensitive assays. HTS assays are performed in multi-well plates (96, 384 
or 1536 well formats) and involve little manual intervention as all the solution 
dispensing and analysis is highly automated.
Despite the obvious advantage that HTS allows screening of all available 
compounds from a collection, there are drawbacks with the methodology. Firstly, it 
is a very expensive process, and secondly there are issues with the stability of 
compounds used in the screen. As all the compounds are dissolved in a universal 
solvent (e.g. DMSO) and are stored for sometimes significant periods of time, the 
chemical matter may have degraded and therefore may give false results (negative or 
positive).
Once hits have been identified, the types of compound that show activity are 
analysed and re-tested in a more accurate assay. Libraries of compounds based 
around the hits are then designed and tested. This determines which compounds are 
synthetically accessible, how much diversity can be added around the basic core of
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the molecule and ultimately identifies the most potent compounds that will form the 
lead series for drug discovery.
In general one or two lead series are carried forward, with one or two back up 
series. A series is a set of compounds based upon a specific core template that can be 
derivitised and to generate a chemically diverse set of compounds.
In the lead optimisation stage, the lead series is investigated in greater detail. 
Examination of the structure activity relationships (SAR) between the molecules and 
their target allows optimisation of the lead series. This involves modification of areas 
of the molecule around the core template. Assays carried out on these modified 
molecules identify which areas of the molecule can be fimctionalised to increase 
potency, increase selectivity, reduce toxicity, alter solubility etc. Once a molecule 
enters lead optimisation, many types of pharmacological assay are performed to 
monitor as many properties of the compounds as possible. Toxicity and solubility 
problems can be identified at this stage, preventing further investment in molecules 
that are likely to fail later in the drug discovery process. The DMPK (Drug 
Metabolism Pharmacokinetics) and ADMET (Adsorption, Distribution, Metabolism, 
Excretion and Toxicity) characteristics are assessed at this stage.
1.7.3 Toxicology and clinical trials
Once a compound that shows the correct potency, selectivity, DMPK and 
ADMET characteristics has been developed, full toxicological studies have to be 
carried out. Some of these toxicological studies are run as part of phase I clinical 
trials, where healthy patients take the drug to allow assessment of the 
pharmacokinetics. Phase II trials are carried out upon a small group of patients to 
allow assessment of dose levels before full scale phase III trials are entered. Phase II
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clinical trials are arguably the most expensive section of the drug discovery process, 
with each trial costing up to 300 million US dollars. In phase III studies large 
samples of patients are studied and the effect of the novel compound is compared to 
the best available drug for the chosen disease area. Placebo trials are also carried out 
as a control where patients receive a treatment that has no effect. Phase III trials are 
generally carried out using ‘double blind’ methodology, where neither the patient nor 
the doctor are aware if the preparation is the active formulation or the placebo.
If the phase III trial is successful and the drug is approved by the Food and 
Drug Administration (FDA) the new drug can be marketed.
1.8 The impact of structural biology on the drug discovery process
As a result of the recent advances in protein structure determination by X-ray 
crystallography and NMR, the use of structural information has impacted greatly at 
all stages of the drug discovery process from target validation through lead 
optimisation. The ‘traditional’ position for structural biology in the drug discovery 
process was around the hit to lead step, where structure based drug design (or 
rational drug design) was implemented. Currently, the availability of a crystal 
structure of a target can impact on the target validation stage as this allows structure 
based procedures to be implemented in the process, hence making the target more 
attractive for development.
The advent of high throughput crystallography has allowed the development 
of structure based lead development as implemented by Astex Technology Ltd, 
Cambridge, UK (Blundell et al, 2001). In this methodology small molecule 
fragments are soaked into crystals of the target protein in order to identify high
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affinity binding sites within the active site. From these fragments entire molecules 
can be constructed that show high potency.
Structural biology plays a major role during the lead optimisation stage in the 
development pipeline. As the SAR for a target is investigated, the availability of 
many crystal structures of the target in complex with compounds allows the 
rationalisation of the SAR results. This not only guides the lead optimisation towards 
probing areas of the active site not fully investigated, but may also prevent costly (in 
time and money) investigations into altering areas of the molecule that will not 
improve the potency or selectivity.
1.8.1 Structure based drug design
Structure based drug design is in general an iterative process whereby firstly 
the structure of a drug target is determined by X-ray crystallography or NMR 
spectroscopy, preferably in complex with a ligand. A detailed analysis of the ligand 
binding site is then carried out using computational methods to either suggest 
alterations to the ligand that will improve its binding affinity, or to analyse potential 
electrostatic or steric interactions within the binding site allowing the de novo 
generation of potential high affinity ligands. The modified ligands are subsequently 
synthesised and assayed for activity towards the target protein and structures 
obtained of the ligands in complex with the target. The cycle begins again with 
analysis of the new ligand -  target complexes and the procedure is followed until a 
high affinity ligand is generated.
The first example of structure based ligand design reported was the design of 
a compound to mimic diphosphoglycerate, the alosteric effector of haemoglobin 
(Beddell et a i, 1976). However, the first drug to be successfully designed using
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structural information was the antihypertensive captopril, which inhibits the 
carboxypeptidase agiotensin-converting enzyme (ACE) (Cushman et a l, 1977). In 
this case an initial lead molecule had been identified from snake venom, however 
using the crystal structure of the related protein carboxypeptidase A (Lipscomb et al, 
1968) as a guide, the lead molecule was modified to produce the blockbuster drug. 
The structure of the captopril target human ACE-I has only recently determined 
(Natesh et a l, 2003).
The most famous success of structure based design is in the development of 
the peptidomimetic HIV-protease inhibitors nelfmavir, saquinavir, ritonavir, 
indinavir and lopinavir (Greer et a l, 1994). Structure based design has also played a 
major role facilitating the design of inhibitors targeting sialidases (Taylor 1996). The 
anti-influenza drug zanamivir (Relenza) (Varghese, 1999) was developed with major 
input from structural biology.
1.9 Aims
The primary aim of the work undertaken in this thesis was to identify novel 
selective inhibitors of type II 3-dehydroquinase from Mycobacterium tuberculosis 
using structure based ligand design methods. Large differences in inhibitor affinities 
and kinetic parameters have been observed between different type II 3- 
dehydroquinases. A key aim was therefore to determine the 3D structure of the type 
II 3-dehydroquinase from Helicobacter pylori. This structure has been used to aid the 
structure based ligand design, providing insight into the differing affinities for 
ligands shown by the various type II 3-dehydroquinases.
A secondary aim of the project was to develop a novel assay for 3- 
dehydroquinase activity that is amenable to high throughput screening.
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The specific objectives were therefore:
1) Over-express and purify type II 3-dehydroquinases from M. tuberculosis 
and H. pylori.
2) Solve the structure of type II 3-dehydroquinase from H. pylori by X-ray 
crystallography in complex with a specific inhibitor identified from High 
Throughput Screening (HTS)
3) Analyse the available crystal structures of type II 3-dehydroquinases from 
M. tuberculosis, Streptomyces coelicolor and H. pylori to determine factors 
affecting ligand specificity.
4) Create pharmacophore models for type II 3-dehydroquinase from M. 
tuberculosis against which a compound library will be searched to identify 
potential inhibitors.
5) Screen compounds identified from the in silico screen for activity against 
type II 3-dehydroquinase from M. uberculosis.
6) Develop a high throughput assay for 3-dehydroquinase activity.
Figure 1.15 illustrates the process for structure based ligand design used in this 
thesis. The diagonal boxes illustrate at which stage of the process the studies upon 
each enzyme are at the outset of the project.
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Figure 1,15: Flow chart illustrating the structure based process to followed in this thesis. 
Diagonal boxes show where each enzyme entered the process.
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Chapter 2 -  Materials and Methods
2.1.1 Chemicals
Chemicals and biochemicals unless otherwise stated were analytical grade or 
the highest available. Unless otherwise stated all chemicals were obtained from the 
Sigma Aldrich Company Ltd., England or Fisher Scientific, UK. Agarose was 
obtained from GIBCO BRL Life Technologies, Scotland. EDTA free Protease 
Inhibitor cocktail tablets were obtained from Boehringer Mannheim, UK.
2.1.2 Proteins and Enzymes
Restriction enzymes and their appropriate buffers were obtained from 
Promega Corporation, England.
Pfu DNA polymerase was obtained from Promega Corporation, England, VENT 
DNA polymerase was obtained from New England Biolabs Incorporated, England, 
Tag DNA polymerase was obtained from Sigma Aldrich Company Ltd., England and 
from Invitrogen, UK.
2.1.3 Oligonucleotides
Oligonucleotides were obtained from either GIBCO BRL Life Technologies, 
Scotland, Cruachem Ltd., Scotland or MWG Biotech,Germany.
2.1.4 Chromatography Media
Amylose resin was obtained from New England Biolabs Ltd., England. Q- 
Sepharose was obtained from Amersham Pharmacia, England and Ni-NTA resin 
purchased from Qiagen, England. Amersham Pharmacia XK-16/20 columns were
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used to pack all media. Pre-packed Superdex-200 and Mono-Q columns were 
obtained from Amersham Pharmacia, England.
2.2 Media and Supplements
2.1 Media for Bacterial Growth
E. coli strains BL21(DE3)pLysS and DH5a were routinely cultured in 
Miller’s Luria Bertani Broth (LB) obtained from Sigma Aldrich Company Ltd., 
England. Solid media was prepared by addition of 1.2% bacto agar (Difco, USA) to 
liquid LB.
2.2.2 Antibiotics
Antibiotics were used at the following concentrations in all experiments. 
Ampicillin- 100p,g/ml 
Tetracycline -  12.5|Xg/ml 
Chloramphenicol - 34|ig/ml 
Kanamycin - 25|xg/ml
i) Ampicillin
A lOOmg/ml stock solution was prepared using sterile water, and the 
solution filter sterilised by passage through a 0.22p.m filter. 1ml aliquots 
were stored at -20°C. Growth media was allowed to cool to 55-50°C 
before addition of Ampicillin to a final concentration of 100p.g/ml
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ii) Tetracycline
A stock solution of 12.5mg/ml was prepared in bulk ethanol and stored at 
-20°C in the dark. Growth media was allowed to cool to 55-50°C before 
addition of antibiotic to a final concentration of 12.5|ig/ml
iii) Chloramphenicol
A stock solution of 34mg/ml was prepared in bulk ethanol and stored at - 
20°C. Growth media was allowed to cool to 55-50°C before addition of 
antibiotic to a final concentration of 34|ig/ml
iv) Kanamycin
A stock solution of Kanamycin was prepared at 50mg/ml in sterile water. 
Solution was filter sterilised by passage through a 0.22|xm filter and 
stored at room temperature. Growth media was allowed to cool to 55- 
50°C before addition of antibiotic to a final concentration of 25p.g/ml.
All media and plates were stored at 4°C and used within 4 weeks of 
preparation.
2.2.3 Isopropyl-P-D-thiogalactopyranoside (IPTG)
A stock solution was prepared at IM concentration and filter sterilised by 
passage through a 0.22|im filter. 1ml aliquots were stored at -20°C
2.3 General Molecular Biology Methods
General molecular biology methods were carried out as described in 
Sambrook er. a/. ,(1989)
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2.4 Bacterial strains and cloning vectors
2.4.1 Storage of Bacterial Strains
Bacterial strains were stored as glycerol stocks. These stocks were prepared 
by addition of 60% (v/v) glycerol/water to bacterial cultures to a final concentration 
of 30% (v/v). Stocks were stored at -80°C. Cultures were temporarily stored on agar 
plates at 4°C for up to 4 weeks.
2.4.2 Bacterial strains
The bacterial strains and plasmids used in this thesis are listed in tables 2.1 
and 2.3.
2A 3  Growth of Plasmid containing E. coli
E. coli cells containing plasmids of interest were grown on LB media 
supplemented with the appropriate antibiotic to select for cells containing the correct 
plasmid.
2.4.4 Growth of cells and isolation of plasmids
Plasmid DNA was isolated by overnight growth of a 3ml LB culture (with 
appropriate antibiotics), inoculated with a single colony of the correct strain. Cells 
were grown overnight at 37°C with shaking. Plasmid isolation was performed either 
using the method if Bimboim and Dolly (Sambrook at at, 1989) or using the Qiaprep 
Spin mini-prep kit.
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2.4.5 Transformation protocol
Unless otherwise instructed by manufacturers protocols the following 
transformation methodology was used. Chemically competent cells were allowed to 
thaw on ice for 30 minutes prior to use. 2\i\ of plasmid DNA was added to pre­
cooled eppendorf tube and 20|il of competent cells added with gentle mixing. The 
cells were left on ice for 30 minutes before heat shocking at 42°C for 40 seconds.
The cells were again placed on ice for 2 minutes before addition of SOpl of SOC 
medium (LB medium + 2.5mM KCl, lOmM MgCli, 20mM Glucose) (Invitrogen) 
warmed to 37°C. Cells were incubated at 37 °C with shaking for 60 minutes before 
being plated onto LB agar plates.
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Bacterial strain Genotype Reference
Escherichia coli DH5a F(j)80d/acZAM15 recAl endAl gyrA96 
thi-1 hsdR17(X]^m.] )^ supE44 relAl deoR 
à(lacZY-argF)\J 169
Hanahan, 1985
Escherichia coli 
BL21(DE3)pLysS
F  ompT hsdSBTBjTriB dcm galXDE3 
pLysS Cm”^
Studier and 
Moffat, 1986
Escherichia coli 
NovaBlue Singles
EndAl hsdR17(rKi2 MKi2^) supE44 thi-I 
recAl gyrA96 relAl lac F'[proA^B^ lacP 
ZAM15::TnlO (Tc^)]
Novagen
Table 2.1 Bacterial Strains used for general cloning purposes
Plasmid Antibiotic resistance Reference
pMAL-c2x Ampicillin MB? fusion expression plasmid 
New England Biolabs
p-T7Blue-3 Ampicillin/Kanamycin Blunt cloning vector 
Novagen
pET-15b Ampicillin N-term 6xHis tag expression plasmid 
Novagen
pCR®2,l-
TOPO®
Ampicillin/Kanamycin TOPO cloning vector 
Invitrogen
Table 2.2 Plasmids used for general cloning
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2.5 Manipulations of DNA
2.5.1 Restriction digests
Digests contained 3-10|ig of DNA with 1-2 units of each restriction 
endonuclease in the appropriate reaction buffer. Digests were carried out at 37°C for 
one hour.
2.5.2 Gel electrophoresis
Gel electrophoresis of DNA samples was performed using 1% agarose (w/v) 
(Gibco-BRL) gel in IxTAE buffer (Sigma) containing approximately 0.5pg/ml 
ethidium bromide. Samples were loaded in 5x Nucleic Acid Electrophoresis Stain 
(Biorad). Standard molecular weight markers, such as Ikb ladder (Promega), 
molecular weight markers XIV and VI (Boehringer), were used on all gels to identify 
the size of separated bands. Gels were run at room temperature in the Mini-Sub GT 
(Biorad) gel tank at 80mA until the sample stain neared the end of the gels. DNA 
bands were visualised by viewing under UV light.
2.5.3 Gel Purification of DNA fragments
DNA fragments were purified by electrophoresis on 1% low melting point 
agarose gels. Bands of interest were excised from the gel and DNA purified using 
either QIAquick or QIEx II gel extraction kits (Qiagen)
2.5.4 DNA Ligation
Ligation reactions were carried out using Ipl T4 DNA ligase (Promega) and 
l|il of the appropriate buffer along with various ratios of vector:insert DNA (1:1, 2:1, 
1:2) to a final volume of 20|il. Reactions were carried out at 16°C for 16 hours.
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2.6 Cloning by Polymerase Chain Reaction (PCR)
2.6.1 Primers for PCR
PCR primers were designed to incorporate restriction sites to facilitate easier 
cloning of the amplified DNA fragments into new vector systems. Primer 
oligonucleotides were ordered from MWG Biotech, Germany, and stored as lOOpM 
stock solutions in water. A list of all primers used is given in Table 2.3.
38
Chapter 2 Materials and Methods
I
g
(U f
i
<o
Î
U-1
%
I
I
I S
. ' â
I Ioq q
iI  ^cd
i I
Ü o
W)
«
i
U~)
II
I Î
Ü qj
.o
1) 1—1 
■3 tH 
%
IQ
Û5 O)
^1
S ÏC
i f
Ü o
Is
I
o W
îS
I CL,IU
o
l iOQ B 
.B 
U
s  »
i f
Ü o
Ic/5
I
a
g
i
5
I
u
I 
0
0^
cn
§
g
s
m
i
g
g
g
I
w
I
§
§
vn
g
g
a
g
B
g
g
i
§
Ü
<
i
;
wn
cn
i
ens
i
a
g
g
0
5
a
g
a
g
i
U
un
i
I
S
i
g
i
§
8
P
un
S
üu
g
E
S
t
g
aî
I
0
«o en
a
E
g
Ei
aa
E
;
un
en
g
1 Ik %en Q pqg %U UH cy cy
Table 2.3.1 Oligonucleotides used for molecular cloning -  PCR primers
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Oligonucleotide Sequence Usage
HPSEQl 5’-AAT AAC AAC AAC CTC GGG 
ATC-3’
Sequencing pMAL-haq 
from 5’ region of 
pMAL-c2x vector
HPSEQ2 5 -CGA CGT TGT AAA ACG ACG 
GCC-3’
Sequencing pMAL-haq 
from 3’ region of 
pMAL-c2x vector
Table 2.3.2 Oligonucleotides used for molecular cloning -  Custom sequencing 
primers
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2.6.2 PCR reactions
PCR reactions were carried out using Pfu DNA polymerase (Promega) unless 
otherwise stated. Reactions were carried out in 0.2ml PCR tubes, using a Biorad 
Gene Cycler. Primer mixes consisted of the primers required for PCR at a 
concentration of 10|iM. As DNA from M. tuberculosis has a high G/C content, 
DMSO was added to the PCR reaction mixes to a final concentration of 10% (v/v) 
The PCR reaction mixes were prepared as follows:
5|il lOx Pfu reaction buffer (200mM Tris-HCl pH8.8, lOOmM KCl,
lOOmM (NH4)2S0 4 , 200mM MgS0 4 , 1% Triton-XlOO, Img/ml BSA) 
Ijil dNTP mix (dATP, dCTP, dGTP and dTTP,10mM stock of each)
5|il Primer mix (Both Oligonucleotide primers at 10|iM concentration)
2|xl Template DNA 
1 -3jil MgS0 4  ( 1 OOmM stock)
5|il DMSO
Water to 49|xl
The mix was incubated at 94°C for 5 minutes before l|il of polymerase was 
added to the reaction.
The following temperature profile was used for 30 cycles in the gene cycler: 
30 seconds @ 94°C
30 seconds @ 65°C -  annealing temperature of primers 
60 seconds @ 72°C -  extension of amplified strand 
A final elongation step of 5 minutes at 72°C was performed at the end of the 
amplification reaction to ensure that all amplified material was full length. Primer 
annealing temperatures were those determined theoretically by the supplier.
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2.6.3 Cloning Methods
2.6.3.1 Blunt Cloning
Cloning of PCR product into an acceptor vector by blunt ended ligation was 
carried out using the Perfectly Blunt® Cloning kit form Novagen. Blunt ended 
cloning allows the use of high fidelity proof reading polymerises in the initial PCR 
amplification, therefore reducing the possibilities of PCR errors. The PCR product is 
treated with ‘End conversion mix’, which removes any overhanging bases and 
phosphorylates the DNA at the 5’ termini. The acceptor vector is purchased pre­
linearised and de-phosphorylated, allowing ligation of the insert and vector using T4- 
DNA ligase. The resulting vector is then transformed into NovaBlue Singles 
competent cells, and plated out onto solid media.
2.7.2 TOPO® Cloning
TOPO cloning is a method by which PCR products can be directly inserted 
into a plasmid vector in the absence of DNA ligase. In this project the TOPO TA kit 
from Invitrogen was used. The PCR is carried out with Tag polymerase, which adds 
a single deoxyadenosine to the 3’ end of the DNA strand. The linearised vector 
supplied has a single deoxythymidine residue at the 3’ end, thus allowing the ligation 
of the PCR product to the vector.
The linearised vector is bound to molecules of topoisomerase I via the 3’ 
hydroxyls, which are covalently bound to Tyr-274 of the enzyme. This 
phosphotyrosyl bond is attacked by the 5’ hydroxyl of the PCR product, releasing the 
topoisomerase.
The PCR amplification is carried out with Tag polymerase and the product 
gel purified. The amplified gene is then incubated with the TOPO-vector at room
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temperature allowing the ligation to take place, with the resulting vector transformed 
into chemically competent E. coli DH5a and plated out onto solid media
2.7 Over-expression of recombinant type II Dehydroquinases
Four 25ml cultures of LB + ampicillin (lOOpg/ml) were inoculated with 
either a freshly picked colony from an agar plate or directly from a glycerol stock. 
These were grown overnight with shaking at 37°C and used to inoculate 4x 500ml 
LB + ampicillin (100|ig./ml) cultures. The 500ml cultures were grown at 37°C with 
shaking until the ODôoo was between 0.4 and 0.6. IPTG was added to a final 
concentration of 0.8mM to induce expression of the target protein, and the cultures 
grown for a further 4 hours. Cells were harvested by centrifugation at 4000g for 20 
minutes (Sigma 4K 15 centrifuge, 11150 rotor, 4x 13350 buckets). Cells were 
resuspended in phosphate buffered saline (PBS) and collected in 50ml culture tubes. 
Cells were again pelleted by centrifugation at 4000g for 20 minutes (Sigma 4K 15 
centrifuge, 12690 rotor) and stored at -20°C.
Cells were broken by passage through a French pressure cell (2x950psi). Cell 
debris was removed by centrifugation 8000g 60 minutes (Sigma 4K 15, 12690 rotor) 
and the crude lysate passed through a sterile 0.22|im filter. The resultant supernatant 
was removed and used in subsequent purification steps.
2.8 Purification
All type II DHQases studied in this thesis were purified by liquid 
chromatography using the Fast Protein Liquid Chromatography (FPLC) system 
(Amersham Pharmacia). The first step in purification was affinity chromatography
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with further purification achieved by ion exchange chromatography or size exclusion 
chromatography
2.8.1 Purification by Affinity Cbromatograpby
2.8.1.1 MBP affinity cbromatograpby
The MBP domain of the MBP-DHQase fusion peptides show high affinity 
towards Amylose resin (New England Biolabs), which mimics the natural substrate 
maltose. The crude lysate is passed through the amylose column, immobilising the 
MBP-DHQase fusion.
The column was equilibrated with buffer A (50mM Tris-HCl pH 7.8, 
lOOmM NaCl, ImM EDTA, ImM DTT), before the crude lysate, also in buffer A, 
was passed through the column, which was washed until Aigo reached the baseline 
level. The fusion peptide was eluted with buffer A + lOmM maltose. The maltose 
competes with the amylose for binding to the MBP, releasing the MBP-DHQase 
fusion.
2.8.1.2 Ni-NTA affinity cbromatograpby
Poly-histidine tags show high affinity for nickel ions, therefore affinity 
chromatography can be carried out by passage of the sample through a nickel 
charged metal chelate column. The media used was Ni-NTA Superflow (Qiagen). 
Cell pastes were re-suspended in buffer A (20mM Tris-HCl pH8.0, 3OOmM NaCl (to 
prevent non-specific charged interactions), 20mM Imidazole), lysed and the 
supernatant isolated. The column was equilibrated with buffer A and the lysate was 
passed through and washed until the A280 of the flow through reached baseline level. 
A second wash step was carried out with buffer B (20mM Tris-HCl pH 8.0, 3OOmM
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NaCl, 75mM Imidazole) before elution of the tagged DHQase with buffer C (20mM 
Tris-HCl, 300mM NaCl, 200mM Imidazole).
As the project progressed it became apparent the high imidazole 
concentration made the protein unstable, therefore 3ml fractions of the eluted protein 
were collected in tubes containing 3ml lOmM Tris-HCl pH7.0, ImM EDTA. The 
EDTA was present to prevent aggregation of protein around Ni ions flushed from the 
column matrix.
2.8.2 Ion exchange chromatography
As a second purification step, to remove MBP contaminants from DHQase 
expressed as MBP-DHQase fusion peptides, or to further purify DHQase expressed 
with an N-terminal 6x His tag, ion exchange chromatography was carried out using 
Q-Sepharose anion exchange resin (Amersham Pharmacia). The protein was dialysed 
into buffer A (50mM Tris-HCl pH 7.5, lOOmM NaCl, ImM EDTA) before being 
applied to the column (previously equilibrated with buffer A). The column was 
washed with buffer A until A280 reached baseline level. A linear gradient was set up 
between buffer A and buffer B (50mM Tris-HCl pH 7.5, 500mM NaCl, ImM 
EDTA) to run at 1.5 ml/min for 60 minutes. The pure DHQase was eluted from the 
column near the mid-point of this gradient around 250mM NaCl.
2.8.3. Size exclusion chromatography
To separate DHQase from MBP contaminants, size exclusion 
chromatography was carried out using a Superdex-200 column (Amersham 
Pharmacia). The column was equilibrated with 150ml 50mM Tris-HCl pH 7.8, 
lOOmM NaCl, ImM EDTA, before a 1ml concentrated sample of DHQase/MBP
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mixture was loaded. The column was washed with 150ml of equilibration buffer, at a 
flow rate of 0.5ml/min. Peaks were observed for DHQase, MBP and MBP-DHQase 
fusion.
2.9 Protein quantification and analysis
2.9.1 SDS-PAGE
Sodium dodecylsulphate poly acrylamide gel electrophoresis (SDS-PAGE) is 
a method by which proteins can be separated on the basis of mass, allowing rapid 
analysis of protein solutions to determine the presence, or purity, of a target protein. 
The Hoefer Scientific Mighty Small system was used for all SDS-PAGE. The system 
was assembled according to the manufacturers instructions and 15% resolving gel 
solution and stacking gel solutions prepared (Sambrook et al., 1989).
Analysis of the elctrophoretic profiles was performed by staining the gel with 
Coomassie Brilliant Blue (CBB R-250, Sigma Aldrich Company Ltd., England). The 
gel was incubated in 100 ml staining solution (0.1% CBB-R250, 50% (v/v) ethanol) 
for 20 minutes, before being rinsed with water. The background stain was removed 
by immersion of the gel in 200ml water heated to around 80°C for 10 minutes.
2.9.2 Dynamic Light Scattering
To determine the fraction of poly dispersity within a protein sample, dynamic 
light scattering was performed using the Dynapro-801 system (Protein Solutions). 
The protein sample (200-400|il) is passed into the sample chamber through a 0.1 jim 
sterile filter. In the chamber the sample is illuminated with a laser, and the scattered 
light detected by a photo diode array. The software calculates a hydrodynamic radius 
(R h) for the sample, which is used to estimate the molecular weight of the protein
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based upon a globular model. The instrument also indicates if the sample is mono or 
poly-disperse by mono-modal curve fit analysis.
2.9.3 Protein concentration calculation using Absorbance at 280nm (A280)
The concentration of a protein sample in solution can be calculated using the 
Beer-Lambert equation (Equation 2.1)
A = 8 c1
Equation 2.1: Beer-Lam bert law facilitating the calculation o f the concentration of a protein (c), 
when the absorbance (A), sample path length (!) in cm and m olar extinction coefficient (e) are 
known
Protein molecules absorb radiation in the near UV region (-280nm) due to 
presence of tryptophan, tyrosine, and to a lesser extent cysteine and phenylalanine 
residues. Calculation of the molar extinction coefficient {€) at 280 nm is based upon 
the numbers of these residues within the protein (Equation 2.2) (Pace et ai, 1995). 
This allows a quantative measurement to be made of the protein concentration.
[l280ny + 5960nW + 120nC]
Mwt
Equation 2.2: Calculation o f m olar extinction coefficient (e, cm'^) at 280nm  when the
num ber o f tyrosine (nY), tryptophan (n W ), cysteine (nC) residues and the molecular weight 
(M wt) are known
All spectroscopic measurements were carried out using a Perkin Elmer 
Lambda 800 UV/vis spectrophotometer.
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2.10 Standard Dehydroquinase Assay
To determine the activity of a DHQase sample, a simple standard assay can 
be carried out (White, 1990). The natural substrate 3 -dehydroquinate is added to the 
protein sample, and the rate of conversion of this to 3-dehydroshikimate is followed 
by the increase in absorbance at 234nm. 3-dehydroshikimate absorbs light at 234nm 
due to the conjugated system between Cl and the C3 carbonyl (red in figure 2.1).
HO.. ^CO ,- T'
I I
ÔH ÔH
Figure 2.1: Formation o f conjugated system in the conversion o f 3-dehydroquinate to 3- 
dehydroshikim ate
The standard assay is performed in 1ml quartz cuvettes (Helma), using 50mM 
Tris-Acetate buffer pH 7.0, and 20jig of substrate. Assays were carried out using a 
Jasco V560 spectrophotometer, and data analysed with Origin 5.0 (MicroCal Corp.)
2.11 Inhibitors of type II Dehydroquinase
The inhibitors of type II dehydroquinase used in this project are shown in 
table 2.4. Compounds FAl, F A3 and FA4 were obtained from Dr. Chris Abell, 
University of Cambridge. AH9095, GR78752X and GR122160X were identified 
from an in-house high throughput screen (HTS) at GSK.
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Table 2.4 Inhibitors of type II Dehydroquinase used in this thesis
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2.11.1 Synthesis of GR122160X
The compound GR122160X was identified from high throughput screen 
(HTS) against HPDHQase, carried out at GSK. No sample was available from the in- 
house compound library, or from any chemical company. The monomer 5-Methyl- 
[l,3,4]thiadiazole-2-thiol was available from Sigma Aldrich (cat 18,857-3) and 
formation of a di-sulphide link between two thiol groups was carried out. Many 
reviews of thiol chemistry are available (Procter 2001) and the procedure of 
Noureldin et al. (1998) was identified as a simple route to form the required di­
sulphide (Figure 2.2).
N N N------ N N------ N
K M n 0 4 / C u S 0 4 .5 H 2 0
H3C s  SH CH2CI2 H3C S------- S S CH3
Figure2.2: Oxidation of 5-M ethyl-[l,3,4]thiadiazole-2-thioI to form GR122160X  
A 1:1 (w/w) mixture of KMn0 4  and CUSO4.5H2O was used as the oxidant, and was 
prepared by grinding until homogenous. 0.8g of the oxidant and 2.5mMoles of the 
thiol were added 20ml DCM in 50ml round bottomed flask. The heterogeneous 
mixture was stirred at room temperature overnight, and the contents of the flask 
filtered through celite (Fluka) and washed with DCM (2x10ml) and ethanol (10ml). 
The product was isolated by evaporation under reduced pressure, and the product 
analysed by mass spectroscopy. A 78.8% yield was obtained as determined by mass.
2.12 Crystallisation of biological macromolecules
There are many current texts and publications available upon the methodolgy 
of crystallisation of biogical macromolecules (McPherson, 1999, Ducruix and Giege 
1992, Bergfors 1999).
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2.12.1 Crystallisation by sitting drop vapour diffusion
All crystallisations were performed by the sitting drop vapour diffusion 
method using 24-well Cryschem Plate™ (Hampton Research Ltd.) at room 
temperature unless otherwise stated. The reservoir chamber was filled with 800|il of 
the precipitant solution, and a Ipl aliquot of the concentrated protein solution added 
to the crystallisation well. A Ijil aliquot of the precipitant solution was then added to 
the protein drop, thus reducing the respective concentrations of the solutions by half. 
The plates were sealed with Crystal Clear sealing tape (Hampton Research Ltd.).
This ensured that the crystallisation drops were within a sealed system, allowing 
slow equilibration with the excess reservoir solution by vapour diffusion, bringing 
the drop to the point of supersaturation. Crystal trays were checked for crystals 2 
days, 4 days, 7 days and 14 days after they were prepared.
2.12.2 Crystallisation Screens
Various commercial and in-house sparse matrix crystallisation screens were 
used in this project (Table 2.5). Sparse matrix screens sample a wide portion of 
crystallisation space, therefore identifying précipitants, buffers and additives, at 
approximate concentrations and pH that may facilitate crystal growth. From these 
initial conditions, variation of precipitant, buffer and additive concentrations, and 
pH, allow finer sampling of crystallisation space to identify conditions that yield 
diffraction quality crystals. In addition to sparse matrix screening, a grid screen, 
sampling ammonium sulphate concentration and various pHs, was also employed 
(Table 2.6)
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Screen No. Conditions Source/Reference
M Screen 114 In-house
N Screen 60 In-house
Magic 50 50 Jancarik and Kim, 1991
PEG Footprint Screen 24 Stura, 1991
Crystal Screen I 48 Hampton Research Ltd.
Crystal Screen II 48 Hampton Research Ltd.
Wizard I 48 Emerald Biostructures
Wizard II 48 Emerald Biostructures
Cryo I 48 Emerald Biostructures
Cryo II 48 Emerald Biostructures
Table 2.5: Sparse m atrix crystallisation screens
2.0M AS 1.8M AS 1.6M AS 1.4M AS 1.2M AS l.OM AS
O.IM 
Acetate 
pH 5.5
O.IM 
MOPS 
pH 6.5
O.IM 
HEPES 
pH 7.5
O.IM 
Tris-HCl 
pH 8.5
Table 2.6: Ammonium Sulphate Grid Screen
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Chapter 3- Wet lab results
3.1 Cloning, expression and purification of type II DHQases as Maltose Binding 
Protein Fusion
The published purification strategy for type II DHQases involved five steps 
which were uneconomical and time consuming, therefore a new strategy utilising 
affinity chromatography was investigated. To over-express, and purify, type II 
DHQase, the pMAL expression system from New England Bioloabs was used 
initially. This system involves expression of the target protein with an N-terminal 
Maltose Binding Protein (MBP) tag (Maina et al., 1988). This tag can act as a folding 
leader for proteins that fail to adopt native conformations under over-expression 
conditions (Kapust and Waugh, 1999), and, for our purposes as an affinity tag for 
purification. Located in the linker region between the MBP and the target protein is a 
Factor Xa protease cleavage site for removal of the MBP tag.
The aroQ gene that encodes the type II DHQase in H. pylori had previously 
been cloned from genomic DNA (Bottomley et al., 1996), and subcloned into pUC- 
18 as a Hindlll - S a d  insert. These restriction sites were unsuitable for direct sub­
cloning of the gene into the pMAL-c2x vector as the restriction sites were 
incompatible, therefore H. pylori aroQ was amplified from the pUC-18 vector by the 
Polymerase Chain Reaction, with the addition of a 5’ BamHI and a 3’ Hind III 
restriction site.
The aroD gene from M. tuberculosis had previously been cloned into pMAL- 
c2x by our collaborators at GSK.
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3.1.1 PCR amplification and sub-cloning of aroQ from H. pylori
Using the H. p_y/on_aroQ-pUC18 vector as template DNA, aroQ  was 
amplified using 30 cycles of PCR as outlined in section 2-6, with the oligonucleotide 
primers DHPF and DHPR (Table 2.3), using the proofreading polymerase Pfu 
(Promega). Analysis of the PCR reaction was carried out on a 1% agarose gel stained 
with ethidium bromide, using the BVI DNA ladder (Boehringer) as a marker.
M 1 2
I
! •
1033bp ________
5i7bp
Figure 2.1: Agarose gel showing result of PCR amplification of H. pylori aroQ. M -marker BVI,
I -  lOpJ PCR product, 2- lOpJ PCR Product 1:10 dilution
From the gel it can be seen that the PCR produced a single section of DNA 
slightly greater than 517bp in length. The expected length of the PCR product is 
530bp. The PCR product was washed using the QIAquick kit (Qiagen) using the 
manufacturer instructions, and eluted in 50pl of water.
Both the clean PCR product and pMAL-c2x were double digested for 4 hours 
at 37°C using BamHI and H indlll (Promega) and the products isolated by gel 
purification using the Qiaquick gel extraction kit (Qiagen). H. pylori aroQ  was 
cloned into pMAL-c2x by ligation with T4 DNA ligase (Promega) to generate the 
vector pMAL-haQ. The ligation reactions were incubated at 16°C overnight. The 
vector pMAL-haQ was transformed into chemically competent E. coli D H 5a cells
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(Life Technologies) and plated onto LB-Agar plates containing 100|ig/ml ampicillin. 
The plates were incubated overnight at 37°C and the number of colonies noted.
3.1.2 Identification of positive pMAL-haQ clones
Colonies were picked from the LB-Agar plates using clean sterile pipette tips 
and dotted onto fresh LB-Agar/Ampicillin plates then the remaining material on the 
tip was solubilised in lOpl sterile water and heated to 99°C for 10 minutes. l|il of the 
heated mixture was used as template DNA for PCR reactions carried out as described 
previously. The product of each PCR reaction was run on a 1% agarose gel stained 
with ethidium bromide. Successful clones were identified as those that gave PCR 
products corresponding in size to H .pylori aroQ.
Successful clones were grown overnight at 37°C in 5ml LB/Ampicillin and 
plasmid DNA extracted using the Qia-quick mini-prep kit (Qiagen).
Oligonucleotides were designed for DNA sequencing reactions incorporating the 5’ 
and 3’ ends of H. pylori aroQ and the respective flanking sequences in the pMAL- 
c2x sequence (Table 2.3). All successful clones were shown by sequencing to be in 
the correct reading frame for expression and no errors had been incorporated in the 
PCR process.
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3.1.3 Over-expression of H. pylori and M. tuberculosis DHQase as a MBP fusion
The vectors pMAL-haq and pMAL-mtd were transformed into chemically 
competent E.coli BL21 DE3 (pLysS) cells (Invitrogen) for over-expression. To 
maximise the yield of target protein per preparation, expression studies were carried 
out to determine the optimal incubation time following induction with I PTC. A time 
course was followed using induced cells, and non-induced cells as a control. 
Typically the time course ran, from the point of inoculation of the culture with IPTG, 
for three hours. The levels of protein expression were monitored by SDS PAGE (Fig. 
2 .2)
M 0- 0+ 1- 1+ 2- 2+ 3- 3+ M
55kD
-  — MBP-MTDHQase
♦ ^  '
T
Figure 2.2 SDS PAGE time course of M BP-M TDHQase expression after induction with ImM  
IPTG, M- molecular weight m arker, 0 -  pre induction, 1 - 1  hour after induction, 2- 2 hours 
after induction, 3 - 3  hours after induction, - control, + IPTG added. All lanes have lOpJ of 
sam ple loaded
The pairs of tracks on the gel shown in figure 2.2 show the level of protein 
expression over a 3 hour time course. Samples induced with IPTG are indicated (-H or 
-) with the corresponding incubation time in hours
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3.1.4 Purification of MBP-DHQase fusion peptides
Following over-expression, each MBP-DHQase fusion was purified using a 
50ml amylose affinity column as described in section 2.8.1 to yield protein typically 
greater than 95% pure as monitored by SDS PAGE (Figure 2.3)
M 1 2
66kD
55kD
. MBP-HPDHQase
I »
r
Figure 2.3 SDS PAGE of M BP-HPDHQase purification. M- molecular weight marker, 1-crude 
lysate, 2- column wash, 3- maltose eluted fraction M BP-HPDHQase. Lanes 1-3 have lOpJ of 
sample loaded
Parallel experiments were carried out analysing expression of the M. 
tuberculosis construct (results not shown).
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3.1.5 Factor Xa Cleavage of MBP-DHQase fusion peptides
To determine the optimal ratio of fusion peptide to factor Xa required for 
efficient cleavage of the MBP-DHQase fusion peptides, different ratios of 
protein:protease were incubated overnight at 4°C using MBP-MTDHQase. The 
results were analysed by SDS PAGE (Figure 2.4).
M ‘ 1 2 3 ■ 4 5 ~ 6 -M
55kD
36kD
MBP-MTDHQase 
  MBP
MTDHQase
Figure 2.4 SDS PAGE showing results o f MBP-M TDHQase cleavage with Factor Xa. M- 
m olecular weight marker, (1) M BP-M TDHQase fusion, (2) 1000:1 peptide:protease, (3) 500:1 
peptide:protease, (4) 100:1 peptide:protease, (5) 50:1 peptide:protease, (6) 10:1 
peptide:protease. All lanes have lOpJ sample loaded
The experiment shows that a 50:1 protein:protease ratio was optimal for 
overnight cleavage at 4°C
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3.1.6 Separation of DHQase from MBP
The manufacturers protocol for separation of the target protein from MBP 
following cleavage suggests re-loading the mixture of proteins onto the Amylose 
resin, allowing the MBP to bind to the column and the target protein to flow through.
When this was attempted with the MTDHQase/MBP mixture the flow through 
fractions contained both proteins. The most likely reason for this was that the MBP 
fusion peptide was eluted from the amylose resin using maltose, which has been 
shown to be difficult to remove from MBP (Silhavy et al., 1975). The retention of 
maltose by the MBP prevents binding of MBP to the Amylose resin. To overcome 
this problem three purification strategies were investigated. Firstly separation by size 
exclusion chromatography, secondly ion exchange chromatography and finally heat 
shocking the mixture to take advantage of the heat stability of type II DHQase. The 
results were analysed by SDS PAGE (Figure 3.5).
.  M C/ S 1 2 3 4 5
55kD  ^  ^ _________________________________  MBP-MTDHQase
36kD
MBP
14kD -----► ^  < -----  MTDHQase
Figure 3.5a Separation of M BP/M TDHQase by ion exchange chromatography monitored by 
SDS PAGE, M M olecular weight marker, C/S crude sam ple, 1-5 ion exchange fractions. All 
lanes have lOpJ of sample loaded
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55kD  ^  M C/S 1 2 3 4 5------6 ^ -----  MBP-MTDHOase
36kD  ►
14kD ►   < -----  MTDHQase
Figure 3.5b Separation of M BP/M TDHQase by size exclusion chromatography and heat 
shocking monitored by SDS PAGE. M- molecular weight marker, C/S -  crude sample, 1-5 -  size 
exclusion fractions, 6- Heat shock soluble fraction. All lanes have lOpJ sam ple loading
These experiments indicated that ion exchange chromatography using a 
mono-Q anion exchange column proved the best method of purification of the type II 
DHQases. The results of a typical purification of are shown below (Figure 3.6)
M C/s' 1 2 3 4 5 6
__________________________MBP
35kD  ►
21kD  ► A—^  ^ ___  HPDHQase
Figure 3.6 SDS PAGE monitoring separation by ion exchange chromatography of 
M BP/HPDHQase, M- molecular weight marker, C/S- crude sample, Fractions 1-2 MBP, 
Fractions 3-6 HPDHQase. All lanes have lOpJ sam ple loaded
A small band approximately 4kD smaller than the main 19kD band 
corresponding to HPDHQase was observed on SDS PAGE. This is likely to be a
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product of the protease cleavage of the MBP-HPDHQase fusion peptide, although no 
factor Xa cleavage site was identified in the protein sequence.
3.2 Crystallisation of type II DHQases expressed as MBP fusion peptides.
All crystallisation experiments were performed by the ‘sitting drop’ vapour 
diffusion method. Initial screening for crystallisation conditions was performed using 
a variety of in-house sparse matrix screens (Jancarik and Kim, 1991). Optimisation 
of initial conditions was achieved by varying precipitant concentration, pH, additives 
and protein concentration as described in section 2.12. Co-crystallisation experiments 
with transition state analogues (Table 2.4) were carried out by incubating protein 
with lOOmM inhibitor in a 25:1 (v/v) ratio at room temperature for 30 mins before 
setting up the crystallisation experiment.
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3.2.1 Crystallisation of MTDHQase
Initial crystallisation experiments used protein concentrated to lOmg/ml, 
however this led to the formation of protein ‘skins’ on top of the crystallisation 
drops. This indicated that this protein concentration was too high and subsequent 
crystallisations use protein concentrations of 7-8 mg/ml. Sparse matrix screening 
yielded small crystals of MTDHQase/FA3 and MTDHQase/FA4 complexes in 20% 
(w/v) PEG 8K, Ü.2M NaCl, O.IM Tris-HCL pH 8.5. These conditions were 
optimised and larger crystals were obtained in 15% (w/v) PEG 8K, 0.2M NaCl, O.IM 
Tris-HCl pH 8.8 (Figure 3.7). These crystals were taken to the DESY synchrotron 
(Hamburg), however no diffraction was observed.
1
Figure 3.7 Crystal o f M TDHQase + FA4 in 15% (w/v) PEG 8K, 0.2M NaCl, O.IM Tris-HCl pH 
8.8
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3.2.2 Crystallisation of HPDHQase
Initial crystallisation experiments used HPDHQase concentrated to lOmg/ml. 
Initial crystals of HPDHQase/FA 1 complex were obtained in 20% (w/v) PEG 4K, 
0.2M MgCl], O.IM Tris-HCl pH 8.5. These conditions were optimised to yield 
diffraction quality crystals in 14% (w/v) PEG 4K, 0.2M MgCL, O.IM Tris-HCl pH 
8.8 (Figure 3.8). The crystals were octahedral in morphology, with dimensions 
0.05mm x 0.05mm x 0.05mm. These crystals were found to diffract to 3.2Â on 
beamline BW-7B (DESY, Hamburg)
Figure 2.8 Crystal of HPDHQase + F A l grown in 14% (w/v) PEG 4K, 0.2M MgClz, O.IM Tris- 
HCl pH 8.8
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3.2.3 Reasons for poor diffraction
Crystals grown using protein expressed via the MBP fusion system proved 
difficult to grow and showed poor or no diffraction when tested at a synchrotron 
source. This was almost certainly due to the poor quality of the protein preparation 
(Section 3.1,6). In particular, when cleavage of the fusion peptides had not gone to 
100% completion, a fraction of the DHQase still carried the MBP tag. As type II 
DHQase is dodecameric, it is possible that dodecamers may exist with some 
monomers still tagged, while others have been cleaved successfully.
During crystallogenesis rogue tags will poison the crystal growth, resulting in 
small crystals of poor quality. In the case of HPDHQase a significant degradation 
product was observed on SDS PAGE that was not removable by chromatographic 
methods. This impurity may also contribute to the poor quality of the crystals.
From this point, expression of DHQases as MBP fusions was abandoned, and 
a new expression and purification strategy adopted.
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3.3 Cloning, expression and purification of type II Dehydroquinases with an N- 
terminal poly-histidine tag.
Expression and purification of type II DHQases using the MBP fusion 
expression system had proven to be problematic, and did not result in the growth of 
diffraction quality crystals. However, affinity chromatography methods were still 
applied to ease purification of type II DHQases using an N-terminal poly- histidine 
tag. The vector pET-15b (Invitrogen) was used to express type II DHQase with a 6x 
His tag, followed by a thrombin protease cleavage site, joined by a linker region to 
the N-terminal of the protein.
3.3.1 Sub-cloning of M. tuberculosis aroD and H. pylori aroQ into pT7-Blue3
The multiple cloning site of pET-15b contains only three restriction sites in 
the following order (5’-3’) Nde 7, Xho I  and Bam 777. These sites were not compatible 
with the restriction sites in pMAL-mtd and pMAL-hpq therefore new restriction sites 
had to be engineered by PCR. Primer oligonucleotides were designed to incorporate 
a 5’ Nde I  site and a 3’ Bam 777 site on M. tuberculosis aroD and 77. pylori aroQ 
(Table 2.3). PCR was carried out using these primers, Taq polymerase, with pMAL- 
mtd and pMAL-hpq as template DNA to amplify each gene.
The PCR products were purified by gel electrophoresis and purified using the 
QIEXII kit (Qiagen) and cloned into p-T7-Blue3 (Novagen) by blunt end ligation 
(Section 2.6.3) using the ‘Perfectly Blunt’ Cloning kit (Novagen) to generate the 
vectors p-BIue-mtd and p-Blue-hpq. The products from the ligation reactions were 
transformed into Novablue Singles Competent Cells (Novagen) and plated out on
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Agar plates containing 100p,mg/ml Ampicillin + IPTG + X-gal. This allowed 
identification of successful transformants by blue/white screening.
Three colonies were picked and grown overnight in 5ml LB + lOOpg/ml 
ampicillin, and plasmid DNA prepared by the method of Bimdoin and Dolly (1979). 
Positive clones were identified by restriction digests and were sequenced, to confirm 
that no mutations had accumulated during the PCR process.
3.3.2 Sub-cloning of M. tuberculosis aroD and H. pylori aroQ into pET-15b
The vector pBlue-mtd and pBlue-hpq were digested with Nde I  and the linear 
vector DNA isolated by gel electrophoresis. The linear fragments were digested with 
Bam HI, releasing the 0.5kb insert from the vector DNA, which were isolated by gel 
electrophoresis. The vector pEE-65 (pET-15b with a l.lkb  insert) was obtained from 
Dr. E. Ellis (University of Strathclyde) and digested in a similar manner, with the 
5.7kb pET-15b vector DNA purified.
Ligation reactions were carried out and the resultant constructs transformed 
into E. coli DH5a and plated out on agar plates + 100|Xg/ml ampicillin. Ten colonies 
were picked and 5ml cultures grown at 37°C overnight in LB + lOOpg/ml 
ampicillin. Plasmid DNA was isolated using the QlSpin kit (Qiagen) and restriction 
digest analysis performed with Nde I  and Bam HI.
3.3.3 Expression studies upon 6xHis tagged DHQase
To optimise the overexpression of target protein from each preparation, 
expression studies were carried out to identify the optimal concentration of IPTG 
required for maximal expression. The vectors MpET (encoding 6xHis -  MTDHQase)
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and HpET (encoding 6xHis- HPDHQase) were transformed in to E.coli BL21 
(plysS) cells and colonies propagated at 37°C overnight in 2ml of LB + lOOpg/ml 
ampicillin + 34|ig/ml chloramphenicol. 200pl of each overnight culture were used to 
inoculate 4x2ml LB + lOOjig/ml ampicillin, which were grown at 37°C until ODeoo 
reached 0.6. The four cultures were inoculated with OmM, 0.4mM, 0.8mM and 
1 .OmM IPTG respectively and grown for a further 3 hours. Total cell protein from 
the crude cell extract of these cultures were analysed by SDS PAGE (Figure 3.9)
MpET 
M l  2 3 4 5
HpET 
6 7 8 9 10
20kD
MTDHQase
14kD
HPDHQase
Figure 3.9 M onitoring of expression of 6xHis- DHQases by SDS PAGE. M molecular weight 
marker, 1-2 MpET no induction, 3-5 3 hours after induction with 0.4mM , 0.8mM and ImM  
IPTG respectively, 6-7 HpET no induction, 8-10 3 hours after induction with 0.4mM , 0.8mM  
and ImM  IPTG respectively. All lanes have 5|il o f sample loaded
From this experiment it can be seen that maximal expression occurred after 
induction with 0.8mM IPTG.
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3.3.4 Purification of 6xHis tagged DHQases
Following over-expression, 6xhis tagged DHQases were purified by affinity 
chromatography using a 5ml Ni-NTA column as described in section 2.8.1 to yield 
protein of purity greater than 99%. Ion exchange chromatography (section 2.8.2) 
using a 10ml Q-sepahrose column was used to further purify and concentrate the 
protein samples. Protein purification was monitored by SDS PAGE (Figure 3.10)
1 2  3 4w
20kD   .. ^  HPDHQaseI
Figure 3.10 M onitoring purification of 6xHis-HPDHQase by SDS PAGE. M- m olecular weight 
marker, 2- cell lysate, 3- Ni-NTA w ashl, 4- Ni-NTA wash2, 4- Ni-NTA product, 5- Q-sepharose 
peak fraction. All lanes have lOpJ of sample loaded
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3.4 Crystallisation of 6xHis tagged DHQases
The problems encountered after cleaving the MBP affinity tag from previous 
DHQase constructs, namely separating the target protein from the tag and non­
specific cleavage of the target protein, were deemed to be detrimental to the growth 
of diffraction quality crystals. Therefore no attempt was made to remove the 6xHis 
tag from the target protein before crystallisation experiments.
3.4.1 Crystallisation of 6xHis-MTDHQase
Samples of 6xHis-MTDHQase were concentrated using centricon centrifugal 
concentrators (Amicon) to 7mg/ml and crystallisation experiments carried out using 
the sitting drop vapour diffusion method. In-house sparse matrix screens and the 
commercial crystallisation screens Crystal screen I, Crystal screen II, Wizard I, 
Wizard II, Cryo I and Cryo II (Emerald Biostructures) were used, however no 
promising crystals were observed from these screens
3.4.2 Crystallisation of 6xHis-HPDHQase
Co-crystallisation experiments were carried out with transition state 
analogues FAl, F A3, FA4 and GSK inhibitors AH9095, GR78752X and 
GR1221 lOX. The transition state analogues were water soluble however as they are 
acidic compounds the pH of the inhibitor solution had to be adjusted. The GSK 
inhibitors were insoluble in aqueous solution therefore were dissolved in 100% 
DMSO. Protein was concentrated to lOmg/ml in lOmM Tris-HCl pH 7.5, and shaken 
overnight at 4°C in the presence of 50mM inhibitor. Crystallisation experiments 
using the sitting drop vapour diffusion method were set up using in-house sparse
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matrix screens and the commercial crystallisation screens Crystal screen 1, Crystal 
screen 11, Wizard 1, Wizard 11, Cryo 1 and Cryo 11 (Emerald Biostructures).
3.4.2.1 Crystallisation of HPDHQase and FAl
Initial sparse matrix screening provided several initial crystallisation 
conditions for this complex and two conditions were optimised to provide diffraction 
quality crystals. Initial crystals grown in 20% MPD, O.IM Citrate pH4.5 were tested 
at BM ID 14.4 (ESRF, Grenoble) and showed diffraction to 3.5Â resolution. Larger 
crystals (0.2mm x 0.1mm x 0.1mm) were obtained following optimisation of 
conditions to 16% MPD, O.IM Citrate pH4.2, however no increase in resolution was 
obtained.
A second crystal form was identified grown in 30% 1,4 butandiol, O.IM Na 
Acetate pH 4.5 (Figure 3.11). These crystals diffracted to 3.1 A at beamline 9.5 (SRS, 
Daresbury) and a complete data set was collected.
Figure 3.11 Crystal o f HPDHQase + F A l grown in 30% 1,4 butandiol, O.IM Na Acetate pH 4.5
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3.4.2.2 Crystallisation of HPDHQase and AH9095
Small octahedral crystals were observed in wells containing IM Na Acetate, 
O.IM Imidazole-HCl pH 8.0 during initial screening. This condition was optimised to 
l.OM Na Acetate, O.IM Imidazole-HCl pH 8.2 to yield crystals of dimensions 0.3mm 
X 0.3 mm x 0.3mm after two days growth (Figure 3.12). These crystals diffracted to 
2.5A on the in-house rotating anode source (Nonius FR591) and to 1.55Â at 
beamline 9.6 (SRS, Daresbury). Complete data sets were collected using both 
sources.
Figure 3.12 Crystal of HPDHQase + AH9095 grown in to l.OM Na Acetate, O.IM Imidazole-HCl 
pH 8.2
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3.4.2.3 Crystallisation of HPDHQase and GR122110X
After initial screening, crystals were observed in wells containing 20% 1,4 
butandiol, O.IM Na Acetate pH 4.5 (Figure 3.13). These crystals diffracted to 2.9Â 
resolution on beamline 9.6 (SRS, Daresbury) and a complete data set collected. 
Despite attempts to optimise the crystallisation conditions no improvement in 
diffraction was observed.
Figure 2.13 Crystals of HPDHQase + GR122110X grown in 20% 1,4 butandiol, O.IM Na Acetate 
pH 4.5
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3 4.2.4 Crystallisation of HPDHQase and Phosphate
Phosphate ions have been shown to inhibit type II DHQase (Kleanthous et 
a i ,  1992), and have been observed bound in the active site of MTDHQase and S. 
coelicolor DHQase (Evans et a l ,  2002). Sparse matrix screening was carried out 
upon HPDHQase in the presence of lOmM Ammonium phosphate. Octahedral 
crystals of dimensions 0.1mm x 0.1mm x 0.1mm were observed in conditions 
containing IM ammonium acetate, O.IM Tris-HCl pH 7.5 (Figure 3.14) after two 
weeks. These crystals showed no diffraction on the in-house rotating anode source. A 
second crystal form was identified in conditions containing 30% Isopropanol, 0.2M 
ammonium acetate, O.IM Tris-HCl pH 7.5 however no diffraction was observed 
using the in-house rotating anode source.
Figure 3.14 Crystals o f HPDHQase + lOmM Ammonium Phosphate grown in IM  Ammonium  
Acetate, O.IM Tris-HCl pH 7.5
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3.4.3 Soaking experiments with HPDHQase
The best crystals obtained were those of HPDHQase complexed with 
AH9095. Soaking experiments were attempted to exchange this ligand for other 
ligands within the crystal. Large numbers of crystals of HPDHQase + AH9095 were 
prepared. Drops containing the corresponding crystallisation conditions were 
prepared with high concentrations of GR78752X, GR122160X or FAl instead of the 
HPDHQase/AH9095 mixture, and left to equilibrate. After 48 hours, crystals of 
HPDHQase + AH9095 were transferred to the pre-equilibrated drops and incubated 
for a further 48 hours before diffraction experiments were carried out.
GR78752X was only soluble in DMSO, and the presence of high 
concentrations of DMSO resulted in destruction of the crystals. Therefore solid 
GR78752X was added to drops of pre-equilibrated artificial mother liquor prior to 
addition of the crystal. A crystal treated in this manner diffracted to 2.5Â on 
beamline 9.5 (SRS, Daresbury) and a complete data set collected. However, after the 
data were processed and the structure phased it was apparent that AH9095 had not 
been competed out of the active site.
Soaking experiments using GR1221 lOX and FAl resulted in complete loss of 
diffraction from the crystals. This suggests that these compounds probably displaced 
AH9095, but this also results in disrupting the crystal contacts, hence disturbing the 
order of the crystals.
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3.5 Discussion
Samples of MTDHQase and HPDHQase over-expressed and purified using 
the pMAL expression system and amylose resin affinity chromatography were 
obtained in high yield, however crystals grown using these samples were of poor 
quality. This can be attributed to problems with obtaining mono-disperse samples of 
the proteins, a result of non-complete cleavage of the MBP fusion peptide, and 
subsequent incomplete separation of the cleaved MDP form the DHQsae.
Diffraction quality crystals of HPDHQase were obtained with protein that 
was over-expressed using the pET-15b expression vector, and subsequently purified 
using Ni-NTA affinity chromatography. The best crystals were obtained when the 
protein was co-crystallised with the ligand AH9095, however crystals grown in the 
presence of other ligands were of diffraction quality. No crystals of MTDHQase 
expressed and purified by this protocol were obtained.
Despite repeated attempts, the crystallisation conditions for HPDHQase 
published by Kwak et a l (2001) were non-reproducible. It is noted that in our hands 
we used HPDHQase with an N-terminal 6xHis tag plus linker, whereas Kwak et al. 
purified and crystallised native protein.
75
Chapter 4___________________ Collection and Processing of X-ray Diffraction data
Chapter 4 -  Collection and Processing of X-ray diffraction data
4.1 Protein Crystallography
Since the pioneering work of Bernal and Crowfoot upon the collection of an 
X-ray diffraction pattern from a crystal of pepsin (Bemal and Crowfoot 1934) and 
the determination of the structure of myoglobin in 1957 (Kendrew et ai, 1958), the 
field of protein crystallography has become one of the most powerful tools in modem 
biology. The determination of the precise 3D structure of biological macromolecules 
not only provides topological information, but can also provide unprecedented 
insight into enzymatic regulation and function.
Despite the development of crystallographic methods and innovations in 
computational techniques, the underlying theory of protein stmcture determination 
has remained unchanged since the birth of the field. Many excellent texts have been 
published that describe crystallographic theory (Blundell and Johnson, 1976; Drenth, 
1994; McRee, 1999), therefore in this thesis only the basic concepts and 
methodologies that relate directly to the work carried out will be described.
4.1.1 Scattering of X-rays by an atom
When atoms are placed in a beam of electromagnetic radiation, the atoms 
begin to oscillate, thus becoming a source of radiation themselves, scattering the 
incident beam. Electrons within an atom oscillate at the same frequency as the 
incident radiation and therefore emit radiation at the same frequency as the incident 
radiation (Figure 4.1).
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Incident Beam
Figure 4.1: Electrom agnetic radiation scattered by a single atom
If the atoms are in a periodic arrangement (such as in a crystal), the scattered 
waves interfere with each other, resulting in constructive and destructive interference 
depending upon the phase of the waves (Figure 4.2).
Incident Beam
Reflected Beam
Figure 4.2: Scattering from a periodic arrangement o f atom s produces a characteristic 
diffraction pattern  
4.1.2 Bragg’s Law
If we visualise a crystal as a series of planes of atoms, we can consider 
diffraction arising from the reflection of the incident beam by planes within the 
crystal.
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t o
Figure 4.3 The Bragg construction describing reflection of X-rays from planes of atom s within a 
crystal.
Figure 4.3 illustrates the Bragg’s theory of the reflection of X-rays by 
‘reflecting planes’ of atoms within a crystal lattice. The path difference between 
waves scattered by atoms from adjacent lattice planes of spacing d is given by
(AB + BC) = (f/sinG + cfsinG) = 2Jsin0 
For constructive interference this path distance must equal an integer number of 
wavelengths of the incident X-rays.
nk = 2(fsinG
where « is an integer and k  the wavelength of the incident radiation.
4.1.3 The Ewald Construction
Despite describing the condition required for diffraction of X-rays by a 
crystal, the Bragg construction does not illustrate the geometric conditions required 
for collection of all structure factors from a diffracting crystal. The Ewald 
construction, or synthesis, is a geometrical formulation of Bragg’s law describing the 
interaction between the reciprocal lattice and a ‘limiting sphere of reflection’ (Figure
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4.4). The radiation of wavelength X is represented by a sphere of radius 1/A, centred 
upon the X-ray beam. The crystal is represented by the reciprocal lattice, with its 
origin at the point on the Ewald sphere where the direct beam leaves it. The 
relationship between the Ewald construction and the Bragg construction is as 
follows; each reciprocal lattice point lies at the end of a vector perpendicular to a 
plane within the crystal. Any reciprocal lattice point that lies upon the surface of the 
Ewald sphere fulfils the criteria for Bragg diffraction.
Figure 4.4 The Ewald construction; The Ewald sphere is shown as a circle o f radius 1/1 centered 
upon the origin o f the reciprocal lattice. The reciprocal lattice is shown as green dots (Figure 
from  D a u ter , 1999)
4.2 Collection of X ray diffraction data by the Rotation Method
At any particular crystal orientation, only a few lattice points will be in a 
diffracting position. Therefore, to collect a full set of diffraction data either the 
Ewald sphere must move (by changing the wavelength of the incident radiation), or 
the reciprocal lattice must move (by rotating the crystal). By rotating the crystal, 
successive lattice points are brought to the surface of the Ewald sphere, into 
diffracting position. This method is known as the rotation method, and is the method
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most commonly used in the routine collection of X-ray diffraction data from crystals 
of macromolecules.
4.2.1 The Rotation Method
In the rotation method the crystal is rotated, therefore the reciprocal lattice is 
rotated, such that lattice points are brought to a position where they satisfy the 
criteria for Bragg reflection of monochromatic radiation. Figure 4.5 illustrates how 
rotation of the lattice results in different lattice points intersecting the Ewald sphere.
Figure 4.5 Rotation o f the reciprocal lattice with respect to the Ewald sphere. Panel A shows the 
dihTracted X-rays from one orientation, Panel B shows the diffracted beams generated when we 
rotate the reciprocal lattice. (Figure from  Dauter, 1999)
For visualisation purposes it is easier to represent rotation of the crystal 
during data collection by moving the Ewald sphere and keeping the lattice stationary. 
Figure 4.6 shows the movement of the Ewald sphere around an axis in the plane of 
the page. This shows that an area of reciprocal space is missed by the rotation of the 
Ewald sphere; and area known as the blind region. To fully record these reflections, 
the crystal must be re-orientated such that this area of reciprocal space is traversed by 
the Ewald sphere.
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Limiting sphere
Ewald sphere
1 /d,
Rotation Axis Blind Region
Figure 4.6; Rotation of the Ewald sphere around an axis normal to the plane of the paper 
illustrating the area of reciprocal space traversed and the blind region
The entire reciprocal lattice cannot be sampled in a single rotation as this 
would generate too many spots on the image to allow accurate indexing. Therefore 
the rotation is split into a series of oscillations, typically 0.5° - 2°, after which the 
diffraction pattern is recorded. The choice of oscillation angle is critical for the 
collection of a high quality data set. If the oscillation is too large, too many spots will 
appear on the image, resulting in spot overlap. If the range is too small, only a few 
reflections will be recorded per image, with the majority of reflections being partially 
recorded over several images. The theoretical optimum oscillation angle, A(])max, can 
be calculated by considering the separation between adjacent spots, a*, the maximum 
resolution, dmax, and the maximum oscillation angle which a particular spot is 
observable, (|>r, in the following manner
A (j)n ia x  — a  /  d m a x  "
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The variable (|)r is dependent upon several factors, notably the mosaicity of 
the crystal and characteristics of the incident X-ray beam.
4.2.2 Crystal Mosaicity
To determine the optimum oscillation range, the degree of mosaicity, or 
mosaic spread, of the crystal has to be taken into consideration. Crystals are not 
perfect and do not consist of a uniform lattice. Instead they exist as a series of mosaic 
blocks, which do not merge precisely with neighbouring blocks (Figure 4.7)
Figure 4.7 Illustration of a macromolecular crystal with high mosaic spread
The result of this feature is that reciprocal lattice points become smeared, i.e. 
the perfect lattice point would consist of an infinitesimal point in space, however in 
reality they are smudged, covering a larger area of space. If now consider the Ewald 
sphere passing through the reciprocal lattice, the larger lattice points will remain in 
the diffracting position, hence may be spread over many images.
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4.3 Data Collection Strategy
The first stage in collecting a high quality X-ray diffraction data set is to 
determine features of the crystal relating to the data collection. Determination of;
■ Unit Cell Dimensions
■ Laue Class
■ Approximate mosaicity
■ Diffraction limit of the crystal
These factors relate to the strategy employed in the data collection, and can be 
approximately determined from initial processing of a few initial images. 
Consideration of the unit cell dimensions and mosaicity influence the oscillation 
angle employed in the data collection. If there is a particularly long unit cell length, 
this results in diffraction spots overlapping each other, possibly too close to resolve. 
By reducing the oscillation angle (fine slicing), less spots will appear on the image 
reducing spot overlap. Similar considerations are made for highly mosaic samples.
The diffraction limit significantly influences the strategy for collecting a 
complete data set. The intensity of diffraction spots drops of as the Bragg angle 
increases, i.e. high resolution data is inherently weaker than low resolution data. If 
high resolution data is to be collected, exposure times may increase resulting in 
overloaded reflections at lower resolution. To collect high resolution data, unless the 
detector has the capacity to move off axis, the detector will be close to the sample. If 
the detector is very close to the sample, the spots near the edge of the image will be 
well be easily resolved whereas those close to the centre of the image will overlap. 
Due to the considerations above if high resolution data collection using a single 
rotation axis is to be collected, a high resolution data set is collected and processed 
omitting poorly measured low resolution data. A second pass through reciprocal
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space with a greater crystal to detector distance is collected to record the low 
resolution data.
The oscillation range required to collect the unique portion of x-ray 
diffraction data is determined by the space group of the sample. If the crystal is in a 
low symmetry space group, greater than 180° of data must be sampled. Conversely if 
the crystal is of a high symmetry space group less than 30° data needs to be 
collected.
4.4 Collection of X-ray diffraction data from Helicobacter pylori type II 
Dehydroquinase + AH9095
In section 3.4.4.2 the growth of large crystals of HPDHQase + AH9095 was 
described. In this section, the data collection strategy used to obtain a complete data 
set is described.
4.4.1 Initial data collection of HPDHQase + AH9095 using a rotating anode 
source
A large single crystal of HPDHQase + AH9095 was taken from a well using 
a 0.2mm cryoloop (Hampton) and immersed in mother liquor + 20% glycerol to act 
as a cryoprotectant. The crystal was then frozen in a stream of gaseous dry nitrogen 
at lOOK using an Oxford Systems Cryostream and orientated into the centre of the X- 
ray beam. The rotating anode source was a Nonius FR591, with a copper target 
generating Cu Ka radiation (wavelength 1.5418Â) equipped with focussing mirrors. 
The goniometer had a single (|) rotation axis and the detector was a MAC Science 
DIP 2000 double image plate. The crystal to detector distance was adjusted to 
140mm, resulting in a dmax at the edge of the image plate of 2.5Â. The crystal was
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exposed for 20 minutes per image, with an oscillation angle of 1°. Figure 4.8 shows a 
typical image.
Figure 4.8 A typical image of the diffraction pattern measured from a crystal of HPDHQsae + 
AH9095 using the rotation method with a rotating anode source.
4.4.2 Determination of data collection strategy for HPDHQase + AH9095
A single initial image was processed using DENZO from the HKL suite 
(Otwinowski and Minor, 1997). The first step in the process is to identify the well 
defined reflections on the image and attempt to index them. This generates initial 
values for the unit cell dimensions and the orientation of the crystal in relation to the 
incident beam.
The well defined reflections are picked as opposed to the strongest reflections 
as the indexing routine requires very accurate spot positions. At the centre of a strong 
reflection the detector may become overloaded, therefore many pixels will have the 
same intensity. Overloaded spots have poor profiles, therefore the exact centre of the 
spot cannot be accurately determined. If we choose a slightly weaker spot, the 
intensity will not be as great at the centre of the spot, giving rise to a more accurate 
spot profile, therefore the centre point will be easily determined (Figure 4.9).
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Overloaded
Reflection
Well Defined 
Reflection
Figure 4.9: Spot profiles for and overloaded reflection and a well defined reflection.
To determine which Bravais lattice type the crystal belongs to, a cell with the 
initial unit cell dimensions is generated. This cell is then forced to obey the 
constraints of each Bravais lattice and a deformation matrix (a measure of the force 
required) is calculated for each lattice type. The lattice types with corresponding unit 
cell dimensions and deformation matrices are displayed in order of symmetry. The 
lattice type with the highest symmetry, with the lowest deformation matrix is the 
correct solution. Using these hypothesised values, a data collection strategy can be 
formulated. Determination of the space group can only be determined once the data 
has been scaled by analysis of the merging R- factor (Rmerge) statistics (section 4.4.3)
For HPDHQase + AH9095, an F centred cubic unit cell was the suggested 
Bravais lattice with unit cell dimension a = b = c = 130.5Â a  = p = y = 90°. For this 
high symmetry space group very little unique data is required (7.5°) for a complete 
data set, therefore 30° of data were collected (30 images, 1° oscillation) to give an 
overall multiplicity of 3.4.
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4.4.3 Processing of data - HPDHQ + AH9095
The 30 images collected were processed with the HKL suite. The data 
processing routine is complex and only a brief overview of the methods implemented 
in the HKL suite will be described. The initial stages are performed with the program 
DENZO. From the predicted crystal characteristics (unit cell dimensions, space 
group, mosaicity, crystal orientation) the program predicts the position of reflections 
on the image. The intensity of these regions is measured, a process referred to as spot 
integration.
Denzo performs 2D spot integration by mapping the profile of the diffraction 
spot. A box is created around the predicted spot position, within which areas are 
defined as spot, safety and background (Figure 4.9). The average intensity across the 
background area is calculated and subtracted from the intensity within the spot 
region. The safety region acts as a buffer between spot and background to prevent 
rogue spots which are smeared into the background region affecting the intensity 
calculation.
Figure 7.9 Spot integration using Denzo. The predicted spot position is indicated by the coloured 
circles. The area within the central white circle is the spot area, the area between the two white 
circles the safety region. The rem aining area within the box is defined as background.
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Profile fitting is then carried out upon the spot intensity profiles. The profiles 
of spots within a defined radius are analysed to create a predicted spot profile. The 
observed and predicted spot profiles are then combined, the spot positions defined 
and an accurate spot intensities calculated.
The subsequent processing is carried put with the program Scalepack. Due to 
differences in crystal and beam characteristics throughout the data collection, a scale 
factor has to be applied to the data to take these differences into account. Two 
corrections are applied to the integrated spot intensities as the observed spot intensity 
lo to estimate the desired intensity measurement /, the Lorentz-Polarisation 
corrections.
L
1 =
LP
Diffraction images collected using the rotation method show a distorted view 
of the reciprocal lattice due to the diffraction geometry. Reciprocal lattice points that 
lie on, or near, the rotation axis will spend longer traversing through the Ewald 
sphere than reciprocal lattice points far from the rotation axis. This is corrected by 
the Lorentz kinematical factor (L). The polarisation correction (P) relates to the 
polarisation content of the X-ray beam as it travels from source to detection.
Scalepack also presents statistics about how complete a data set is, what the 
average intensity of the reflections above noise level (I / al) and an R-factor ( R m e r g e  
or Rsym) that describes the quality of the data. The definition of Rmerge is shown below
R
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The data collection statistics for HPDHQ + AH9095 are shown in table 4.1
HPDHQ + AH9095 In-house data collection
Wavelength 1.5418A
Detector DIP 2000
Crystal to detector distance 140mm
Resolution range 30-2.53Â
Completeness 99%
Completeness Highest resolution shell 97%
Total number of reflections 20,693
Unique Reflections 6,274
Average Redundancy 3.4
I / a l 11.6
I / a l Highest resolution shell 2.25
R m e r g e 9.9%
R m e r g e  Highest resolution shell 51.1%
Table 4.1 Statistics for HPDHQase + AH9095 data collected using in-house rotating anode 
source
4.5 High resolution data collection -  HPDHQase + AH9095
Crystals of HPDHQase + AH9095 similar to those used for in-house 
experiments were taken to the Synchrotron Radiation Source (SRS) at Daresbury, 
UK, for diffraction experiments with synchrotron radiation.
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4.5.1 Synchrotron radiation sources
A synchrotron circulates charged particles (positrons or electrons) around a 
‘ring’ at nearly the speed of light. The particles are accelerated using a linaer 
accelerator (LINAC) and injected in the synchrotron storage ring. The orbit of the 
particles is controlled by magnets (~1 Tesla, ESRF), which deflect the path of the 
particles. When the particles change direction, they emit electromagnetic radiation at 
a tangent to the path deflection. This radiation can be harnessed for many 
experimental purposes, including X-ray crystallography. X-rays can be generated 
from the particle beam either at the bending magnets (which are used to control the 
orbit) or at insertion devices such as wigglers and undulators.
4.5.2 Advantages of Synchrotron radiation
There are many advantages associated with diffraction experiments using 
synchrotron radiation as opposed to CuKa radiation from a rotating anode source. 
The characteristics of the X-ray beam generated at a synchrotron source are ideal for 
the collection of diffraction data from macromolecular crystals. The intensity of the 
beam generated from a synchrotron is at least 2 orders of magnitude greater than that 
generated from a rotating anode. For modem synchrotrons (e.g. ESRF Grenoble FR, 
APS Argonne USA, Spring-8 JP) the radiation generated can be up to 7 orders of 
magnitude more intense. This results in much shorter exposure times for the 
collection of diffraction images (<10 secs per image - beamline ID 14-4, ESRF) and 
the observation of higher resolution reflections, too weak to be observed with less 
intense radiation. Synchrotron radiation is highly focused onto the sample and the 
beam itself has very low divergence, resulting in small, well defined diffraction 
spots.
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The wavelength of the radiation focussed upon the sample is typically around 
1.0Â, however many synchrotron beamlines can be ‘tuned’, allowing a wide 
spectrum of wavelengths to be selected. This attribute is used in the collection of 
multiple wavelength anomalous dispersion (MAD) and single wavelength anomalous 
dispersion (SAD) data to obtain experimental phasing information. The shorter 
exposure times coupled with the shorter wavelength of the incident radiation results 
in less background scatter, therefore a better signal to noise ratio for the data 
collection.
Data was collected upon crystals of HPDHQase 4- AH9095 at beamline 9.6 
at SRS Daresbury. The radiation is generated by a wiggler insertion device and the 
resultant beam has a wavelength of 0.87Â. The beamline is equipped with an ADSC 
quantum 4r CCD detector with an active area of 188mm x 188mm.
4.5.3 High resolution data collection statistics -  HPDHQase + AH9095
A single crystal of HPDHQase + AH9095 was looped from a well and 
transferred briefly to an artificial mother liquor + 20% (v/v) glycerol to act as a 
cryoprotectant. The crystal was the flash frozen in stream of dry gaseous nitrogen 
cooled to lOOK. Initial 1 minute exposures with an oscillation angle of 1° were 
collected and diffraction spots were observed to -1.5Â. A typical image is shown in 
Figure 4.10.
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Figure 4.10 A typical diffraction pattern from HPDHQase + AH9095 collected at SRS beamline 
9.6 using the ADSC Quantum-4r detector
Initial processing of the images showed the crystal to be isomorphous with 
the crystal used for in-house data collection, therefore the data collection strategy 
was identical. Due to the large number of reflections that are systematically absent in 
F23 (table 4.2) indexing of all the reflections on the image was possible without any 
problems of spot overlap.
hkl h+k, k~hl — 2n
Okl k, I = 2n
hhl h+l=2n
hOO h = 2n
Table 7.2 Reflection conditions for the space group F23. h, k and I are cyclically permeable 
Despite the exposure time being optimal for collection of high resolution 
data, this did not result in overloaded reflections at low resolution, therefore there
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was no need for high and low resolution passes. The data collection consisted of 120 
images of 1° phi oscillation, with 1 minute exposures. Final data collection statistics 
are shown in table 4.3.
HPDHQ + AH9095 SRS 9.6 data collection
Wavelength
Detector
Crystal to detector distance 
Resolution range 
Completeness
Completeness Highest resolution shell 
Total number of reflections 
Unique Reflections 
Average Redundancy 
I / oI
I / a l  Highest resolution shell
R m e r g e
Rmerge Highest resolution shell
0.87A
ADSC Q4r CCD 
163mm 
50-1 .5Â  
100%
100%
334,701
27,302
12.2
59.1
2.01 
4.4%
80.8%
Table 4.3 Statistics for HPDHQase + AH9095 data collected on SRS beamline 9.6
The data set collected at SRS 9.6 was of good quality despite the very high 
R m e r g e  in the highest resolution shell. Highly redundant data improves the I / a l 
(signal to noise), however Rmerge is also influenced by the redundancy of the data, 
with highly redundant data increasing the Rmerge- Data is usually cut off where 50% 
of the reflections within the resolution shell have I / a l =3, however data beyond 
this resolution can still be useful and is therefore included.
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4.6 Collection of diffraction data from other HPDHQase crystals
4.6.1 HPDHQase + GR78752X Soak
Data were collected from a crystal of HPDHQase soaked in a solution of 
GR78752X (section 3.4.3). The data were collected at beamline 9.5 at SRS 
(Daresbury). The crystal diffracted weakly to 2.4Â resolution and the space group 
was F23. A typical diffraction image is shown in Figure 4.11
Figure 4.11 A typical diffraction image from a HPDHQase crystal soaked in GR78752X  
recorded on beamline 9.5 at SRS (Daresbury) using the MAR-165 CCD detector.
Due to the low resolution of the diffraction and the large number of 
systematic absences in the space group F23 the data was collected in a single pass. 
56 frames were collected with an oscillation angle of 1°. Data collection and 
processing statistics are shown in table 4.4.
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HPDHQ + GR78752 Soak SRS 9.5 data collection
Space Group F23
Unit Cell a = b = c = 130.53À
Wavelength i.oA
Detector MAR 165 CCD
Crystal to detector distance 170mm
Resolution range 50-2 .4Â
Completeness 99.4%
Completeness Highest resolution shell 99.5%
Total number of reflections 38,721
Unique Reflections 7,489
Average Redundancy 5.17
I / a l 11.05
I / a l Highest resolution shell 1.52
R m e r g e 12.1%
R m e r g e  Highest resolution shell 79.0%
Table 4.4 Data collection statistics for HPDHQ + GR78752 soak.
4.6.2 HPDHQase + FAl
Data were collected from crystals of HPDHQase + FAl, prepared as 
described in section 3.4.2.1. The data were collected at beamline 9.5 at SRS 
(Daresbury). Diffraction spots were observed to 3.1 A resolution and initial data 
processing suggested the crystals belonged to a primitive trigonal space group. A 
typical diffraction image is shown in figure 4.12. 130 frames were collected with an 
oscillation angle of 1°. Data collection and processing statistics are shown in table 
4.5.
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Figure 4.12 A typical diffraction image from a HPDHQase + F A l crystal recorded on beamline 
9.5 at SRS (Daresbury) using the M AR-165 CCD detector.
HPDHQ + FAl SRS 9.5 data collection
Space Group 
Unit Cell 
Wavelength 
Detector
Crystal to detector distance 
Resolution range 
Completeness
Completeness Highest resolution shell 
Total number of reflections 
Unique Reflections 
Average Redundancy 
I / a l
I / a l  Highest resolution shell
R m e r g e
Rmerge Highest resolution shell
P3,
a = b =  103.86Âc = 217.53Â
1.0Â
MAR 165 CCD 
190mm 
5 0 -3 .3 Â  
92.4%
82.2%
124,789
37,103
3.36
9.64
1.47
8.0%
44.8%
Table 4.5 Data collection statistics for HPDHQ + F A l
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As this data indexed in a trigonal system there are 5 possible Laue groups that 
the crystal could belong to. To begin the space group determination the data were 
indexed in P3, the subsequently scaled in space groups representative of each Laue 
group (Table 4.6).
Space Group Laue Group Rmeree (%) ChP
P3i -3 9.5 0.86
P3il2 -3ml 10.3 0.85
P3i21 -31m 10.3 0.85
P6i 6/m 10.3 0.85
P6i22 6/mmm 10.6 0.85
Table 4.6 Scaling statistics for HPDHQase + F A l data processed in the 5 possible Laue groups 
that obey a primitive trigonal Bravais lattice.
There does not appear to be significant rise in Rmerge as that data is scaled in 
space groups with higher symmetry, however analysis of the systematic absences 
showed that the general reflection condition (0,0,3n) was obeyed indicating that the 
crystal system was trigonal as opposed to hexagonal (where the condition (0,0,6n) 
would be satisfied). The data were therefore scaled in space groups belonging to both 
-3m l and -31m Laue groups and molecular replacement attempted (Section 5.5). No 
molecular replacement solution was found in any -3m l or -31m space group, 
therefore the data was re-processed in a lower symmetry space group P3i. In this 
case a molecular replacement was found indicating that P3i was indeed the correct 
space group.
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4.6.3 HPDHQase + GR122110
Data were collected from crystals of HPDHQase + OR 122110, prepared as 
described in section 3.4.2.3. The data were collected at beamline 9.6 at SRS 
(Daresbury). Diffraction spots were observed to 2.9Â resolution and initial data 
processing suggested the crystals belonged to a rhombohedral space group R32. A 
typical diffraction image is shown in figure 4.13a. The presence of spots along one 
direction with very fine d-spacing (Figure 4.13b) suggested that one unit cell axis 
was very long. The calculated unit cell dimensions for this crystal were a = b = 
182.95Âc = 658.83Â.
Due to the long unit cell axis, an oscillation angle of 0.5° was used per frame 
and 120 frames were collected. Data collection statistics are shown in table 4.7
Figure 4.13a A typical diffraction image from a HPDHQase + GR122110 crystal recorded on 
beamline 9.6 at SRS (Daresbury) using the ADSC Quantum 4r CCD detector.
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Figure 4.12b Diffraction spots with small d-spacing collected from a crystal of HPDHQase + 
GR122110. The small d-spacing relates to the long length of one of the unit cell axes.
HPDHQ + GR122160 SRS 9.6 data collection
Space Group 
Unit Cell 
Wavelength 
Detector
Crystal to detector distance 
Resolution range 
Completeness
Completeness Highest resolution shell 
Total number of reflections 
Unique Reflections 
Average Redundancy 
I /oI
I / Gil Highest resolution shell
Rmerge
Rmerge Highest resolution shell
R32
a = b = 182.95Â c = 658.834Â y = 120°
0.87Â
ADSC Q4r CCD 
240mm 
3 0 - 3 . IÂ 
99.4%
99.9%
262,992
76,880
3.42
8.46
1.58
10.2%
45.3%
Table 4.7 Data collection statistics for HPDHQ + GR122110
99
Chapter 4___________________ Collection and Processing of X-ray Diffraction data
4.7 Structure Factor Equation
The information obtained from X-ray diffraction data collection is the 
intensities of Bragg reflections and their Miller indices hkl. Each Bragg reflection 
has a corresponding structure factor (F^/), which describes the amplitude and phase 
of the reflection. The standard notation of the structure factor is shown below
N
Fhki = ' ^ f j  exp[2m{hxj+kyj + Izi)]
As each Bragg reflection can be represented as a wave, the structure factor can be 
described in terms of an amplitude \Fhki\ and phase a
Fhki = |Fw| Qxp{2mcxhki)
From the X-ray diffraction data we have recorded the reflection intensities (Ihki) 
which are related to the square of the structure factor intensities as shown. The figure 
^ is a scaling factor.
\Fhkl\ =  k^Ihkl
The conversion of Bragg reflection intensities to structure factor amplitudes was 
carried out using the CCP4 program Truncate (CCP4, 1994).
Unfortunately no estimation of the phase of the structure factor can be 
obtained from observed X-ray diffraction data. A complete estimation of the 
structure factor can’t be calculated directly from a single data set, unless there are 
atoms present that do not obey classical scattering of X-rays. This phenomenon is 
anomalous scattering which facilitates phase estimation by Muliple wavelength 
Anomalous Dispersion (MAD) or Single wavelength Anomalous Dispersion (SAD), 
however as neither of these techniques were carried out in the work in this thesis they 
will not be described.
100
Chapter 4___________________ Collection and Processing of X-ray Diffraction data
If an analogous protein structure has been determined previously, the 
molecular replacement technique (Rossmann and Blow, 1962), can be applied to gain 
initial phase information
4.8 Conclusion
Complete sets of X-ray diffraction data have been collected for HPDHQase + 
AH9095 using an in-house rotating anode X-ray source and a synchrotron radiation 
source. The in-house data set was complete to 2.5Â resolution and the synchrotron 
data set complete to 1.5Â resolution. The observed reflection intensities were 
converted to structure factor amplitudes and the data sets prepared for phase 
estimation by molecular replacement.
Complete data sets were also collected from a crystal of HPDHQase soaked 
in GR75872 to 2.4Â resolution and HPDHQase + FAl to 3.3Â resolution, both of 
which could be taken forward for phasing by molecular replacement. A data set from 
a crystal of HPDHQase + GR122110 was collected to 3.1 Â, however the very large 
unit cell dimensions calculated for this crystal would make phasing a refinement 
problematic therefore this data was taken no further.
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Chapter 5 -  Structure solution of H.pylori DHQase by Molecular Replacement
In order to gain initial phase information for structure refinement a variety of 
techniques is currently routinely performed. If no analogous structure information is 
available, methods such as multiple isomorphous replacement (MIR), multi­
wavelength anomalous dispersion (MAD) and in some cases direct methods, can be 
applied to obtain initial phase information. In the case of HPDHQase, the crystal 
structures of the type II DHQases from M. tuberculosis and S. coelicolor have been 
solved previously, therefore the molecular replacement (MR) technique was applied 
for structure determination. Many molecular replacement packages are currently 
available such as AMoRe (Navazza, 1994), MOLREP (Vagin and Teplyakov, 1997), 
BEAST (Read, 2001) and EPMR (Kissinger et al, 1999). As each program treats the 
MR process differently, an overview of the methods applied in this thesis will be 
given.
5.1 Molecular Replacement
The molecular replacement method, first proposed by Rossmann and Blow in 
1962, was first developed to utilise non-crystallographic symmetry (NCS) to reduce 
phase uncertainties in ab-initio structure determination. However, as the number of 
structures in the protein data bank (PDB) has grown, molecular replacement has been 
used to gain initial phase information using the structure of a homologous protein as 
search model. The position of the molecular model within the crystal is determined 
by the rotation (R) and the translation (T) that move the model from a reference 
initial position (r ), to the current position (r).
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r = R / + T
Equation 1: Position r after rotation (R) and translation (T) from  reference point r ’
Most MR packages are based upon the properties of the Patterson function, 
which requires no phase information.
h k I
hkl cos 27t{hu + + Iw)
Equation 2: Patterson function. P(u,v,w) is a contour m ap in which peaks correspond to inter­
atom ic vectors
As the molecular replacement problem has six search variables (three rotational 
and three translational), to compute all six variables simultaneously, despite modem 
computing speeds, is not feasible. Therefore most MR packages split the search into 
a rotation search, followed by a translation search, and the Patterson function too can 
be split into parts that are sensitive to these parameters.
1. Self-Patterson vectors - Short intramolecular vectors between atoms of the same 
molecule
2. Cross-Patterson vectors -  Vectors arising from intermolecular atoms
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Simple Structure with 2-fold axis
B
Patterson Function
• f
Crass-Patlersoii vectors
*  ^ ® Self Patterson vectors
Figure 5.1: (A)- two tri-atomic molecules related by a two-fold rotation axis and (B) the 
resulting Patterson function showing self-vectors (black) and cross vectors (red)
5.1.1 The Rotation Function
For MR to be successful, the rotation applied to the search model must be as 
accurate as possible, increasing the likelihood of a successful translation search. The 
rotation function should find the orientation of the search model that results in the 
maximal overlap of the Patterson self-vectors as these are sensitive to the orientation 
of the model, but not to interactions with other molecules (i.e. position within the 
crystal). As it is only the correlation between the self Patterson vectors that are of 
interest, only a shell of Patterson space is analysed omitting the cross Patterson 
vectors and the Patterson origin peak. For validation of the rotation function, a 
correlation coefficient is calculated between the search model and the target 
structure.
Many current MR packages such as AMoRe utilise the Crowther fast rotation 
function (Crowther, 1972) which approximates Pattersons by spherical harmonics.
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allowing the rotation function to be calculated by FFT. Packages such as AMoRe and 
MOLREP take the top ranking solutions from the rotation function and proceed to 
perform the translation search.
5.1.2 The Translation Function
Having determined the correct rotation of the search model, the search model 
can then be translated within the target unit cell, taking into account symmetry 
elements. Patterson methods can again be used, this time analysing the overlap of the 
cross Patterson vectors, however many current MR packages calculate an R-factor 
between the search model and its symmetry mates as they are translated around the 
unit cell.
y ,  j|F*(oèj)| -  Â:|Fft(caZc)[|
Equation 5.3: R factor calculated between observed and calculated structure factor amplitudes 
for the translation function, k is a scaling factor
The solutions found with the lowest R-factors are considered to be the top 
ranking results. The final stage in MR is to perform rigid body refinement upon the 
best solutions and calculate a final R factor for that solution.
5.1.3 Multidimensional Molecular replacement
As stated previously, traditional approaches to molecular replacement have 
been split into a rotation search followed by a translation search. Although this
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approach results in greatly reduced computation times, there are various 
disadvantages associated with the methodology. Firstly, there is a very low signal to 
noise ratio observed for the critical rotation function, and secondly, a successful 
translation search is heavily reliant upon an accurate rotation function. Six 
dimensional searches involve large amounts of calculations and until recently were 
seen to be unfeasible (Sherriff et a l, 1999). However, with advances in 
computational strategy such as genetic algorithms and evolutionary programming, 
six dimensional searches have been successfully implemented in molecular 
replacement packages (Kissinger et a l, 1999).
5.1.4 Molecular Replacement by Evolutionary Search
The program EPMR (Kissenger et a l, 1999) uses an evolutionary algorithm 
to perform rapid six dimensional molecular replacement searches. In evolutionary 
algorithms, the global optimum of a function is found through the iterative 
optimisation of a population of initially random trial solutions. As each cycle 
progresses, each solution is ranked and the top solutions retained to serve as ‘parents’ 
of the next generation. Random variations are applied to the ‘parent’ solutions to 
generate a new population and the process repeated iteratively. In the case of 
molecular replacement by evolutionary searching, an initial population of molecular 
replacement solutions is generated, assigning a random orientation and position to 
each member of the population. A correlation coefficient is calculated for each 
solution and compared with a small number of other randomly chosen solutions. The 
number of these ‘competitions’ that a particular solution wins is used to rank the 
solutions and to determine which solutions ‘survive’ to be parents in the next round.
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These solutions enter the next stage unmodified, but are also used to generate 
the new population by applying random variations of orientation and position. The 
general method applied by EPMR is as follows.
Calculation of structure factors for each solution
Rigid body refinement using conjugate gradient optimisation 
performed on the best solution
Random alterations made to survivors to generate offspring to 
restore population
Survivors from tournament which compares CC of solution with 
randomly chosen individuals from population
Solutions ranked using linear correlation coefficient (CC) between 
observed and calculated structure factors
Initial set of 300 trial solutions with random values for the six 
parameters describing orientation and translation
50
Generations 
Per cycle
Figure 5.2: Outline o f the procedure carried out by EPM R for m olecular replacement.
5.2 Attempts to solve HPDHQase structure using AMoRe
In previous work upon complexes of MTDHQase, molecular replacement 
using AMoRe had been successful in structure solution. However, when AMoRe was 
used upon the data from HPDHQase + AH9095, no obvious solutions were found. A 
variety of search models was used, including main chain traces of MTDHQase, 
SCDHQase and type II DHQase from Bacillus subtilis (BSDHQase). The main
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problem appeared to be that no significant peaks were observed in the rotation 
function, resulting in a poor translation search (table 5.1)
M odel % Sequence 
identity
C C for  
highest peak  
in Rotation  
function
N o of peaks 
>50%  
maximum  
peak height
Best solution  
CC
Best soluti 
R (% )
MTDHQ 33.5 17.8 32 28.5 67.4
SCDHQ 34.1 12.8 53 24.7 64.1
BSDHQ 37.5 13.3 46 25.4 67.9
MT_MAIN - 19.6 34 33.2 66.7
SC_MAIN - 19.5 34 38.1 65.9
BS_MAIN 15.4 48 34.7 64.8
Table 5.1: Sum m ary o f results from attempts to solve HPDHQase by m olecular replacement 
with AM oRe
One reason for the failure of AMoRe to find a correct solution for the rotation 
function may occur due to the high symmetry of the HPDHQase crystals. As outlined 
previously, many MR packages compare self-Patterson vectors to analyse the success 
or failure of a rotation solution. In a space group such as F23 there is a great deal of 
overlap between the areas of Patterson space occupied by self-vectors and cross­
vectors, as the unit cell is tightly packed with extensive crystal contacts in all 
directions. This may result in problems partitioning self and cross vectors for rotation 
validation.
To address this issue the evolutionary search program EPMR was used for 
the molecular replacement.
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5.3 Structure solution of HPDHQase using EPMR
As ongoing attempts to solve the HPDHQase structure by conventional 
molecular replacement methodologies, EPMR was used in parallel. After initial 
experimentation with the program, a poly-alanine model based upon the MTDHQase 
structure was used as the search model. A population size of 400 was generated, with 
a minimum intermolecular distance (as calculated from the centre of mass of the 
model) of 20A input. Initially the program was set to run for 100 cycles, but was 
terminated after 10.
HPDHQase Molecular Replacement from EPMR
4 5 6 7
C ycle N um ber
10
Graph 5.1: Graph showing Correlation Coefficient (blue) and R-factor (maroon) for 10 cycles of 
evolutionary searching using EPM R.
The first solution from EPMR had a correlation coefficient of 33.8% and an 
R factor of 55.4%, better than any solution thus far generated by AMoRe.
To determine the validity of the molecular replacement solution, the packing 
of monomers within the unit cell generated from the model was analysed with 
Quanta (Accelrys) to identify any steric clashes (Figure 5.3). No steric clashes were 
apparent within the unit cell suggesting the MR solution was correct.
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p
i
Figure 5.3 Packing of monomers within the F23 unit cell of HPDHQase generated from the MR 
solution.
5.4 Removal of phase bias by Density Modification
Molecular replacement has the disadvantage that initial phases will be biased 
towards the search model. Any method which can help escape from this is useful, 
especially at the initial stages of refinement when the fit between the structure and 
the model is poor.
Structure factors with SIGMAA weighted phases were calculated from the 
poly-alanine molecular replacement model before phase modification using the 
program DM.
The program DM (Cowtan, 1994) is primarily used to improve experimental 
phases (i.e. those attained from MIR, SIR, MAD etc.) by applying real space 
constraints upon features of electron density maps, but in this case it was used to 
reduce the phase bias contributed by the molecular replacement model. In general, 
initial phases are used to calculate electron density maps, and a mask built around 
what is deemed to be ‘protein like’ density and solvent density. Solvent flattening 
(Wang, 1985) and histogram matching (Zhang and Main, 1990) are the main 
processes carried out by DM.
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This procedure does not rely upon the atomic coordinates of a model, 
therefore the modified phases will have less bias towards the molecular replacement 
model.
The modified phases produced from DM were used to calculate a 2Fo-Fc electron 
density map (Figure 5.4).
Figure 5.4: 2Fo-Fc map contoured at 1 (purple) and 2 (orange) sigma, calculated using modified 
phases from DM. M TDHQase poly-alanine model is also shown.
The maps generated after rigid body refinement and density modification 
were of good quality and indicated that the molecular replacement solution was 
correct.
5.5 Structure solution of HPDHQase + FAl by molecular replacement
Molecular replacement was carried out to phase the data collected upon 
HPDHQase + FAl described in section 4.6.2. The initial data processing suggested 
that the crystal belonged to a space group within the -31m or -3ml Laue groups.
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space groups with 6 symmetry operators. Estimation of the content of the asymmetric 
unit was carried out by calculation of the Matthews coefficient (Vm) (Matthews, 
1968) which is derived below where Vceii is the volume of the unit cell, MW is the 
molecular weight of the protein and Z is the number of symmetry operators in the 
unit cell.
Vu=
MWZ
Assuming a protein density of 1.35g/cm^, the Vm should be between 1.66 and 
4, which corresponds to a solvent content of the crystal between 30% and 75% 
respectively
For 4 molecules per asymmetric unit, resulting in 24 molecules per unit cell, 
the Vm = 4.1 (69.77% solvent), and for 6 molecules per asymmetric unit Vm = 2.33 
(54.66% solvent).
Molecular replacement was attempted with AMoRe and EPMR, using a 
monomer and trimer of HPDHQase as the search model, however no solution was 
identified with either program.
To solve the molecular replacement the data was re-processed in the lower 
symmetry space group P3i which has only 3 equivalent positions within the unit cell. 
The calculated Vm in this space group for a complete HPDHQase dodecamer was 2.8 
corresponding to 56.4% solvent. Molecular replacement was carried out with 
AMoRe using the HPDHQase trimer as the search model. 12 peaks of identical 
height were found in the rotation search corresponding to the 12 trimers in unit cell. 
No other peaks were found above 50% of the maximum peak height. The final MR 
solution had a correlation coefficient of 69.9% and an R-factor of 34.4%.
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The crystal packing within the unit cell was analysed with Quanta (Figure 
5.5) which showed no steric clashses. The MR solution formed a complete 
dodecamer within the asymmetric unit.
f
Figure 5.5 Crystal packing of HPDHQase + F A l within the P3, unit cell.
5.6 Conclusion
In this chapter the basic principles of the molecular replacement technique 
have been outlined and shown how they were used in the structure solution of the 
type II DHQase from H. pylori.
Attempts to solve the molecular replacement using the program AMoRe were 
unsuccessful, despite the use of several type 11 DHQases as search models. A 
possible explanation for the failure of the program was the requirement of an
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accurate solution of the rotation search. The high symmetry space group and close 
packing of the crystals would result in a complex Patterson function, hindering the 
rotation search.
A good molecular replacement solution was found using the program EPMR 
which performs a 6D search through space using genetic algorithms, with a poly­
alanine model of type II DHQase from M. tuberculosis used as a search model. The 
packing of monomers within the unit cell was analysed and no obvious steric clashes 
were observed suggesting the MR solution was correct. SIGMAA weighted phases 
were calculated from the poly alanine MR solution which were modified with the 
program DM, and initial 2Fo-Fc maps calculated. The good quality of the maps 
suggested that the molecular replacement solution was correct.
Despite problems in accurately determining the space group of the 
HPDHQase + FAl crystal a correct molecular replacement solution was found using 
AMoRe. Initial data processing had suggested that the space group was of higher 
symmetry than the correct solution, however this can be accounted for by the large 
amount of non crystallographic symmetry within the asymmetric unit.
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Chapter 6 - Refinement and Model Building of HPDHQase + AH9095
Two high quality data sets have been collected upon crystals of type II 
DHQase from H. pylori in the presence of the inhibitor AH9095. A molecular 
replacement solution was found using the program EPMR using a poly-alanine 
model of the type II DHQase from M. tuberculosis as a search model. Refinement 
must now be carried out upon the model.
6.1 Refinement of Macromolecular Models
In the refinement of macromolecular models, the model coordinates are 
altered slightly and theoretical structure factors calculated for the new model. 
Currently, many methods are used to perform model refinement, namely least 
squares, maximum likelihood, energy minimisation and molecular dynamics. The 
program Refmac (Murshodov et a l, 1997) which applies maximum likelihood 
methods was used for refinement of the HPDHQase + AH9095 model. The quality of 
the model is assessed by comparing new theoretical data, calculated from the new 
model, with the observed data. This relationship is monitored with an R-factor 
(Equation 6.1)
hU
Equation 6.1: The crystallographic R -factor where |Fobsl are the observed structure factor 
am plitudes, |Fcaid is the calculated structure factor am plitude and t  is a scale factor
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Unfortunately the crystallographic R-factor is highly susceptible to over­
fitting where the R-factor can be reduced by fitting more parameters e.g. water 
molecules to structures. Therefore another indicator is required to get an unbiased 
assessment of the fit of the model to the data. To this end a proportion of the 
structure factors (typically 10%) are omitted from refinement. These structure factors 
are referred to as the Rfree set, while the remainder used in refinement are the Rwork, 
are used to calculate the Rfree factor (equation 6.2) (Brunger, 1992). As the Rfree set is 
not refined, it provides an independent assessment of the agreement between the 
model and the observed data. During the refinement process careful analysis of the 
relationship between the Rwork and Rfree indicates the quality of the model. Typically 
the Rfree value is 3-5 % higher than the Rwork-
I F — k I F ca /c ||
R free  =  ^ ----------------------------
h klcJ
Equation 6.2; The crystallographic R-factor where h k lc T  are the Rfree structure factors, |Fobs| 
are the observed structure factor am plitudes, |Fcaid is the calculated structure factor amplitude 
and t  is a scale factor
After each refinement step, new values for Fcaic (calculated structure factor 
amplitudes for the model) and PHIcaic (calculated phases) are generated. Weighted 
values for F and PHI are also calculated which are used to generate electron density 
maps using the program FFT.
116
Chapter 6___________________________________ Refinement and Model Building
6.2 Electron Density Maps
The aim of an X-ray diffraction experiment is ultimately the generation of an 
electron density map. The equation for the calculation of an electron density map, 
p(xyz), is shown below (Equation 6.3) where V is the volume of the unit cell, |Fhki| is 
the structure factor amplitude and tthki the associated phase.
pixyz) = —^\F {hkl)\ cos[2;r(/u:+ky + lz)~ a{hkl)\
^  hkl
Equation 6.3: Equation for the calculation o f an electron density map
This map (an Fobs map) is not entirely useful at this stage as the calculated
phases result in strong electron density for parts of the structure akeady phased while
the electron density for the missing parts of the structure is much weaker resulting in
a map that is biased towards the model. A much more useful map to use at this stage
is a 2Fo-Fc map. In the calculation of this map the component derived from the
observed data (Fo) is amplified to remove some of the bias. In some cases a 3Fo-2Fc
map may be used to enhance this effect further. The equation for the calculation of a
2Fo-Fc map is shown below (Equation 6.4).
p(xyz) = —2  -  |Fcfl/c|)exp[- 2m{hx+ky + lz) + iiXcai^
^  hkl
Equation 6.4: Equation for the calculation of a 2Fo-Fc electron density map
The 2Fo-Fc map is still biased towards the current model, therefore a Fo-Fc, 
or difference, map is generally used in tandem with the 2Fo-Fc map is utilised in the 
later stages of refinement. The difference map, Ap(xyz), uses the difference between 
observed and calculated structure factor amplitudes, A|F(hkl)|, and calculated phases 
a  (Equation 6.5)
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lsp{xyz) = —'^A\F{hkl)\iso cos[2;r(/w: + ky + lz)~  
y  hkl
Equation 6.5: Equation for calculation o f a Fo-Fc electron density map.
Sections of the difference map of positive magnitude indicate areas where 
there is scattering matter (i.e. atoms) not present in the model, that are in the crystal. 
Conversely, areas of negative magnitude indicate areas of the model that are not 
present in the crystal. Analysis of the model, how it fits to the 2Fo-Fc map and how it 
relates to features in the Fo-Fc map allows us to adjust the model to fit the density 
better. In early stages of refinement, when the fit of the model to the data is poor the 
difference map is very noisy and yields little information, however in the later stages 
where the model fits well to the data strong peaks and troughs are observed in the 
map, aiding model building.
6.3 Manual Alteration of the Model
In most cases, manual alteration of the model is required after inspection of 
the electron density maps. Most computer packages cannot perform the kind of 
visual analysis that the human crystallographer can, therefore alteration of side chain 
conformations, modelling of ligands etc. is carried out manually. The module X- 
AUTOFIT within the Quanta package (Accelrys) was used for manual inspection of 
electron density maps and manual alteration of the model. Quanta not only allows 
visualisation of the model and electron density maps, but also can perform local 
refinements upon areas of the model, and can also be used to dock ligands into areas 
of suitable electron density.
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6.4 Refinement and model building of HPDHQase + AH9095.
Initial refinement of the HPDHQase + AH9095 structure was carried out as 
follows. A full atomic model of an MTDHQase monomer was superimposed upon 
the poly-alanine molecular replacement solution. Using the program Quanta, residues 
that were conserved between MTDHQase and HPDHQase were retained in the 
model, and non-glycine residues that were not conserved were cut back to alanines. 
Refmac 5 from the CCP4 suite of programs was used to refine the model against the 
2.5Â data collected in-house. 3 rounds with 6 cycles of refinement were applied to 
give a final model with Rwork = 33.9% and Rfree = 40.1%.
2Fo-Fc and Fo-Fc electron density maps were calculated with the program 
FFT and analysed using Quanta. From the 2Fo-Fc map 90% of the non-glycine 
residues had their side chains modelled successfully. A second round of refinement 
with RefmacS was carried applying 4 rounds of 8 cycles to give a model with final 
statistics of Rwork = 29.1% and Rfree = 36.7 %. Inspection of the resulting 2Fo-Fc map 
indicated the presence of significant density in the active site region to indicate the 
presence of a bound ligand (Figure 6.1)
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i
Figure 6.1: 2Fo-Fc electron density map contoured at 1 (purple) and 2 (orange) sigma of 
HPDHQase + AH9095 centred upon active site region. HPDHQase model is shown in stick 
representation.
At this stage of the refinement, the model started at residue Met 3 and was 
complete until residue 17, the start of the flexible lid domain. This region of structure 
had not been visible in previous MTDHQase structures, but was modelled 
successfully in SCDHQase and BSDHQase. The model continued from residue 26 to 
residue 66 where again no density was visible between residues 66 and 70. This 
section of the structure is a 6 residue loop connecting helix 2 to strand 3, which 
contains more residues in HPDHQase than in other type II DHQases. The model was 
extended to residue 144, the C-terminus of the MTDHQase model, however density 
was visible for an extended terminal a  helix.
6.5 Refinement and model building of HPDHQase + AH9095 with high 
resolution data
At this point in the refinement, the high resolution data became available as 
described in section 4.5. After processing of the higher resolution data it was
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apparent that the two crystals upon which the in-house and synchrotron experiments 
were carried out were isomorphous with each other. The model was now refined 
against the high resolution data that extended to 1.55Â resolution. To allow direct 
comparison of the refinement against the low resolution and high resolution data, the 
Rfree set from the low resolution data set was copied to the high resolution data set 
and extended to 1.55Â.
A further 3 rounds of refinement and model building were carried out with 
manual adjustment of amino acid side chains and the addition of 25 water molecules 
using the X-SOLVATE module in Quanta. By this stage, the model statistics were 
Rwork = 23.7% and Rfree = 26.2%. The flexible lid domain between residues 18 and 26 
was still not visible, but the C-terminal helix was extended to residue 149.
A model for the ligand AH9095 was created and submitted to energy 
minimisation using the program Insight II (Accelrys) and successfully docked into 
the corresponding Fo-Fc electron density in the active site of the model using the 
program X-LIGAND (Accelrys) within Quanta. There was also Fo-Fc density within 
the active site corresponding to the presence of a glycerol molecule. A coordinate file 
for a glycerol molecule was obtained from a complex SCDHQase deposited in the 
PDB (PDB ID IGUl) and the glycerol molecule modelled into the active site in a 
similar manner.
Further rounds of refinement and manual model correction were carried out 
to give final model statistics of Rwork = 20.0% and Rfree = 22.7%. Density was visible 
at the N-terminus corresponding to the linker region and the first residues of the 
6xHis tag, allowing the modelling of 8 extra residues in this region. Attempts to 
model the lid domain were unsuccessful, however the C-terminus was extended to 
residue 157.
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6.5.1 Automated addition of solvent molecules
The addition of ordered solvent molecules to a protein structure improves the 
accuracy of the model as these molecules scatter to the same extent as the protein 
itself. Identifying the location of the ordered water molecules and placing atoms at 
those positions can be tedious and time consuming, therefore an automated 
procedure can be employed.
The program ARP (Lamzin and Wilson, 1993) was designed to refine high 
resolution macromolecular structures by modelling the protein with a series of 
dummy atoms, assessing the validity of the atoms and iteratively removing ‘bad’ 
atoms and placing new ones. This procedure is ideal for the identification of ordered 
solvent molecules in a protein structure. 2 cycles of Refmac in conjunction with ARP 
were run and 196 water molecules added to the model. The validity of these water 
molecules was assessed using Quanta, and 24 of these water molecules were 
discarded as they did not fit the observed electron density.
6.5.2 Restrained Anisotropic B-factor Refinement
When X-ray diffraction data is collected to greater than 1.2Â resolution, we 
can stop treating atoms as perfect spheres, and begin to model the thermal motion of 
the atoms more accurately. The thermal motion of an atom is indicated by its B- 
factor. When dealing with very low resolution structures, the B-factors for groups of 
atom are kept the same. As we refine using higher resolution data we give each 
individual atom an individual B-factor, although adjacent atoms must have similar B- 
factors. This is referred to as isotropic B-factor refinement. At high resolution we can 
model the thermal motion of the atom by assigning not only an overall B-factor but
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we can describe the directional motion of the atom with a series of 6 other values. 
This process is anisotropic B-factor refinement.
This process increases the number of parameters in relation to the number of 
observations hence high resolution data is required. However, within Refamc, 
restrained anisotropic B-factor refinement can be implemented at resolutions less 
than 1.2Â. In this process, more restraints are placed upon the model, effectively 
increasing the number of observations, allowing efficient refinement (Murshudov et 
a l, 1999).
In the final stages of the refinement of HPDHQase + AH9095, anisotropic B- 
factor refinement was carried out as implemented in Refmac. The final model 
statistics were Rwork = 15.6%, Rfree = 19.6%.
6.6 Quality of the final HPDHQase + AH9095 model
Electron density maps calculated from then final HPDHQase + AH9095 
model were of excellent quality. The density around the AH9095 ligand (Figure 6.2) 
is typical of the maps. Figure 6.3 shows a region of one of the central strands of the 
structure. Atomic positions can be clearly identified.
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Figure 6.2: 2Fo-Fc electron density map contoured at 4 sigma around AH9095
Figure 6.3: 2Fo-Fc electron density map contoured at 4 sigma around strand 3 of HPDHQase
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Typically in the refinement of a small molecule structure determined by X- 
ray crystallography is only considered ‘finished’ when the model fits the observed 
data, with an R-factor of around 5%. In proteins the situation is more complex due to 
the poor resolution of the data and the inherent level of disorder within the structure. 
Analysis of the R-factors and model geometry provide a guideline towards how the 
model fits the data, but how realistic the arrangement of atoms is. There are no rules 
governing what R-factors should be expected for a model determined from data of a 
specific resolution. Validation in this respect is carried out by comparison of our 
model the R-factors of existing structures in the PDB of a similar resolution 
(Kleywegt and Jones, 2002)
The programs PROCHECK (Laskowski et a l, 1993) and WHAT IF (Vriend, 
1990) perform automated analysis of a model and identify areas of the models that 
may require further attention with respect deviation from expected values. 
PROCHECK was used to analyse the final HPDHQase + AH9095 model, and plot 
the positions of each residue on a Ramachandran plot. 117 (90%) of the residues 
were in the core allowed regions whereas 9 (6.9%) residues were in the additionally 
allowed regions and 1 (0.8%) residue in the generously allowed region. 3 residues 
(2.3%), His 2, Ser 70 and Tyr 72, were found to lie in the ‘disallowed’ region of the 
Ramachandran plot. Upon inspection of the electron density in these areas of the 
structure it was apparent that the current model fitted the electron density well. His 2 
may be in a twisted conformation as there are contacts between the N-terminal linker 
region, an artefact of the 6xHis tag, with the C-terminal residues. Residues 70 and 72 
are located on a loop between helix 2 and strand 3. Removal of this section of the 
model followed by a round refinement resulted in electron density maps suggesting
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that the ‘disallowed’ conformation of the loop was indeed correct. The 
Ramachandran plot is shown below (Figure 6.4)
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Figure 6.4; Ramachandran plot generated by PROCHECK showing the main chain torsion  
angles o f HPDHQase + AH9095. Core allowed regions are shaded red, allowed regions yellow, 
generously allowed regions pale yellow and disallowed regions white.
The overall geometry of the final model is assessed by analysis of the RMS 
deviation of features such as bond lengths, bond angles and the deviation from 
planarity of planar groups. The diffraction precision index (DPI) as defined by 
Cruickshank (Cruickshank, 1999) provides an estimation of the model accuracy by 
taking into account the number of data, number of parameters, crystallographic R- 
factor and the resolution of the observed data. A Summary of these indicators is 
shown in table 6.1.
Analysis of the B (temperature) factors of atoms in the model also give an 
indication of the quality of the model, although again this measure is not only 
dependant upon the resolution of the observed data but can be affected by the
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refinement program used. A summary of the B-factors for HPDHQase + AH9095 is 
shown in table 6.2.
Indicator Value Target
RMS bond length (A) 0.014 0.022
RMS bond angle (A) 1.597 1.985
RMS planarity (A) 0.006 0.020
Cruickshank DPI 0.0929 -
Table 6.1: Geometric indicators o f the quality of the final HPDHQase + AH9095 model
Chain Description No. of atoms Average B- factor
A HPDHQase monomer 1166 23.2
A AH9095 24 15.6
A Heteroatoms excl. AH9095 17 29.4
W Water molecules 177 45.6
ALL Total Model 1384 26.0
Table 6.2: B-factor statistics for final HPDHQase + AH9095 model.
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6.7 Conclusion
A summary of the refinement procedures and associated model statistics are 
shown in table 6.1
Refinement Cycle________ Description___________Rwork (%)______Rfree (%)
0 MTDHQase poly alanine 
model
49.1 52.2
1-2 Addition of HPDHQase side 
chains
29.1 36.7
3-5 High resolution data added 
Water molecules added
23.7 26.2
6-8 Ligands modelled 20.0 22.7
9-10 Automated addition of water 
molecules (ARP)
17.4 20.6
11-14 Anisotropic B-factor 
refinement
15.6 19.6
Table 6.1: Refinem ent procedure for HPDHQase + AH9095.
The initial MTDHQase poly-alanine model, used to find a molecular 
replacement solution, was modified to include side chains conserved between 
MTDHQase and HPDHQase and refined using Refmac5. HPDHQase side chains 
that were not modelled previously were added to fit the electron density maps 
generated after each round of refinement. The high resolution data was used for 
refinement at this stage and water molecules were added with X-SOLVATE and the 
model refined for 3 more cycles. There was electron density corresponding to the 
ligand AH9095 in the active site region into which a model was successfully docked 
using X-LIGAND. A glycerol molecule was also modelled in this way. After 3
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rounds of refinement and model correction, coordinated solvent molecules were 
automatically added using ARP/wARP. Finally, anisotropic B-factor refinement was 
carried out to produce a model with final crystallographic statistics of R = 15.6% and 
R-ffee = 19.6%.
At this stage, no more cycles of refinement and manual model adjustment 
resulted in a decrease of the R-factors therefore the refinement process was stopped. 
The final model was of good quality as evaluated by PROCHECK, and can now be 
used for analysis and modelling.
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Chapter 7 -  Structural analysis of the type II Dehydroquinase from
Helicobacter pylori
7.1 Crystal Structure of type II DHQase from Helicobacter pylori
The final refined model of the type II DHQase from H. pylori consists of a 
single monomer of 162 residues forming the flavodoxin type ot/p fold observed in 
other type II DHQases. A ribbon cartoon of HPDHQase is shown in figure 7.1
The catalytic lid domain is disordered, between residue 18 and residue 26, as 
are the final 14 residues at the C-terminus. The first 10 residues (numbered -7  to 2) 
at the N-terminus of the model are part of the 6x His tag and linker region used to 
purify the protein. The C-terminal helix is much longer than that observed in any 
other type II DHQase, extending 12 residues (3 1/2 turns) beyond the main body of 
the monomer. A single molecule of the inhibitor AH9095 is bound in the active site.
The complete dodecamer is formed by crystal symmetry and is shown in 
Figure 7.2
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Figure 7.1: Ribbon representation of HPDHQase monomer, ^-strands are coloured green, a- 
helices blue and 3 ,o helices purple. The N-terminal extension corresponding to the 6xHis tag is 
coloured red and the ligand AH9095 is shown in stick representation
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Figure 7.2 HPDHQase dodecamer viewed A- down the crystallographic 3-fold axis, B- down the 
crystallographic 2-fold axis. Each monomer is coloured separately. Figure created with 
RIBBONS (Carson, 1991).
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7.2.1 A comparison of the monomer folds of the type II DHQases from 
Helicobacter pylori and Mycobacterium tuberculosis
The HPDHQase monomer superimposes upon the apo MTDHQase monomer 
(Gourley et a l, 1999 - PDB I D. 2DHQ) with an RMSD of 1.05Âbetween the 
positions of the main chain atoms and an RMSD of 1.01Â between the positions of 
the C a atoms only (Section 7.2.2). All superimpositions were calculated using 
LSQKB from the CCP4 suite of programs.
The central p-strands of the monomers overlay accurately, however the 
presence of additional residues within the loop regions of HPDHQase affects the 
orientation of the loops and helices (Figure 7.3A). The additional residues Gly43 and 
Asn44 located in the loop region between helix a l  and strand p2 not only extend the 
loop but also re-orientate helix a l ,  moving the N-terminal end of the helix away 
from the core of the monomer. The result of this movement is a 10° tilt of helix a l  in 
relation to the position of helix a l  in MTDHQase.
Residue Glu7I, located in the loop between helix a2 and strand P3 is 
present in HPDHQase but not MTDHQase. This addition does not alter the relative 
position of secondary structure features but does extend the loop, making this region 
of the structure more flexible. As a result residues Ser70 and Tyr72 adopt 
unfavourable main chain conformations. These two sequence related differences 
between HPDHQase and MTDHQase account for the major structural differences 
between the models.
Helix H4 in HPDHQase lies 0.4Â closer to the core of the monomer than the 
corresponding helix in MTDHQase, however this region may move as a result of the 
presence and nature of a bound ligand.
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B
Lid domain
Figure 7.3: Stereo pair diagrams of C a  traces o f  HPDHQase m onomers superim posed upon A • 
M TDHQase (2DHQ), B-SCDHQase (IGUO) and C- BSDHQase (IG Q O ). HPDHQase is shown  
in black, other DHQases grey. Figure created with SETOR (Evans, 1993)
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The C-terminal helix (a4) is much longer in HPDHQase than in MTDHQase, 
extending 3 turns beyond the C-terminus of MTDHQase.
7.2.2 Similarity of HPDHQase monomer to other type II DHQase monomers
The HPDHQase monomer was superimposed upon MTDHQae, SCDHQase 
and BSDHQase monomers using LSQKAB from the CCP4 suite of programs. RMS 
deviations between atomic positions of each structure were calculated (Table 7.1)
DHQase MTDHQase SCDHQase BSDHQase HPDHQase
MTDHQase 0.94 1.05 1.05 I
is
U
1
SCDHQase 39.6 0.97 0.95
BSDHQase 42.7 45.9 0.96
HPDHQase 33.5 34.1 37.1
% Sequence Identity
Table 7.1: RMS deviations between atomic positions o f HPDHQase with other type II DHQase 
structures
Initial phasing of the HPDHQase structure was achieved by molecular 
replacement using a C a model of MTDHQase as a search model. Despite sharing the 
lowest sequence identity and the highest main chain RMSD, MTDHQase and 
HPDHQase have the most similar C a positions of all the type II DHQases.
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7.3 Type II dehydroquinase from Helicobacter pylori -  Quaternary Structure
The HPDHQase + AH9095 crystals contained a single monomer in the 
asymmetric unit therefore the dodecameric quaternary structure is defined by 
crystallographic symmetry. The dodecamer has tetrahedral 23 symmetry, an 
arrangement seen rarely in protein structure (Gourley et a l, 1999). Each monomer 
interacts with neighbouring subunits along the 3-fold and 2-fold crystallographic 
axes. Illustrations of the trimer and dimer interfaces are shown in Figures 7.4 and 7.5
7.3.1 Trimer interface
The minimal catalytic unit of type II DHQase is the disc shaped trimer (Price, 
et a l 1999), concave on one face and convex on the other, with the convex faces 
packing into the core of the dodecamer. With respect to a single monomer we can 
consider the trimer interface consisting of two surfaces, surface I packs against 
monomer B and surface 2 interacting with monomer C (Figures 4a and 5a).
Surface 1 measures approximately 605Â^ and is formed by residues from 
helices HI, a3 ’, H2 and H3. These secondary structure elements are located near the 
C-terminal end of the central p sheet. Surface 2 buries 5 7 1 of surface and is 
formed by residues that are located on helices a2 and a3 ” . Surface 1 of monomer A 
interacts with surface 2 of monomer B as described for the structure of SCDHQase 
(Roszak et a l, 2002). The interaction between the two surfaces consists of 7 H-bonds 
and 1 salt bridge. A list of the hydrogen bonds between monomers A and B is shown 
in table 7.2. The residues listed from monomer A are from surface 1, and the residues 
listed from monomer B are from surface 2.
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Figure 7.4: Trim er and dimer interfaces of HPDHQase: A) the arrangements of monomers 
around the trimer interface. B) the dim er interface, formed by strand pS from each 
participating subunit lying antiparralle! to each other, resulting in the extension of the central P- 
sheet between subunits. Figure created with PyM OL (DeLano, 2002)
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Figure 7.5: HPDHQase trim er and dimer interfaces: M olecule A shows location of trimer 
surfaces 1 (magenta) and 2 (red). M olecule B shows the dim er surface coloured blue. Residues 
that form the surfaces are shown, residues that form H-bond interactions are labelled. Figure 
created using DINO (2002)
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Two interactions at the trimer interface are invariant throughout all type II 
DHQases, the interaction between ND2 of Asn 12 with the backbone O atom of Ala 
88, and the salt bridge between Asp91 and Argl 15. Asn 55 and Asp 62 are strongly- 
conserved throughout the type II DHQases, though residue 65 is less conserved. 
Residue 65 is predominately a histidine residue which would only facilitate 
formation of a single H-bond with Asnl4. The presence of a glutamine residue 
allows the formation of two H-bonds with Asn 14, increasing the strength of the 
trimer interaction.
Monomer A Location Monomer B Location Bond Length (À)
Asnl2 ND2 pi Ala88 0 a 3 ” 3.11
Asn 14 ODl HI Gln65 NE2 a l 2.99
Asn 14 ND2 HI Gln65 OEl a l 2.94
Asn55 ND2 P2 Asp62 0D2 a l 2.84
Asn55 ND2 p2 Gln65 OEl a l 3.05
A rgll5N H l H3 Asp91 0D2 a3 ” 2.90
Argll5N H 2 H3 Asp91 ODl a3 ” 2.89
Table 7.2 H-bond interactions at the AB trim er interface o f HPDHQase
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7.3.2 The Dimer interface
The dimer interface is formed between monomers from adjacent trimeric 
units. Strand p5 of each subunit lies anti-parallel with strand p5 of the neighbouring 
subunit, extending the central p-sheet between both monomers (Figure 7.5). The 
nature of this surface is predominately hydrophobic, with H-bond interactions 
formed between main chain atoms from residues Vail27 and Met 109. Additional H- 
bonds are formed between highly conserved residue Asn 107, located adjacent to the 
active site, with main chain atoms of Glyl21 and Cysl24. Each monomer buries 910 
at this surface. Illustrations of the dimer surface are shown in Figures 7.4b and 
7.5b, and a summary of the H-bonds present at the dimer interface is shown in table 
7.3.
Monomer A Monomer B Bond Length (A)
Asnl07 ND2 GlyI21 0 3.03
Asn 107 ND2 Cysl24 0 2.93
Glyl21 O Asn 107 ND2 3.03
Cysl24 O Asn 107 ND2 2.93
Vall27 N Metl29 0 2.92
Vall27 0 Metl29 N 2.98
Metl29 N Vall27 0 2.98
Metl29 0 Vall27 N 2.92
Table 7.3 H-bond interactions at the dim er interface o f HPDHQase
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7.3.3 Contribution from 6x His tag
No attempt had been made to cleave the 6x His tag from the N-terminus of 
the HPDHQase protein before crystallisation as removal of the MBP tag from the 
previous pMAL constructs had proved to be detrimental to the protein. The extra 
residues consist of an N terminal Met followed by a spacer, then the 6x His residues 
followed by a spacer, then the thrombin cleavage sequence. A further spacer lies 
between the cleavage site and the native N-terminal Met residue. Thus the following 
21 residues are added at the N-terminus; MGSSHHHHHHSSGLVPRGSH where 
the 6xHis residues are shown in bold and the thrombin cleavage site is underlined. In 
the HPDHQase/AH9095 crystal structure density was visible for 2 histidine residues 
and the linker region of the 6x His tag. Analysis of the structure revealed that the His 
tag and linker region form crystal contacts with subunits from other dodecamers 
within the unit cell.
The His tag linker region lies across the dimer interface of neighbouring 
subunits (Figure 7.6) forming 3 H-bonds, 2 to one subunit and one to the other. With 
one subunit interactions are formed between the main chain carbonyl oxygen atoms 
of GlyO and Leu-4 with the side chain hydroxyl of Thr38 and the main chain nitrogen 
of Leu 134 respectively, whereas atom NHl of Arg-1 forms an H-bond with OEl of 
Glul49 from the other subunit.
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Figure 7.6: Interactions formed by the 6xHis tag and linker. N-terminal his tag (red monomer) 
lies across the dimer interface of neighbouring subunits (blue and purple); His tag is shown in 
stick representation, residues from the dimer that interact with the his tag are coloured red. 
Figure composed using DINO (2002)
142
Chapter 7 Structural Analysis of HPDHQase
7.4 Ligand Binding of AH9095
The ligand AH9095 is much larger than any ligand previously crystallised 
with a type II DHQase, therefore the binding mode was of great interest. As the 
ligand is large we shall analyse the protein ligand interactions splitting the ligand into 
3 segments, the tetrazole moiety, the sulphonamide moiety and the poly-cyclic 
xanthene moiety (Figure 7.6). Figure 7.7 shows a detailed diagram of the HPDHQase 
active site with AH9095 bound.
H
Figure 7.6: Ligand AH9095; tetrazole moiety (blue), sulphonamide (red) and xanthene (black). 
Numbering of Nitrogen atoms are shown in subscript
>
I
Figure 7.7: Diagram illustrating AH9095 bound in the active site region of HPDHQase. Key 
residues are labelled and H-bonds shown in cyan
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The tetrazole moiety occupies the area of the active site where the main body 
of the substrate dehydroquinate has been shown to bind in SCDHQase (Roszak et a l, 
2002). The tetrazole ring is smaller than dehydroquinate and lies perpendicular to the 
plane of dehydroquinate. H-bonds are formed between the conserved active site 
residues Argl 15 and His84 to atoms N1 and N2 of AH9095 respectively. Both these 
residues interact with the C5 hydroxyl of dehydroquinate, a group that has been 
shown to be critical for activity (Harris, 1996b). An additional H-bond is formed 
from atom N to a bound glycerol molecule from the cryo-protectant solution.
The sulphonamide group of AH9095 forms 5 H-bonds to HPDHQase. Atom
01 forms H-bonds with Asn78 ND2 and the backbone N atom of Leu 105, with atom
02 forming H-bonds with atoms OGl and N of Thrl06. Another H-bond is formed 
between atom N4 and atom NDl of His 104. These interactions are analogous to the 
those observed between polyanions with other type II DHQases (Evans et a l, 2002) 
and the interactions between the Cl hydroxyl and carboxylate of the substrate with 
type II DHQases (Roszak et a l, 2002)
The xanthene moiety lies in the entrance to the active site, packing on one 
face against a flat hydrophobic surface formed by the side chains of Leu 13, Leu 16 
and Leu 105. The other face is open to solvent at the trimer interface, packing against 
Leu95 of the neighbouring subunit. The carbonyl group on ring 2 of the xanthene 
moiety does not interact with any protein residues. A glycerol molecule form the 
cryo-protectant packs against the solvent accessible face of AH9095, occupying the 
rest of the active site.
A list of all the H-bond interactions between AH9095 and HPDHQase is 
shown in table 7.4.
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Protein Ligand Section of Ligand Bond Length (A) Bond Angle (°)
Asn78 ND2 01 Sulphonamide 2.90 168.1
Leu105 N 01 Sulphonamide 2.81 156.4
Thrl06N 02 Sulphonamide 3.03 161.0
Thrl06 OGl 02 Sulphonamide 2.74 107.0
Hisl04NDl N4 Sulphonamide 2.77 164.3
Argl 15 NHl N1 Tetrazole 2.99 136.3
His84 NE2 N2 Tetrazole 2.99 157.3
Table 7.4: H-bond interactions between AH9095 and HPDHQase
7.5 Implications of Ligand Binding Mode
This is the first X-ray structure of a type II DHQase in complex with a non 
‘substrate like’ inhibitor. This is highly significant, as if we are to develop inhibitors 
of type II DHQase as anti-infective agents, as the highly functionalised and 
synthetically challenging transition state analogues previously developed to date 
(Frederickson et a l, 1999, 2002) may not be viable as potential drugs.
Kleanthous et al. (1992) showed that phosphate ions acted as competitive 
inhibitors of type II DHQases and Evans et a l (2002) expanded this work to 
characterise the inhibition of type II DHQases by phosphate and sulphate ions. The 
crystal structures of SCDHQase and MTDHQase in complex with polyanions 
described in this work indicate that inhibition is achieved as the polyanions occupy 
the same position in the active site as the Cl position of dehydroquinate. The binding 
mode of AH9095 clearly indicates that this is indeed the case, with 5 of the 7 
hydrogen bonds formed by the ligand with the protein mimicking those formed by 
the Cl functionalities of dehydroquinate. The sulphonamide oxygen atoms map the
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positions of the C l carboxylate, with the NH group forming similar contacts as the 
Cl hydroxyl.
U
Figure 7.8: Active site of HPDHQase with AH9095 bound and dehydroquinate modelled into 
binding pocket. Dehydroquinate is coloured magenta and based upon the structure of the 
inhibitor FA6.
The sulphonamide moiety mimics the C l functionality of dehydroquinate and the tetrazole 
moiety lies perpendicular to the plane of the dehydroquinate.
A recent patent filed by Arrow Therapeutics also identifies bissulphonamides 
as potent inhibitors of type 11 DHQase and Dehydroquinate synthase (International 
publication number WO 01/28537; Madge et a i ,  2001). Clearly this moiety is of 
great the importance in the generation of high affinity ligands.
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Although the sulphonamide is the most important moiety of the inhibitor, the 
tetrazole moiety plays a role extending the ligand into the active site, creating 
additional interactions with the protein. The addition of these interactions raises the 
affinity of the ligand above the level of inhibition achieved by a simple polyanion.
The xanthene moiety occupies the solvent channel leading to the entrance of 
the active site, packing against an almost perfectly planar hydrophobic surface on 
one side of HPDHQase. The hydrophobic interaction of this group with the active 
site entrance may lead to tighter ligand binding by holding the sulphonamide within 
the substrate cavity. This ‘plugging’ of the solvent channel may also hinder 
displacement of the sulphonamide by substrate.
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7.6 Rationalisation of the specific inhibition by AH9095 of HPDHQase and not 
MTDHQase
High throughput screening data from Glaxo SmithKline indicated that 
AH9095 inhibits HPDHQase effectively but shows no activity against MTDHQase, 
therefore we should be able to rationalise this specificity using structural 
information.
The H-bond interactions between AH9095 and HPDHQase are formed with 
conserved residues within the active site. The sulphonamide and tetrazole moieties 
are smaller than the substrate, therefore it is unlikely that any steric considerations 
hinder binding. If we consider the surface of the active site that AH9095 packs 
against, leucine 13 and leucine 16 are highly conserved residues while leucine 105 is 
conserved as a hydrophobic residue.
Consideration of the monomer in isolation does not explain the difference in 
affinity of AH9095 for MTDHQase and HPDHQase. Consideration of the surface 
contributed by subunit B which closes off the active site however, provides an 
explanation. Residue 95* shows no conservation within type II DHQases despite 
being located at the trimer interface. This residue is generally a small hydrophobic 
residue such as the leucine in HPDHQase, however in MTDHQase, the 
corresponding residue is a glutamic acid, Glu 92*. In MTDHQase, Glu92* forms an 
H-bond with Argl5 at the trimer interface. Argl5 also forms a salt bridge with 
Asp67* (Figure 7,9), therefore the negative charge of Glu92* is not fully neutralised. 
This results in a charged patch on the surface in close proximity to where the 
hydrophobic moiety of AH9095 would lie (Figure 7.10). This would provide a 
repulsive force towards the hydrophobic moiety of the ligand, dramatically reducing 
the binding affinity.
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Glu92*
2 .8 8 A
3 03A
3 00A
Asp67*
Figure 7.9: Interaction between A rgl5 , Glu92* and Asp67* in M TDHQase. H-bonds <3.1A in 
length are shown as green dotted lines.
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Asp91 Asp91*
□i
M e n sMet 15
Asp88- Asp88‘
Figure 7.10: Stereo surface representations of HPDHQase and M TDHQase with AH9095 hound 
in the active site: A) HPDHQase/AH9095 complex; B) M TDHQase with AH9095 modelled into 
the active site. The surface is coloured highlighting patches of positive potential hlue, negative 
potential red and neutral white. Key residues are shown in stick representation and labelled. 
The surfaces were calculated with GRASP (Nichols et al., 1991), figure created with DINO  
(2002)
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7.7 Crystal Structure of HPDHQase + 2,3-anydroquinic acid (FAl)
7.7.1 Refinement and Model Building of HPDHQase + FAl
The model generated from the correct molecular replacement solution was 
refined using REFMAC from the CCP4 suite of programs. Initial rigid body 
refinement was carried out upon the MR model, with each of the 12 chains defined 
as a rigid group. The Rwork and Rfree after this stage were 33.6% and 33.9% 
respectively.
Restrained refinement was carried out for 2 cycles, applying strict NCS 
restraints upon each chain of the dodecamer, and the model altered manually using 
X-AUTOFIT within Quanta (Accelrys). Inspection of the 2Fo-Fc and Fo-Fc maps 
showed visible density within the active site regions corresponding to the presence of 
the ligand FAl. The Rwork and Rfree at this point in refinement were 28.0% and 32.8% 
respectively.
To allow docking of the ligand within the active site, the signal to noise ratio 
of the difference density was increased by averaging the density form each of the 12 
monomers upon chain A. The NCS operators relating chain A to the other chains 
within the asymmetric unit were calculated using LSQKAB (CCP4, 1994), and a 
mask corresponding to the position of chain A was created using NCSMASK (CCP4, 
1994). The program MAPROT (CCP4, 1994) was then used to superimpose the 
density from each monomer onto chain A using the density mask. A model for the 
ligand FAl was obtained from the SCDHQase + FAl complex (PDB I D. IGUl) and 
was successfully docked into the averaged Fo-Fc density within the active site of 
chain A. The NCS matrices calculated previously were inverted and used to 
transform the ligand from chain A into the active site regions of the other monomers.
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A further 2 cycles of refinement were carried out using REFMAC, again 
applying strict NCS restraints. Due to the poor resolution of the diffraction data, the 
B value for the solvent contribution was fixed to 200 to aid the scaling of the Fobs to 
the Fcalc. TLS parameters were also included in refinement with each chain 
described as a single group. The final refinement statistics are shown in table 7.5
Refinement Statistics_________________ HPDHQase + FAl
Resolution Range (A) 30.0-3 .2
Rwork 26.8%
Rfree 29.4%
RMS bond length deviation (A) 0.032
RMS bond angle deviation (°) 2.592
Mean B factor (A) main chain 28.89
Mean B factor (A) side chain 30.06
Mean B factor (A) heteroatom 35.28
Average Intersubunit RMS deviation (A) 0.081
Table 7.5: Refinem ent statistics for HPDHQase + F A l
7.7.2 Structure of HPDHQase + FAl
The crystal structure of HPDHQase + FAl consists of one complete 
dodecamer found in the asymmetric unit. The complete dodecamer is shown in figure 
7.11. The monomer fold is similar to the structure of HPDHQase + AH9095, 
however due to the lower resolution of the diffraction data, density was only visible 
from residue His 2 at the N-terminus and no interpretable density was observed 
beyond residue Phe 153 at the C terminus. No interpretable density was observed in 
the lid domain between residues 19-25. The monomer fold of HPDHQase + FAl is 
shown in figure 7.12
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Figure 7.11: Quaternary structure of HPDHQase + F A l. The dodecam er is viewed down the 3- 
fold NCS axis and each chain is coloured individually
M et2 6 i
Figure 7.12: M onom er fold of HPDHQase + F A l. a-helices are coloured hlue and |3-strands are 
coloured red. The ligand F A l is shown in stick representation within the active site
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7.7.3 Binding mode of ligand FAl to HPDHQase
HPDHQase interacts with the ligand FAl in a similar manner to the 
previously reported SCDHQase + FAl complex (Roszak et a l, 2002). The 
carboxylate subsistuent at the Cl position of the ligand forms 4 H-bonds to the 
protein. Atom 01 interacts with the backbone N atom and the OGl atom of Thrl06 
while atom 02  forms H-bonds with the backbone N atom of Leu 105 and ND2 of 
Asn78. The Cl hydroxyl group forms 2 H-bonds to the protein, with atom ND2 of 
His 104 and with atom ODl of Asn78. Of these 6 H-bonds formed between the 
protein and the Cl substituents of the ligand, 4 H-bonds are formed with residues in 
the H-X-S/T-N motif (residues 104-107) common to type 11 DHQases. Additional H- 
bonds are formed between the C5 hydroxyl group of the ligand with NHl of Argl 15 
and NE2 of His84.
The interaction between the C4 hydroxyl of FAl with the active site Asp 
residue observed in the SCDHQase/FAl and MTDHQase/FAl complexes does not 
appear to be as strong in the HPDHQase/FAl complex. The distance between the 04 
atom with the 0D2 atom of Asp91* is 3.28Â which is outside the distance criteria 
defining a strong H-bond. A list of the H-bonds formed between the ligand FAl and 
HPDHQase are shown in table 7.6 and stereo pair diagram of the interactions 
between FAl and HPDHQase is shown in Figure 7.13
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Protein Ligand Distance (A) Angle (°)
T h rl0 6 N 01 282 146.3
Thr 106 OGl 01 238 137.8
L eu105 N 0 2 2.90 173.2
Asn 78 ND2 0 2 2.62 157.2
His 104 NDl 03 3.05 156.6
Asn 78 ODl 03 2.96 112.9
Arg 115 NHl 05 2.93 138.4
His 84 NE2 05 3.05 158.3
Table 7.6: H-bond interactions between F A l and HPDHQase
Arg115
Leu1OS f
Hl*104,
His84
Asn78 •
/
Thr106
Argils
Lm IOS
His84
His104.
Asn78 '
/
Figure 7.13: Stereo pair diagram showing a detailed view of the HPDHQase active site with F A l 
bound. The 12-fold averaged omit map electron density is shown in green. H-honds < 3.3Â in 
length are shown as magenta dashed lines.
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7.8 Discussion
The HPDHQase + AH9095 complex provides the first crystal structure of the 
type II DHQase from H. pylori. The overall monomer fold is a a/p flavodoxin type 
fold as described for other type II DHQases. The N-terminus is extended due to the 
addition of a 6x His tag and linker region employed in the protein purification. The 
amino acid sequence of HPDHQase is 162 residues in length with an extended C- 
terminal region. This C-terminal region results in the extension of the terminal helix 
a4 which extends below the bulk of the monomer fold.
The ligand AH9095 is the first non-‘substrate-like’ inhibitor to be 
crystallised with a type II DHQase, The sulphonamide moiety of the ligand mimics 
the Cl carbon of dehydroquinate forming 5 of the 6 ligand-protein H-bonds. The 
tetrazole moiety occupies the substrate binding pocket forming a single H-bond to 
the protein, and the xanthene moiety lies in the entrance to the active site packing on 
one side against a hydrophobic surface. This shows that only similarity to the Cl 
position of dehydroquinate is essential for ligand affinity.
The ligand AH9095 has been shown to be active against HPDHQase, but not 
active against MTDHQase. The sulphonamide and tetrazole moieties are smaller then 
the substrate therefore it is unlikely that they play a specific role in the selectivity 
observed. The pocket occupied by the xanthene moiety in HPDHQase is 
hydrophobic, whereas in MTDHQase the glutamic acid at residue 95 confers a 
charge upon this surface, potentially hindering the binding of AH9095.
These observations may pave the way for rational design of specific type II 
DHQase inhibitors. Previously designed type II DHQase inhibitors have been small 
highly functionalised ‘substrate-like’ compounds that are not only synthetically
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challenging, but are very hydrophilic and therefore predicted to be very susceptible 
to first pass metabolism (Lipinski et a l, 1997). Despite being invaluable for the 
elucidation of the enzyme mechanism, they would make very poor anti-infective 
agents. The addition of a large lipophillic group to a sulphonamide derivative will 
improve the solubility characteristics of an inhibitor, making it more ‘drug-like’.
We can derive a general template for new inhibitors of type II DHQases 
based upon AH9095 shown in Figure 7.14.
R 2 ,
o
Figure 7.14: General tem plate for inhibitors o f type II DHQases based upon AH9095.
Group R l, on the amino side of the sulphonamide, could be used to probe the 
substrate binding pocket, thus should be small and potentially functionalised. 
Optimisation of this moiety could increase affinity of a ligand towards type II 
DHQases but not confer specificity.
Group R2 should be large and essentially hydrophobic in character. 
Modification of this group can be used to probe the entrance channel of the active 
site, allowing the specificity of a ligand to be optimised. This group may also be 
altered to change the solubility profile of a ligand without affecting the affinity 
towards type II DHQases.
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7.8.1 Design of specific inhibitors of type II DHQase from M. tuberculosis based 
upon AH9095
The ligand AH9095 shows specificity towards HPDHQase as opposed to 
MTDHQase due to differences within the surfaces at the mouth of the active site.
The MTDHQase active site has a negative charge at one end due to the presence of a 
non-conserved glutamate residue whereas the HPDHQase active site is totally 
hydrophobic. The modification of the R2 group of AH9095 to incorporate a H-bond 
donor to interact with this glutamate residue may increase the specificity, and 
possibility the affinity, of a modified ligand towards MTDHQase. The Rl group 
shall remain a tetrazole as the H-bond interactions between this moiety and 
conserved active site residues should retain some of the affinity shown by AH9095.
As there only appears to be space for a tri-cyclic moiety within this area of 
the active site, the xanthene moiety could be reduced to a chromene skeleton. From 
this chromene skeleton, amino groups can be attached via linkers, or tri-cyclic 
moieties incorporating amino groups can be designed. Ligands designed along these 
lines are shown in table 7.7.
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Ligand
■N
I
:N
Chromene derivative
2-amino
2-methylamino
Pyrrolidine
Pyrazole
Piperidine
amino-cyclopenatdiene
% f
methylamino-cyclopentadiene
'N— (  I
N
Table 7.7: Potential M TDHQase specific ligands based upon AH9095
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Chapter 8 -  Structure Based Design of Mycobacterium tuberculosis type II
Dehydroquinase inhibitors
8.1 Introduction
As more protein structures are elucidated, by methods such as protein 
crystallography and NMR, structural information can be used to drive the generation 
of highly specific enzyme inhibitors, as opposed to the traditional methodology of 
high throughput screening (HTS) and exhaustive structure-activity studies (Blundell, 
1996). Structure based design (SBD) has become an essential part of the modem 
dmg discovery process, and has played an important role in the generation of new 
HIV protease inhibitors amprenavir (Agenerase) and nelfinavir (Viracept) (Greer et 
a l, 1994), the flu drug zanamivir (Relenza) (Varghese, 1999) and rationalisation of 
the action of the protein kinase inhibitor imatinib (Gleevec) (Schindler et a l, 2000)
Many experimental strategies can be employed in SBD, depending upon the 
amount of information available at the outset of the process. The central 
requirements are however an accurate 3D stmcture of the target molecule, and the 
design of pharmacophore models, hypotheses which describe the various potential 
interactions that enable ligand binding within the protein target. An excellent review 
of advances in the SBD process has been published by Klebe (2000).
In this project we have several sources of information. Transition state 
analogues of type II DHQase, used initially to probe the enzyme mechanism, have 
been developed and their activity characterised against type II DHQases from M. 
tuberculosis, S. coelicolor and A. nidulans. Crystal structures are available of type II 
DHQase from M. tuberculosis (Gourley et a l, 1999; Evans et a l, 2002) and S. 
coelicolor (Roszak et a l, 2002) with various transition state analogues bound in the
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active site. The crystal structure of H. pylori type II DHQase has been determined in 
this study and HTS data for this enzyme provided by Glaxo Smithkline.
8.2 Structural validation of selectivity shown by Transition State Analogues
Transition state analogues have long been used as enzyme inhibitors, notably 
in the field of protease inhibition (Radzicka and Wolfenden 1995). Fluoro-shikimate 
analogues have been shown to elicit antibacterial activity (Davies et a l, 1994) and 
transition state analogues been shown to inhibit dehydroquinate synthase 
(Montchamp and Frost 1997).
Initial studies probing the mechanisms of type I and type II DHQases 
developed transition state analogues which showed some efficacy and some 
selectivity between type I and type II DHQases (Harris et a l, 1996b; Bello et al 
1998,2000; Parker et a l 2000). Frederickson and co-workers (Frederickson et a l 
1999, 2002) progressed this work developing selective inhibitors of type II DHQaes 
via a series of compounds that mimicked the proposed transition state for type II 
DHQase. These studies showed that selectivity between different type II DHQases 
could be obtained based upon then nature and geometry of the C3 group of the 
inhibitor. A summary of the inhibition statistics is shown in table 8.1.
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Type I 
S. typhi
T ype II 
A. nidulans
T ype II 
M. tuberculosis
Type II 
S. coelicolor
CO2'
ÔH
FA l
3 ±  1 mM 6 0 ±  lOpM 200 ±  20^iM 30 ±  lOpM
H Q , C O 2
6 h
FA2
4.5 ±  0.5 mM 1.5 ±  0.2 mM 1.2 ± 0 .2  mM 0.6 ±  0.2 mM
H Q , C O 2
O H
FA3
1.5 ± 0.5 mM 50 ±  5jiM 1 0 ± 2 p M 1 5 ± 2 p M
H 0 „ C O 2
O H
FA4
8 ±  1 mM 0.6± 0.1 mM 0.7 ±  0.1 mM 0.7 ±  0.1 mM
HO„ C O 2
6 h
FA5
> 25 mM 2.2 ± 0 .1  mM 0.7 ± 0.1 mM 2.5 ±  0.5 mM
H0„ CO2
HO, X  X
V  OH 
OH
FA6
> 25mM 1 5 ±  IpM 20 ±  2pM 500 ±  200pM
Table 8.1 Inhibition statistics for a series of transition state analogues against different 
DHQases. Figure courtesy of Dr. Martyn Frederickson (University of Cambridge)
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This series investigated the activity of compounds with sp  ^geometry at the 
C3 position (FAl and FA2), and the simulation of the proposed charged C3 enolate 
by an oxime substituent (FA5 and FA6). A striking feature was the difference in Ki 
observed for compounds FAl and FA6 with respect to MTDHQase and SCDHQase. 
The compoimd 2,3-anhydroquinic acid (FAl) has a Ki of 30|iM with respect 
SCDHQase, whereas for MTDHQase the Ki is 200|iM, nearly an order of magnitude 
greater. In contrast, the compound 3-hydroxyimino quinic acid (FA6) showed greater 
affinity towards MTDHQase {Ki = 20|iM) compared with SCDHQase {Ki = SOOpM), 
an order of magnitude greater. This work suggested that sp  ^geometry at the C3 
position of the ligand was indeed very important for selective inhibition of type II 
DHQases. The observation that FA6 is a better inhibitor of type II DHQase than FA5 
showed that mimicking the charge of the transition state enolate increased efficacy. 
However, the low Ki of FA6 with respect to SCDHQase was puzzling.
The 3D structures of native SCDHQase, SCDHQase + FAl, MTDHQase, 
MTDHQase + FAl, MTDHQase +FA6 have been determined previously (Gourley et 
al 1999, Roszak et al. 2002, Robinson et a l, manuscript in preparation). Attempts to 
co-crystallise SCDHQase with FA6 were unsuccessful due to the very low affinity of 
the ligand. From these structures, the binding mode of the ligands will be analysed 
and the basis for the selectivity of FA6 towards MTDHQase will be rationalised.
This information will be used in the design of a structure based design experiment.
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8.2.1 Type II DHQase ligand binding
To design high quality pharmacophore models, the important protein ligand 
interactions have to be identified. High resolution crystal structures of FAl bound to 
MTDHQase, SCDHQase and a low resolution structure of FAl bound to HPDHQase 
(Section 7.7) have been determined. A diagram of the MTDHQase/FAl complex is 
shown in figure 8.1 and a list of protein -  ligand interactions is given in table 8.2. 
From this data it is apparent that the interactions between the Cl substituents of the 
ligand with the H-X-S/T (101-103) segment and Asn75 form the basis of the ligand 
recognition. Clearly these interactions must be included in any pharmacophore 
model.
The interactions between the C4 hydroxyl with Asp88* and the interactions 
between the C5 hydroxyl with His81 and Argl 12 are also important as they would 
orientate the ligand as to fill the substrate binding pocket. The observation from 
Harris et a l (1996b) that 5-deoxy-3 -dehydroquinate is a poor substrate for type II 
DHQases, and 4,5-dideoxy-3-dehydroquinate is a poor inhibitor of type II DHQases 
suggest that the interactions fulfilled by the C5 and C4 hydroxyl groups not only 
orientate the substrate into the correct position for catalysis but are critical for 
binding.
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Arg 108
S e ri 03 Tyr24 '
HislOI ^  HisBI
V - '' P - -------1 Gly78
r
Asp88
\
Asn75
Gly77
Figure 8.1: Detailed view of M TDHQase active site with the inhibitorFAl bound. Hydrogen 
bonds < 3.2A in length are shown in blue
Protein Ligand Bond Length (À) Bond Angle (°)
Ser 103 OG 01 2.97 97.1
Ser 103 N 01 2.79 166.3
lie 102 N 02 2.89 158.1
Asn 75 ND2 02 3.03 163.4
Asn 75 ODl 03 3.12 124.8
His 101 NDl 03 2.87 176.4
His 81 NE2 05 2.92 170.7
Arg 112 NHl 05 2.94 147.9
Asp 88* 0D2 04 2.38 167.5
Table 8.2 Protein -  ligand hydrogen-bond distances and angles for the M TDHQase - F A l 
complex
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8.2.2 Specificity of 3-hydoxyimino quinic acid (FA6) towards MTDHQase
The ligand 3-hydroxyimino quinic acid (FA6) inhibits MTDHQase with a K, 
over an order of magnitude smaller than the equivalent Ki for SCDHQase. Using the 
crystal structures available to structural basis for this selectivity, the SCDHQase/FAl 
complex and the MTDHQase/FA6 complex were superimposed using LSQKAB 
from the CCP4 suite of programs.
The comparison of ligand binding modes between structures was not simple, 
not only due to the differences in sequence between the two enzymes, but also due to 
ligand induced conformational changes that became apparent during the analysis. 
The minimal catalytic unit of the type II DHQases has been shown to be the trimer 
(Price et a l, 1999). This is due to each active site being closed off by a neighbouring 
monomer. As both subunits contribute to ligand binding the trimer unit was 
identified as the template for comparison. Due to the ligand induced movement of 
the loops around the active site, the 3 central p strands (strands 2, 3, and 4) of each 
monomer were used as the reference residues for superimposition.
The ligand FA6 was modelled into the active site of SCDHQase using the 
position of FAl as a reference. The position of the Cl carbonyl and hydroxyl groups 
were matched and the C4 and C5 hydroxyl groups were orientated to the best fit due 
to the difference in ring conformation of the two inhibitors. Figure 8.2 shows the 
position of FA6 modelled into the SCDHQase active site.
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^Ser108
His106
Asn79
His85
Ala82
Ala81
Figure 8.2 Active site of SCDHQase with FA6 modelled into active site based upon 
superposition of SCDH Q +FAl and M TDH Q +FAl complexes. The surface is coloured to show 
proximity of the ligand to the surface. Areas shaded purple show interactions <3.2A but >1.5A, 
areas shaded red show interactions <1.5A, the proposed clash between FA6 and Ala81
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The superimposition clearly shows that a steric clash would occur between 
the hydroxyl group of the oxime and the side chin of AlaSl on the floor of the active 
site, hence perturbing binding of the ligand. The residues that from the floor of the 
active site are not conserved throughout type II DHQases, though they are always 
glycine or alanine residues. MTDHQase has two glycine residues at this position 
whereas SCDHQase has two alanine residues. The nature of the first reside appears 
to affect the binding of FA6 as the catabolic type II DHQase from Aspergillus 
nidulans (ANDHQase) has a glycine at the first position and an alanine at the second 
(Figure 8.3). The Ki for FA6 with respect to ANDHQase is 15|iM, compared to 
20jxM for MTDHQase and 500|xM for SCDHQase.
This shows that selectivity between type II DHQases can be obtained by 
consideration of steric effects within the active site as opposed to charge interactions.
8.2.3 Considerations for design of pharmacophores hased upon DHQase/Iigand 
complexes
In conclusion, from the DHQase/Iigand complexes analysed, 
pharmacophores must take into account interactions satisfied by the Cl 
functionalities of the substrate and must consider that steric effects may influence 
specificity of resultant ligands. Pharmacophore models must therefore have a cluster 
of H-bond acceptor sites that mimic the Cl carbonyl and hydroxyl groups. Figure 8.4 
shows the key areas of the structure that must be considered in pharmacophore 
design. The H-X-S/T segment that coordinates the Cl carbonyl is coloured red, and 
the floor of the active site coloured green.
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Figure 8.3: Sequence alignm ent of type II DHQases. The band below the alignment indicates 
residues that form the floor of the active site. Sequences shown are AROD_STRCO  
(SCDHQase), 3DHQ_ASPNI (ANDHQase), AROD_MYCTU (M TDHQase), AROD_CAM JE  
(CJDHQase) and AROD HELPY (HPDHQase)
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Figure 8.4: Ribbon diagram of an SCDHQase monomer illustrating tbe key areas for 
pharmacophore design. Conserved residues within the active site are shown and labelled. The 
H-X-S/T loop (106-108) is highlighted red and the floor of tbe active site is (81-82) highlighted 
green
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8.3 Generation of Pharmacophore models for structure hased design
To increase the possibility of identifying a novel small molecule that acts a 
selective inhibitor of the type II DHQase from M. tuberculosis, the SBD protocol 
was carried out for not only MTDHQase but also SCDHQase and HPDHQase. 
Pharmacophore models were constructed for MTDHQase, SCDHQase and 
HPDHQase in an identical manner.
The SBD process was carried out using the LUDI module within the Cerius II 
package and the CATALYST package, both from Accelrys (Cambridge, UK). Figure
8.5 shows a flow diagram of the SBD process using this software.
8.3.1 Definition of the Active Site
The first stage in the generation of a pharmacophore model is the definition 
of the 3D area of the protein structure that the pharmacophore will sample. In the 
case of type II DHQase this was trivial as the active site is well defined and all 
structures had the ligand FAl bound in the active site.
The centre of the active site was defined as the centre of mass of the ligand 
FAl (Figure 8 .6 a). From this point a sphere of radius 10Â was selected as the area of 
structure to be analysed to construct the pharmacophores (Figure 8 .6 b).
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Figure 8.5: Structure based design process using the Accelrys software packages CeriusII and 
Catalyst
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Figure 8 .6 a: Definition of the active site of M TDHQase. The ligand F A l is highlighted in yellow
Figure 8 .6 h: Definition of a sphere of radius 10À around the centre of the M TDHQase active 
site. The ligand F A l is highlighted in yellow
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8.3.2 Generation of a ligand interaction map using LUDI
The next stage in the pharmacophore design is to probe the defined active 
site for sites of potential protein-ligand interactions. This was performed using the 
LUDI module within CeriusII. This procedure identifies vectors of potential H-bond 
interactions within the active site, defining the sites as either H-bond donor, H-bond 
acceptor. Lipophilic sites are also identified. This results in an array of potential 
interactions around functional groups within the protein (Figure 8.7a) i.e around a 
backbone carbonyl, an array of H-bond donor sites will be identified.
As modelling each potential interaction would be very complex, the 
interactions are clustered around each protein functionality. The centroid of each 
cluster is then identified and used to describe the interaction. Figure 8.7b shows the 
centroids of the H-bond acceptor sites (red and white) and H-bond donor sites (Blue 
and white) within the active site of MTDHQase. The ligand FAl (yellow) is shown 
to illustrate how the potential interactions map to the real interactions between the 
protein and the ligand. For each DHQase 7 H-bond acceptors sites, 3 H-bond donor 
and 4 lipophilic sites were identified.
8.3.4 Generation of multiple pharmacophore models
In order to maximise the number of hits from the in silico screen, a series of 
pharmacophore models are created using different combinations of the potential 
interactions. Each pharmacophore consists of 5 features, with at least a single H- 
bond acceptor, H-bond donor and lipophilic site. However as we know that the 2 H- 
bond acceptor sites corresponding to the Cl carbonyl are essential for ligand binding 
these interactions are conserved throughout all the pharmacophores. In total, 12 
combinations of interactions were constructed for each DHQase.
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Figure 8.7a: Interaction map generated by LUDI for MTDHQase. H-bond acceptor sites are red 
and white bars, H-bond donor sites blue and white bars and lipohphillic sites grey.
Figure 8.7b: Centroids of interaction clusters in MTDHQase. The ligand F A l is shown in yellow  
to illustrate how the potential interactions map the observed protein ligand interactions.
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As it has been demonstrated that the specificity shown by FA6  towards 
MTDHQase is a result of steric effects within the active site, the pharmacophores 
were designed to accommodate steric constraints. A series of ‘exclusion spheres’ 
were generated mapping the van der Waals surfaces of the protein atoms, and 
incorporated into the pharmacophore models.
An example of a pharmacophore model generated from MTDHQase is shown 
in figure 8 .8 . The H-bond acceptor sites are green spheres, H-bond donor sites pink 
spheres and lipohilic sites blue spheres. The exclusion spheres are shown as grey 
spheres.
Figure 8 .8 : A pharmacophore model generated for MTDHQase
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8.4 Database searching using Catalyst
The pharmacophore models generated for each type II DHQase will now be 
used to search a compound database using the program Catalyst (Accelrys). Catalyst 
searches multiple-conformation databases of compounds identifying hits that satisfy 
pharmacophore models. Multiple conformation databases are used as there is no 
guarantee that a ligand will bind to a protein in the lowest energy conformation, 
easing steric constraints.
The database searched was the Maybridge ’99 database. This database was 
selected as it contains quite a diverse range of compounds which are all 
commercially available. This database contains 55,273 compounds.
Catalyst was run in ‘fast’ mode, which rejects any compounds that collide 
with the exclusion spheres in the pharmacophore model. This took into consideration 
steric effects upon ligand specificity.
Maybridge ’99 was searched by Catalyst using each of the 12 pharmacophore 
models generated for each type II DHQase as templates. The numbers of hits found 
by Catalyst for each type II DHQase are shown in table 8.3
DHQase No. Hits
MTDHQase 111
SCDHQase 881
HPDHQase 386
Table 8.3: Num ber of hits identified by Catalyst searching M aybridge ’99 database using type II 
DHQase pharm acophore models
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Of the 111 hits identified for MTDHQase, 36 were unique hits not identified 
for SCDHQase or HPDHQase. The 36 MTDHQase unique compounds are shown in 
Table 8.4.
8.5 Assay to determine inhibition of MTDHQase by in silico screen hits
The compounds identified as potential selective MTDHQase inhibitors from 
the SBD experiment were obtained from Maybridge. 30 of the 36 hits were available 
for purchase and Img of each available compound was obtained. The compounds 
were dissolved in 100% DMSO at a concentration of lOmM and stored at 4°C. Table
8.4 shows the compounds that were not available.
8.5.1 Activity assay -  first round
Compounds were tested for inhibition of MTDHQase using the standard 
DHQase assay (Section 2.10). The assays were carried out in 1ml quartz cuvettes 
with a path length of 1cm. The assay conditions were 0.5jig MTDHQase, 2mM 
dehydroquinate and 100|iM inhibitor. Table 8.5 and figure 8.9 show the % inhibition 
for each compound under these assay conditions.
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Structure Maybridge 
Catalogue No.
.  .jO
OH OH
BTB 12004
H
HgN N-NHg
0  ^ '
CD 03087
H O ^ O  , 0 H 
OH
JFD 00804
OH \ ^ o
W
Cl
RDR 01608
Hd'
RJC 01330
NHa
t X y V n v
0=^ =0 " L s/'-F
NH, F
SEW 02056
Table 8.4 Compounds identified by structure based design that were not available for purchase
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Compound
Number
Structure Maybridge
Catalogue
No.
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HO
HO BTB 11978
HO
HO
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HO
HO OH
OH
BTB 11990
HO S
HO OH
OH
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26
f"
OH
y " " N  y = 0
0  y »
RJC 03215 73
27
HO,,
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°
RJC 03234 88
28 OH
<
/  \
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OH
0 =N^
0
RJC 03292 17.6
29
— \  H 
0
SB 01887 95
30 OH OH
HO
XBX 00089 100
Table 8.5: Compounds identified by structure based design to be inhibitors o f MTDHQase. 
Inhibition statistics from the first round o f assays are shown
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Figure 8.9: %V/Vma% measured for 30 compounds against MTDHQase. Those marked with a 
star were taken forward into the next round of assays.
8.5.2 Activity assay- Second round
Six compounds that showed the highest inhibition of MTDHQase were taken 
forward into the second round of activity assays. In this assay each result was 
measured in triplicate against 2 concentrations of substrate, 500|iM and lOOpM. The 
inhibitor concentration was 100|iM and the protein concentration 0.5pg/ml. Results 
are shown in table 8 .6 .
The results show that five of the compounds have similar activity against 
MTDHQase in the presence of lOOpM and 500pM dehydroquinate. Compound 16 
appeared to form a precipitate in the presence of 500| l iM  dehydroquinate therefore 
results were not recorded. Compound 28 showed the best inhibition reducing 
MTDHQase activity by greater than 50% in the presence of 500pM dehydroquinate.
186
Chapter 8_____________________Structure Based Design of MTDHQase Inhibitors
8.6 Predicted binding modes of active compounds
As Catalyst performs fitting of molecules into an active site, the predicted 
poses of the 6  most active compounds were analysed. Figure 8.10 shows these 
compounds within the active site of MTDHQase.
Compounds 11 and 16 contain sulphone moieties similar to the HPDHQase 
specific ligand AH9095, however the predicted binding orientation of these 
compounds do not position the sulphone moiety such that it is fully coordinated by 
protein atoms. The coordination of the sulphone groups appears to be restricted by 
steric constraints upon the ligands, thereby not allowing this group to bind in the 
same orientation as the sulphate polyanion.
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Compound
Number
Structure %V/Vmax 
SOOpM DHQate
%V/Vmax 
lOOpM DHQate
1
0
62 58
11 62 60
12
c r " t X -
NHj,
6 8 72
16
Q = S = 0
>■-0 - 0 :
79 N/A
18
X i ,
75 65
28 OH{ OH 
O \  "OH
Q k n ' o h
o=r(
0
41 46
Table 8 .6 : Second round assay results for top six com pounds against M TDHQase
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Figure 8.10: Proposed binding modes of M TDHQase inhibitors. Left panels show a surface 
representation of the enzyme coloured by potential. Right panels show detailed views of the 
active site. H-honds between the ligands and the protein are shown as magenta dotted lines. See 
figure 8 .1  for substrate binding mode
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Compound 28 appears to bind tightly to Seri03 and Arg 108, occupying the 
substrate binding cavity more effectively than the other ligands. As Seri03 is critical 
for substrate binding this suggests a reason why this compound is the most effective 
MTDHQase inhibitor identified.
8.7 Discussion
The use of structure based design has identified a selection of compounds that 
show activity towards MTDHQase. Pharmacophore models were designed to 
represent the H-bond interactions formed by transition state analogues and the 
protein. Analysis of DHQase/transition state analogue crystal structures suggested 
that target specificity could be obtained by consideration of steric constraints within 
the active site, therefore pharmacophore models incorporated exclusion volumes.
The six compounds that show the greatest affinity towards MTDHQase are 
quite diverse, sharing few functional features. Two of the compounds contain 
sulphone groups similar to the HPDHQase specific inhibitor AH9095, however the 
predicted binding mode of these compounds does not result in fiill coordination of 
the sulphone moiety as observed in HPDHQase/AH9095.
Future study should involve analysis of key features of the active compounds 
to generate new pharmacophore models that should enable identification of 
compounds with greater efficacy. The pharmacophores in this study only occupied a 
radius of 10Â around the centre of the substrate binding cavity. As shown in chapter 
7, the specificity of AH9095 towards HPDHQase as opposed to MTDHQase is due 
to differences in topology and charge in the entrance to the active site. Therefore, by 
extending the pharmacophore models to incorporate this area of the active site may 
result in the identification of more potent MTDHQase specific inhibitors.
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Chapter 9 -  Development of a novel assay to follow activity of type II DHQase
9.1 Need for a new DHQase assay
As outlined in section 2.10, the standard assay for DHQase activity follows 
conversion of 3-dehydroquinate to form 3-dehydroshikimate. An increase in 
absorbance at 234nm is observed as the product has a conjugated bond system not 
present in the substrate. This assay is robust, but does require high quality substrate 
and is carried out using quartz cuvettes and a high quality spectrophotometer. This 
assay is suitable to determine kinetic characteristics of DHQases and to study in 
depth the inhibitory properties of potential ligands, but to achieve higher throughput, 
analysing larger number of compounds, the use of cuvettes is severely time limiting. 
Many standard assays are routinely carried out using 96-well plates, however due to 
the low wavelength of the absorbance in this assay, the signal is lost as the plastic 
plates also absorb light in this region of the spectrum. High throughput screens have 
been carried out on DHQases by coupling the assay with that of shikimate 
dehydrogenase (SDH), the next step in the pathway. Shikimate dehydrogenase 
requires NADPH as a cofactor, and the conversion of NADPH to NADP^ can be 
followed by an increase in absorbance at 340nm.
There are problems associated with coupled assays with respect to identifying 
inhibitors of a specific enzyme as the compounds may elicit effects upon the 
coupling enzyme, generating false positives. This is a significant problem with 
coupling enzymes that utilise a co-factor, as many compounds in the screen may 
block the co-factor binding site. In the quest to develop a new assay for DHQase, the 
conversion of 3-dehydroshikimate to protocatechuate (PCA) by 3-dehydroshikimate
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dehydratase (DHSase), an enzyme from the quinate pathway, was investigated 
(Figure 1).
COgH
HQ,
OH
OH
D H Q ase  
 ►
3 -dehydroqu inate
D H Sase
OH SD H
N A D PH ,OH
3 -dehydrosh ik im ate N A D F
OH
P ro tocatechuate
COgH
OH
sh ik im ic  acid
Figure 9.1: Conversion o f 3-dehydroquinate to 3-dehydroshikimate by dehydroquinase 
(DHQase) and its subsequent transformation to shikimic acid, catalysed by shikimate 
dehydrogenase (SDH), and to protocatechuate, catalysed by dehydroshikim ate dehydratase 
(DHSase)
PCA generation has been used to quantify activity in the quinate pathway of 
fungi as PCA forms a strongly coloured complex in the presence of iron (III) 
chloride (Partridge et al., 1972; Grant et a i, 1988), which can be observed on solid 
growth media.
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9.2 Dehydroshikimate dehydratase
Dehydroshikimate dehydratase (DHSase) is the third enzyme in the quinate 
pathway, which converts quinic acid to protocatechuate for use as a carbon source. In 
Neurospora crassa (Case and Giles, 1976) dinà Acinetonbacter calcoaceticus 
(Elsemore and Omston, 1995) this pathway is controlled by a tightly linked cluster of 
four genes (qa 1-4 in N. crassa and quiBCXA in A. calcoaceticus), three of which 
encode for the individual enzymes of the pathway. In Aspergillus nidulans (Grant et 
al, 1988) there are six genes in the cluster (qutCDBAER) consisting of two 
regulatory genes, three enzymes and a permease. The first step in the pathway 
converting quinate to 3-dehydroquinate is catalysed by a NAD dependent quinate 
dehydrogenase. The second step is the DHQase reaction converting 3- 
dehydroquinate to 3-dehydroshikimate, followed by production of protocatechuate 
by DHSase.
DHSase from N. crassa has been purified and characterised (Stroman et al. 
1978), to show that the enzyme is active as a monomer of mass 37kDa. It was also 
noted that DHSase was sensitive to thermal dénaturation, though this was stabilised 
by addition of Mg^  ^ions. The gene quiC encoding the DHSase from A. calcoaceticus 
has also been cloned (Elsemore and Omston, 1995). Expression of this gene in E. 
coli induced production of PCA.
Two compounds were identified that form coloured complexes in the 
presence of PCA. The classical indicator, Fe(III) C I3, forms a complex with PCA that 
absorbs around 500 -  580nm, forming a dark blue solution. The observation that Na2 
M0 O3 forms coloured complexes in the presence of vicinal di-hydroxy phenols was 
also investigated. The complex between PCA and Nai M0 O3 is coloured dark 
yellow, absorbing light between 350 and 450nm. By varying the PCA and indicator
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concentration in a 96 well plate, the minimal amount of indicator and PCA required 
to detect a signal was investigated. The spectroscopic reading of the 96-well plates 
was carried out using a Genosys plate reader (Tecan).
9.3 Absorbance spectra of 3-dehydroquinate and PCA
Before any experiments with indicators were designed, absorbance spectra of 
the substrate, intermediate and product of the assay were recorded to determine if 
they conferred any intrinsic background absorbance in the visible region (Figure 9.2). 
All experiments used 50mM Tris-acetate pH 7.0, 2.5mM MgCli as the assay buffer.
6 .0^
-0.7
200.0 400 600 700 800.0300 500
Figure 9.2: Absorbance spectra in the range 200-800nm of 3-dehydroquinate (Blue) and PCA 
(Red)
This shows that neither substrate nor product absorb light in the visible region.
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9.4 Detection of PCA using Fe(III) CI3 as an indicator
The absorbance spectra in the range 200 -  800nm was recorded for 1 mM 
Fe(III) CI3 , Fe(III) CI3 + ImM 3-dehydroquinate, Fe(III) CI3 -f ImM 3- 
dehydroshikimate and Fe(III) CI3 -+- ImM PCA (Figure 9.3, Figure 9.4)
6.5 ^
-0.2 :
200.0 300 400 500 600 700 800.0
Figure 9.3: Absorbance spectra in the range 200 -  800nm for ImM Fe(III) CI3 (Blue), Fe(lII) CI3 
+ ImM  3-dehydroquinate (Red), Fe(III) CI3 + ImM  3-dehydroshikimate (Green) and Fe(IlI) CI3 
+ Im M  PCA (Pink)
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Figure 9.4: Expansion of absorbance spectra in the range 400 -  800nm for Im M  Fe(III) CI3 
(Blue), F e (lll)  CI3 + Im M  3-dehydroquinate (Red), Fe(III) CI3 + ImM  3-dehydroshikimate 
(Green) and F e(lll)  CI3 + Im M  PCA (Pink)
This experiment shows that Fe(III) CI3 + PCA absorbs light in the range 460 -  
600nm
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9.5 Optimisation of Fe(III) CI3 /PCA concentrations required to detect PCA in 
96 -  well plate format
The previous experiment to show the colour change upon the formation of the 
Fe(III) CI3 /PCA complex was carried out using 1cm path length quartz cuvettes. In 
this experiment the assay was transferred to 96-well plate format, using a range of 
Fe(III) CI3 and PCA concentrations. The range of concentrations used were, for 
Fe(III) CI3 l|iM  -  5mM, and for PCA O.OSpM -  5mM (Figure 8.5). The absorbance 
was measured at 590nm, and the results plotted using Origin 5.0 (Figure 9.6).
From Figure 8 .6  it can be seen that using 5mM Fe(III) CI3, 50|iM is the minimum 
concentration of PCA that can be detected as an increase in A590. Using ImM Fe(III) 
CI3, lOOpM PCA may be the limit of detection, although there is a spurious result in 
the experiment at that value.
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Figure 9.5: 96-well plate illustrating the colour change observed upon addition of the Fe(III) CI3 
to PCA at various concentrations
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Figure 9.6: Plot of A590 vs PCA concentration using various concentrations of Fe(III) CI3
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9.6 Detection of PCA using Naz M0 O3 as an indicator
In the presence of vicinal di- (or tri) hydroxy phenols, solutions of Na% M0 O3 
form complexes that are coloured dark yellow, absorbing light around 400 -  450nm. 
PCA is a vicinal di-hydroxy phenol; therefore the use of Na2 M0 O3 as an indicator 
for the presence of PCA was investigated (Figure 9.7, 9.8).
5.0 
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Figure 9.7: Absorbance spectra in tbe range 200 -  800nm for Im M  Nai M 0 O3 (Blue), Nai M 0 O3 
+ Im M  3-dehydroquinate (Red), Naz M 0 O3 + Im M  3-debydrosbikimate (Green) and Na% M 0 O3 
+ Im M  PCA (Pink)
1.0 0 .
0.8 
0.6
A
0 .4 .
0 .2 .
0 .0 0 .
350 .0 400 4 50 500 550 600 .0
Figure 9.8: Expansion of absorbance spectra in the range 350 -  600nm for Im M  Naz M 0 O3 
(Blue), Na2 M 0 O3 + ImM  3-dehydroquinate (Red), Naz M 0 O3 + ImM  3-dehydroshikimate 
(Green) and Naz M 0 O3 + Im M  PCA (Pink)
Figures 9.7 and 9.8 show that PCA and Na% M0 O3 form a complex that absorbs 
strongly in the range 350- 450nm.
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9.7 Optimisation of Naz M0 O3 /PCA concentrations required to detect PCA in 
96 -  well plate format
The previous experiment illustrated that using 1cm path length quartz 
cuvettes, PCA can be detected by the formation of a complex with Na% M0 O3 that 
absorbs strongly between 350 and 450 nm. This assay was then transferred to 96- 
well plate format and the signal to noise ratio determined using various 
concentrations of PCA and Naz M0 O3. Figure 9.9 shows the colour change observed 
on the plate, and figure 9.10 shows plot of absorbance at 405nm as a function of 
PCA concentration, using different concentrations of Na% M0 O3.
From figure 9.10 it can be seen that there is a large absorbance at 405nm in 
the presence of 5mM PCA and 5mM Naz M0 O3, however this absorbance drops 
rapidly to noise level as the concentrations of PCA and Naz M0 O3 are reduced. The 
minimal detectable levels of PCA are 0.5mM using 5mM Naz M0 O3 as an indicator, 
and ImM PCA using ImM Naz M0 O3 as an indicator.
This level of detection is not as sensitive as the classical Fe(III) CI3 method.
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Figure 9.9: 96-well plate illustrating the colour change observed upon addition of Na2 M 0 O3 to 
PCA at various concentrations
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Figure 9.10: Plot o f A405 vs PCA concentration using various concentrations of Naz M 0 O3
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9.8 Cloning of Dehydroshikimate dehydratase
A purification method for purification of DHSase for N. crassa has been 
established previously (Stroman et a l 1978), however, large-scale growth of the 
fungi is problematic, and the 7 step purification very long. Elsemore and Omston 
cloned a 2.0kb Hind III fragment of A. calcoaceticus DNA that included the quiC 
gene encoding DHSase into the p-Bluescript vector pBSK (Stratagene). DHSase 
activity was detected in E.coli DH5a cells expressing the resultant plasmid pZR564 
(Elsemore and Omston, 1995).
A colony of E colt DH5a cells containing plasmid pZR564 was obtained 
from Prof. L.N. Omston (Dept, of Biology, Yale University, New Haven, 
Connecticut) and the plasmid propagated and purified. To ease expression and 
purification of DHSase, the quiC gene was sub-cloned into pET-15b (Novagen) to 
express the protein with an N-terminal 6xHis tag. The restriction sites present in the 
pBSK vector were incompatible with the Nde I  and Bam HI sites in pET-15b, 
therefore PCR was required to add appropriate restriction sites onto the quiC gene.
9.9.1 Amplification of quiC by PCR
Oligonucleotide primers were designed to amplify the 1.49kb quiC gene with 
the appropriate 5’ Mfg /  and 3’ Bam ///restriction sites for cloning into pET-15b. 
PCR was carried out as outlined in section 2.6 using Taq DNA polymerase 
(Invitrogen), and pZR564 as template DNA. The results were analysed by gel 
electrophoresis (Figure 9.11) and PCR products of the correct size purified by gel 
electrophoresis.
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1 2  3 4
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^ —  quic
Figure 9.11: Gel electrophoresis of quiC  PCR; 1, Boehringer XIV marker 2,Promega Ikb ladder 
3, PCR product IpJ 4, PCR product 5pi
9.9.2 TOPO® cloning of quiC
To allow the PCR product to be sequenced, and to ease the digestion of the 
quiC  gene by restriction endonucleases, the PCR product was inserted into the pCR 
®2.1 TOPO® vector using the TOPO TA kit (section 2.7.2) to generate the vector 
pCRquiC. The vector pCRquiC was transformed into chemically competent E.coli 
D H 5a and plated out on the LB-Agar + lOOpg/ml ampicillin plates. After incubation 
overnight at 37°C, 10 colonies had grown on the LB-Agar -i- 100|ig/ml ampicillin 
plates. Each colony was picked from the plate and used to inoculate 2ml LB -i- 
lOOpg/ml ampicillin which was incubated overnight at 37°C with shaking. Plasmid 
DNA was extracted from the 2ml cultures using the Qiaquick Spin kit (Qiagen)
Positive clones were analysed by digestion with the restriction endonuclease 
E go RI. The pCR ®2.1 TOPO® vector has two E co RI sites, one upstream of the
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cloning and site and another downstream of the cloning site. When the vector is 
digested with Eco RI, two bands, one corresponding to the length of the vector and 
the other corresponding to the length of the cloned sequence, can be separated by gel 
electrophoresis. All 10 clones were shown to contain an insert sequence of the 
correct length by this method. One positive clone, pCRquiCl was sequenced to 
check for errors resulting from the PCR process and it was shown to contain no 
errors. This clone was used for all resulting manipulations.
9.9.3 Subcloning of quiC into pET-15b
The expression vector pET-15b had been used to successfully over-express 
type II DHQase, therefore it was chosen for the over-expression of DHSase.
The vectors pCRquiCl and HpET were propagated using E.coli DH5a in 5ml 
cultures of LB + the appropriate antibiotic and plasmid DNA isolated using the 
Qiaquick Spin kit (Qiagen). 30|il of each vector was double digested using the 
restriction endonucleases Ndel and BamHI (Promega) in Promega buffer D. Buffer D 
was chosen as it is the optimal buffer for Ndel activity and BamHI has 75% activity 
in this buffer system. Ndel has little or no activity in other buffer systems. The 
resulting DNA fragments were analysed by gel electrophoresis, and bands 
corresponding to pET-15b and quiC were extracted using the Quiex II kit (Qiagen).
Ligation of the pET-15b and quiC fragments was carried out overnight at 
16°C using T4 DNA Ligase (Promega) as outlined in section 2.5.4 to generate the 
vector pETquiC. The ligation products were transformed into chemically competent 
E. coli DH5a cells and plated out on LB-Agar + 100p,g/ml ampicillin plates. The 
plates
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were incubated overnight at 37°C, after which time 25 colonies were visible. 10 
colonies were picked and grown overnight with shaking at 37°C in 2ml LB + 
lOOjig/ml ampicillin and vector DNA isolated using the Qiaquick Spin kit. Clones 
were analysed by restriction digests with Ndel and BamHI and all 10 clones were 
shown to be positive by gel electrophoresis.
9.9.4 Expression of QuiC in E, coli BL21
The vector pETquiC was transformed into chemically competent E. coli 
BL21 (pLysS S) and plated out on LB-Agar + 100p.g/ml ampicillin plates. The plates 
were incubated overnight at 37°C. A single colony was picked from the plate and 
used to inoculate 5ml LB + lOOpg/ml ampicillin which was incubated at 37°C with 
shaking overnight.
1ml of the overnight culture was removed; the cells were pelleted by 
centrifugation and stored on ice for future analysis by SDS PAGE. 2ml samples were 
used to inoculate 2 x 25ml LB + lOOjig/ml ampicillin cultures which were grown 
with shaking at 37°C until the ODeoo was between 0.4 and 0.6. IPTG to a final 
concentration of ImM was added to one culture and water added to the other culture 
to act as a control. Both cultures were incubated with shaking at 37°C for 3 hours.
After 3 hours 1 ml samples were removed from each culture and the cells 
pelleted by centrifugation and stored on ice. The cell pellet from the induced culture 
was re-suspended in 500pl of cytobuster reagent (Invitrogen) and incubated at room 
temperature for 30 minutes to lyse the cells. A 20 pi aliquot was removed for SDS 
PAGE analysis before the remainder of the sample was centrifuged (13000 rpm, 5 
minutes) to separate the soluble and insoluble components. The soluble fraction was 
removed and both soluble and insoluble fractions were stored on ice.
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The remainder of the 25ml sample induced with IPTG was centrifuged to 
isolate the cell pellet (4000g, 20 minutes). The cell pellet was then resuspended in 
20mM Tris-HCl pH 8.0, 300mM NaCl, 20mM imidazole, 2.5mM MgCli. The cells 
were lysed by passage through a French press (2 x 950 psi) and solid debris removed 
by centrifugation (8000g, 60 minutes). The supernatant was loaded onto a pre­
equilibrated Ni-NTA superflow column (Qiagen) and then flow through collected. 
The column was washed with 20mM Tris-HCl pH 8.0, 300mM NaCl, 75mM 
imidazole, 2.5mM MgCl2 and the flow through collected. Bound protein was eluted 
by washing the column with 20mM Tris-HCl pH 8.0, 300mM NaCl, 200mM 
imidazole, 2.5mM MgCli and the peak fraction collected.
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9.9.5 Analysis of QuiC expression by SDS PAGE
The following samples were loaded onto a 12.5% SDS polyaccrylamide gel 
for analysis; 1- Low molecular weight marker, 2 - overnight culture total cell protein, 
3 - un-induced sample total cell protein, 4 - induced sample total cell protein, 5 - 
induced sample insoluble fraction, 6 - induced sample soluble fraction, 7 -  Ni-NTA 
flow through, 8 -  Ni-NTA wash flow through, 9 -  Ni-NTA eluted fraction. The 
stained gel is shown in Figure 9.12
6 7
6 6  kDa
45 kDa
8
QuiC
'Z S S t
Figure 9.12: SDS PAGE analysis of QuiC  expression.
The SDS PAGE analysis shows that QuiC  is heavily over-expressed in E. coli
BL21 cells, even without the addition of IPTG, however most of the expressed 
protein appears in the insoluble fraction. A small band appears to be enriched in the 
eluant from the Ni-NTA column, however if this is indeed a small amount of soluble 
QuiC, the yield is very low.
Stroman et al. (1978) showed that the DHSase from N. crassa  was thermally 
unstable and required Mg "^" ions to stabilise it in solution. Expression of DHSase at 
lower temperature (20°C) may increase the yield of soluble protein. A similar 
experiment varying the concentration of Mg2‘^ ions present in the media and 
purification buffers may also result in production of soluble protein.
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9.10 Conclusion
There is a need for a DHQase activity assay that is amenable for high 
throughput screening methods is great. Coupling DHQase activity to DHSase to 
generate protocatechuate allows easy detection by a strong colour change in the 
presence of Fe(III) ions. The intensity of the colour change allows detection of sub 
mM quantities of PCA in 96 well plate format.
The gene for the DHSase for A. calcoaceticus was obtained from Prof L.N. 
Omston (Yale University, New Haven, CT) and subcloned into the pET-15b vector 
for over expression in E. coli. The protein produced from this expression system was 
shown to be insoluble, however modification of the expression protocol and buffer 
contents may yield soluble protein, allowing full development of this assay.
The use of coupling the activity of dehydroquinate synthase and DHQase to 
DHSase, generating concentrations PCA detectable using Fe(III) ions has recently 
been outlined in a recent patent filed by Arrow Therapeutics (US patent 6,406,878).
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Chapter 10 -  Conclusions
The rise in the incidence of the human disease tuberculosis (TB) caused by 
infection with the pathogen Mycobacterium tuberculosis is extremely worrying. This 
fact coupled with the rise in strains of M. tuberculosis that are resistant to at least one of 
the current frontline anti-tubercular drugs has hastened the need for novel TB drugs. The 
Action TB initiative, funded by GlaxoSmithKline, and the Global Alliance for TB drug 
development (http://www.tballiance.org) (Global Alliance for TB drug development, 
2001) are committed to research and development to identify novel drugs active against 
M. tuberculosis. Enzymes of the shikimate pathway have become attractive drug targets 
and the use of structural information upon potential drug targets will be of prime 
importance in the development of novel drugs. This is reflected in the recent structure of 
TB shikimate kinase (Gu et al, 2002) and the large number of groups who have and 
signed up to study the enzymes of the pathway in the TB structural genomics consortium 
(http://www.doe-mbi.ucla.edu/TB/). In addition, structures of almost all the enzymes of 
the pathway have now been solved including structures of shikimate dehydrogenase and 
related iso-enzymes by non-profit organisations, structural genomics organisations and 
commercial organisations (Michel et al, 2003; Benach et al, 2003; Y t e t  al,  2003; 
Padyana and Burley, 2003; commentary in Vogan, 2003).
The primary result from the studies presented in this thesis is the identification of 
a novel, non substrate-like inhibitor of type II 3-dehydroquinase from M. tuberculosis 
(MTDHQase) by structure based ligand design methods. After analysis of the available 
structures of MTDHQase determined by X-ray crystallography, pharmacaphore models 
were generated which describe potential electrostatic, steric and hydrophobic
209
Chapter 10____________________________________________________ Conclusions
interactions within the active site. These models were used to screen a virtual compound 
library in silico to generate a list of compounds that potentially satisfy the criteria of the 
pharmacaphore models, hence should inhibit MTDHQase in vitro. Similar screens were 
carried out against the same database using pharmacaphores derived from crystal 
structures of type II 3-dehydroquinases from Streptomyces coelicolor (SCDHQase) and 
Helicobacter pylori (HPDHQase). These searches generated 36 hits for compounds that 
were unique hits for MTDHQase and the testing of these compounds in an in vitro assay 
resulted in the identification of 6 compounds that showed inhibitory activity.
Future study upon these compounds should involve characterisation of their 
inhibition profiles against other type II DHQases. The structure determination of 
MTDHQase in complex with these compounds will progress this work to the next stage, 
using structural information to optimise ligand potency.
This example of structure based ligand design was carried out on a small scale 
yet active compounds were identified illustrating proof of concept of the experiment 
design. Currently, structural information is highly sought after for drug targets in the 
pharmaceutical industry with most major pharmaceutical and biotech companies either 
having teams of structural biologists and computational chemists, or have contracts with 
companies that specialise in protein structure determination.
The major advantage of using a structure based approach was to search for non­
substrate-like inhibitors that are more ‘drug-like’. Most current inhibitors of type II 3- 
dehydroquinase are transition state analogues, hence are small, hydrophilic and 
extensively functionalised, hence not ideal for development as drugs.
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The structure determination of HPDHQase in complex with the ligand AH9095 
represents the first structure of a type II DHQase in complex with a non-substrate like 
inhibitor. AH9095 was identified by high throughput screening methods and was shown 
to be a specific HPDHQase inhibitor, showing no potency against MTDHQase. 
Comparison of the HPDHQase and MTDHQase structures suggested that the presence 
of a negatively charged patch on the surface of MTDHQase near the entrance to the 
active site may hinder the binding of ligands with large polar moieties such as the 
xanthene moiety of AH9095. This area of the active site has not been investigated in 
previous studies attempting to design specific type II DHQase inhibitors, therefore 
probing this area of the active site may provide an opportunity to build specificity into 
more potent generic type II DHQase inhibitors. A recent study by Toscano and co­
workers (Toscano et al, 2003) probed a hydrophilic pocket in the active site of 
SCDHQase (identified by a glycerol fortuitously bound to the structure) with only 
limited success.
The recent publication of HPDHQase at 2.5Â resolution will help to provide 
further insight towards generation of novel inhibitors of type II DHQase (Lee et a l ,
2003 PDB I D. 1J2Y). After re-assessment of the experimental data submitted to the 
PDB, it is apparent that the electron density observed within the active site corresponds 
to a molecule of citrate, which they report to have used as precipitant in the 
crystallisation media (Kwak et al, 2001) as opposed to the reported ligand, the substrate 
3-dehydroquinate. Hence there are three structures of HPDHQase available with three 
different types of ligand; one rational design (FAl), one identified form HTS (AH9095) 
and one identified via serendipity (citrate). Citrate appears to bind tightly in the active
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site of HPDHQase, therefore full investigation of inhibition of type II DHQases by 
citrate and related molecules should be carried out.
This study has shown that novel enzyme inhibitors can be identified by the 
structure based ligand design methodologies. Further analysis of these, and related 
compounds may yield inhibitors that are more potent and selective than the current first 
generation inhibitors. In addition novel non substrate like inhibitors identified may have 
better solubility profiles necessary for further drug development leading to a successful 
therapeutic agent.
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